Professional Documents
Culture Documents
Mims-Indonesia June 2015 en Sample
Mims-Indonesia June 2015 en Sample
com in June
2015
by soluXio (contact@soluxio.com)
Product Name
2-4 Zalf
Manufacturer
Nufarindo
3TC
GlaxoSmithKline Indonesia
3TC-HBV
GlaxoSmithKline Indonesia
5-Fluorouracil Ebewe
Ferron/Ebewe
8Y
Ikapharmindo
A Scabs
Aafact
A-B Vask
Abajos
HOE
Graha Farma
Lapi
Nufarindo
Abbotic/Abbotic
Granule/Abbotic XL
Abbott
Abdelyn
Coronet
Abilify Discmelt
Otsuka
Abilify Injection
Otsuka
Otsuka
Abilify Tablet
Otsuka
Abirom
Abixim
Actavis
Accolate
AstraZeneca
Accupril
Pfizer
Acendril
Harsen
Acenor-M
Bristol-Myers Squibb
Acepress
Bernofarm
Acetated Ringer's
Euro-Med
Acetensa
Fahrenheit
Acetin 600
Sanbe
Acetram
Prima Medika
Dankos
Aciblock
Molex Ayus
Acidrine
Solvay Pharma
Acifar
Ifars
Acifar Cream
Ifars
Acilaz
Otto
Acitral
Interbat
Aclam
Lapi
Aclasta
Novartis Indonesia
Aclonac
Pharos
Acna Care
Mega Lifesciences
Acne Feldin
Galenium
Acne-Aid
Stiefel
Acnezol
Bernofarm
Acpulsif 5
Dexa Medica
Acran
Sanbe
Acrios
Actavis
Actabone
Actavis
Actacef
Actavis
Actal
Actalipid
Actavis
Actapin
Actavis
Actaryl
Actavis
Actazolam
Actavis
Actemra
Roche
Act-HIB
Sanofi Pasteur
Acticoat
Kalbe Farma
Actifed
Glaxo Wellcome
Glaxo Wellcome
Actigesic
GlaxoSmithKline Indonesia
Actilyse
Boehringer Ingelheim
Actimmune 250/Actimmune
600
Pharos
Active Joint
Ikapharmindo
Actonel
Sanofi Aventis
Sanofi Aventis
Actoplatin
Actavis
Actos
Takeda
Actosmet
Takeda
Actrapid
Novo Nordisk
Acuatim
Otsuka
Acyclovir Hexpharm
Hexpharm
AD Fluor
Apex Pharma
A-D Plex
Kalbe Farma
Adalat
Bayer Healthcare
Adalat OROS
Bayer Healthcare
Adant Dispo
Meiji
Adebion
Adecco
Pharos
Adelysin
Prafa
Adfer
Fahrenheit
Tanabe Indonesia
Adrenalini Bitartras
Adricin
Novell Pharma
Adrome
Landson
Advantan
Aerius
Aerius D-12
Aeroson
Aerrane
Kalbe Farma
Aethylcarbonas Chinin
(Euchinin)
Kimia Farma
Afamed
Futamed
Afinitor
Novartis Indonesia
Afomix
Nufarindo
Afrin
Afucid
Ferron
Aggravan
Ferron
Aggrenox
Boehringer Ingelheim
Agrelano
Ikapharmindo
Agrezol
Meprofarm
Agrippal S1
Novartis Indonesia
Agrylin
Fahrenheit
Agulan
Darya-Varia
Akilen
Sanbe
Sanbe Vision
Akita
Ifars
Akrinor
Akrofen
Nufarindo
Akta Vol
Nicholas
Aktace
Nicholas
Aktazet
Nicholas
AL 110
Nestl
Ala 600
Simex
Alabetic
Futamed
Alanox
Darya-Varia
Albapure 20
Albiotin
Kalbe Farma
Albothyl
Pharos/Nycomed
Albucid
Nicholas
Albuman 20%
Graha Farma
Albuminar-25
Albumin-Human 20%
Kimia Farma
Alburaas
Combiphar
Albutein
Alco
Interbat
Alcon Cilox
Alcon
Aldactone
Aldapres
Pharos/Actavis
Aldazide
Aldiab
Merck
Aldin
Merck
Aldisa SR
Sanbe
Aldomer
Mersifarma TM
Aldovas
Dexa Medica
Alegi
Lapi
Alegysal
Ferron/Santen
Alenoxal
Sandoz
Alerdex
Armoxindo Farma
Alerfed
Guardian Pharmatama
Alodan
Hexpharm Jaya
Alernitis
Ikapharmindo
Aleros
Actavis
Alerson
Alerten
Mega Lifesciences
Alexan
Ferron
Alflam
Mugi Labs
Alganax
Guardian Pharmatama
Algesal Superactive
Solvay Pharma
Algut
Merck
Alicron
Ferron
Alimta
Eli Lilly
Alinamin
Takeda
Alista
Novell Pharma
Alkeran
GlaxoSmithKline Indonesia
Allerin
Medifarma
Allohex
Kalbe Farma
Allopurinol Hexpharm
Hexpharm Jaya
Allopurinol Landson
Landson
Alloris
Sanbe
Alluric
Kalbe Farma
Almacon
Pyridam
Aloclair
Kalbe Farma
Aloclair Plus
Kalbe Farma
Alodan
Hexpharm Jaya
Alofar
Ifars
Alomide
Alcon
Alopros
Pharmacore
Alora
Pharos
Alostil
Pharos
Alovell
Novell Pharma
Aloxid
Interbat
Aloxtra
Pharos
Alpain
Apex Pharma
Alpara
Molex Ayus
Alpenaso
Alpentin
Actavis
Alphacort
Apex Pharma
Alphadine
Apex Pharma/Nycomed
Alphadine Gargle
Nycomed
Alphadryl
Apex Pharma/Nycomed
Alphagesic
Apex Pharma
Alphahist
Apex Pharma
Alphamid
Actavis
Alphamol
Molex Ayus
Dexa Medica
Mersifarma TM
Alsine
Apex Pharma/Nycomed
Altofen
Sanbe
Aludonna
Armoxindo Farma
Aludonna D
Armoxindo Farma
Alupent
Boehringer Ingelheim
Aluvia
Abbott
Alviz
Pharos
Alxil
Bernofarm
Alynol
Pharos
Alzim
Fahrenheit
Amadiab
Lapi
Amaropo Plus
Phapros
Amaryl
Sanofi Aventis
Amaryl M
Sanofi Aventis
Ambiopi
Mersifarma TM
Amboid
Nufarindo
Ambril
Merck
Indo Farma
Amcillin
Actavis
Amcor
Merck
Amdixal
Sandoz
Amerol
Aminefron
Dexa Medica
Aminofluid
Otsuka
Aminofusin Hepar
Kalbe Farma
Aminofusin L 600
Kalbe Farma
Aminofusin Paed
Kalbe Farma
Aminoleban Infusion
Otsuka
Aminoleban Oral
Otsuka
Indo Farma
Aminoral
Aminosteril
Fresenius Kabi
Aminosteril Infant
Fresenius Kabi
Aminosteril N-Hepa
Fresenius Kabi
Aminovel 600
Otsuka
Amiosin
Dexa Medica
Amiparen
Otsuka
Amiten
Sanbe
Amlocor
Novell Pharma
Amlodipine Fahrenheit
Fahrenheit
Amlodipine Hexpharm
Hexpharm Jaya
Medikon
Amlogal
Galenium
Amlogrix
Sanofi Aventis
Amnorel 600
Sanbe
Amobiotic
Bernofarm
Amocomb
Bernofarm
Amosine
Mugi Labs
Amoxicillin Dankos
Dankos
Amoxicillin Hexpharm
Hexpharm
Amoxil
GlaxoSmithKline Indonesia
Amoxillin
Pharos
Amoxsan
Caprifarmindo
Indo Farma
Ampi
Interbat
Indo Farma
Amtocort
Pharos
Amvar
Simex
Anabion
Anacetine
Anadex
Interbat
Anadium
Guardian Pharmatama
Anafen
Bernofarm
Anaflu
Mecosin
Anafranil
Novartis Indonesia
Anakonidin
Konimex
Analsik
Sanbe
Analspec
Metiska Farma
Analtram
Lapi
Anaprin
Kalbe Farma
Anatensol
Bristol-Myers Squibb
Anavit
Nufarindo
Anbacim
Sanbe
Anbiolid
Meprofarm
Ancefa
Meprofarm
Ancla
Meprofarm
Andalan Injection
Harsen/DKT Indonesia
Harsen/DKT Indonesia
Andalpha
Actavis
Andantol
Andep
Medikon
Andikap
Supra Ferbindo
Andonex
Meprofarm
Andriol Testocaps
Androcur
Bayer Healthcare
Androlon
Meprofarm
Anelat
Ifars
Anemolat
Phapros/Rajawali
Anerocid
Ferron
Anesfar
Fahrenheit
Anesject
Danpac Pharma
Anexate
Roche
Anexia
Pharos
Anexin
Sanbe
Anfix
Anflat
Kalbe Farma
Anfuhex
Hexpharm
Anfuhex Cream
Hexpharm Jaya
Angeliq
Bayer Healthcare
Angintriz MR
Novell Pharma
Angioten
Kalbe Farma
Anhissen
Sunthi Sepuri
Anitid
Bernofarm
Anlos
Sandoz
Anmerob
Medikon
Anmum
Fonterra PT
Anmum Essential 3
Fonterra PT
Anmum Essential 4
Fonterra PT
Anmum Infacare 1
Fonterra PT
Anmum Infacare 2
Fonterra PT
Fonterra PT
Fonterra PT
Fonterra PT
Fonterra PT
Anore
Kalbe Farma
Anpiride
Sanbe
Anrema
Mecosin
Ansi
Bernofarm
Anstrep
Solas
Antalgin Berlico
Antalgin Corsa
Corsa
Indo Farma
Anthramed
SDM Lab
Anti Stries
Ikapharmindo
Antidine
Kimia Farma
Antikun
Interbat
Anti-Maag
Pyridam
Antion
Landson
Antiplat
Dexa Medica
Antipres
Sandoz
Antiprestin
Pharos
Antiza
Coronet
Antox
Interbat
Antrain
Interbat
Antrexol
Solas
Antrotik
Pyridam
Anuva
Novartis Indonesia
Anvomer B6
Dexa Medica
Anxibloc
Dexa Medica
Anzatax
Apazol
Dexa Medica
Apecur
Simex
Apeton
IPI
Apialys
Lapi
Apidra
Sanofi Aventis
Apisate
Sunthi Sepuri/Wyeth-Ayerst
Apolar
Actavis
Apolar-N
Actavis
Aprion
Pharos
Aprovel
Sanofi Aventis
Cynergen Health
Cynergen Health
Cynergen Health
Aptor
Nicholas
Araclof
Armoxindo Farma
Arava
Sanofi Aventis
Arbiten-I
Arcalion 200
Servier
Arcamox
Armoxindo Farma
Arcapec
Meprofarm
Arcodryl
Armoxindo Farma
Arcored
Armoxindo Farma
Arcoxia
Ardium CVD
Servier
Ardium HD
Servier
Ardivit-PL
Novell Pharma
Aredia
Novartis Indonesia
Arespin
Pharos
Arfen
Solas
Argensol
Solas
Argomed
Futamed
Aricept
Eisai
Aricept Evess
Eisai
Arimed
Promed
Arimidex
AstraZeneca
Ariski
Actavis
Arixtra
GlaxoSmithKline Indonesia
Arkine
Pyridam
Armacort
Ifars
Armolev 500
Armoxindo Farma
Armovit
Armoxindo Farma
Arnid
Pharos
Aromasin
Pfizer
Arsinal
Meprofarm
Arsitam
Meprofarm
Artane
Lederle
Artem
Arteoptic LA
Otsuka
Artepid
Pharos
Arthrifen
Armoxindo Farma
Arthrifen Plus
Armoxindo Farma
Artoflam
Artovit
Pharos/Cardinal
Artricom
Combiphar
Artrilox
Combiphar
Artriox
Medikon
Artritin
Teguhsindo Lestaritama
Artro
Ikapharmindo
Artro Plus
Ikapharmindo
Artrodar
Combiphar
Asabium
Otto
Indo Farma
Landson
Asamnex
Metiska Farma
Ascardia
Pharos
Ascarzan
Mecosin
Ascavin
Dexa Medica
Ascomin
Minorock Mandiri
Ascoplex
Actavis
Ascorbec
Pharos
Asedas
Pyridam
Asepta
Konimex
Asering-5
Otsuka
Asidrat
Pharos
Asimat
Mersifarma TM
Askorbin
Kimia Farma
Asmacare
Kimia Farma
Asmadex
Dexa Medica
Asmano
Corsa
Asmasolon
Medifarma
Aspar
Tanabe Indonesia
Aspar-K
Tanabe Indonesia
Aspil
Fahrenheit
Aspilets
Medifarma
Aspirin Bayer
Aspitrom
Interbat
Asta Plus
Simex
Astacor
Astaderm
Astadiab
Astamax
Nufarindo
Astaplus
Simex
Astatin
Novell Pharma
Astaxanthin
Asten
Solas
Astharol
Sanbe
Asthin B-OND
Asthin Force
Asthin Force 6
Asthma Soho
Astika
Ikapharmindo
Astina
Puspa Pharma
Astria
Landson
Asvex
Tanabe Indonesia
Atarax
Mersifarma TM
Ataroc
Novell Pharma
Ativan
Sunthi Sepuri/Wyeth-Ayerst
Atmacid
Graha Farma
Atofar
Fahrenheit
Atopiclair
Atorsan
Sandoz
Atorvastatin Yarindo
Yarindo Farmatama
Atorwin
Sanofi Aventis
ATP Kalbe
Kalbe Farma
Atracurium-Hameln
Combiphar
Atranac
Corsa
Atrocox 7.5/Atrocox 15
Simex
Atrovent
Boehringer Ingelheim
Augmentin
GlaxoSmithKline Indonesia
Augmentin BID
GlaxoSmithKline Indonesia
Augmentin IV
GlaxoSmithKline Indonesia
Aurorix
Roche
Auspilic
Pharos
Ikapharmindo
Avamys
GlaxoSmithKline Indonesia
Avandamet
GlaxoSmithKline Indonesia
Avandaryl
GlaxoSmithKline Indonesia
Avandia
GlaxoSmithKline Indonesia
Avastin
Roche
Avaxim
Sanofi Pasteur
Avelox
Bayer Healthcare
Avemar
Lapi
Avil
Sanofi Aventis
Aviter
Interbat
Avloclor
AstraZeneca
Avocel
Pharos
Avodart
GlaxoSmithKline Indonesia
Avogin
Lapi
Axamed
Futamed
Axamed Plus
Futamed
Axanthin
Axtan
Solas
Axtan Syr
Solas
Aza 20
Pharmacore
Azathioprine
Combiphar/Pharmachemie
Combiphar/Pharmachemie
Azmacon
Armoxindo Farma
Azol
Merck
Azomax
Dexa Medica
Azopt
Alcon
Aztrin/Aztrin DS
Pharos
Azvit
Ikapharmindo
Azyter
Kalbe Vision
bacbutINH
Armoxindo Farma
Bacbutol
Armoxindo Farma
Bactazon
Graha Farma
Bactesyn
Kalbe Farma
Bactigras
Kalbe Farma
Bactiprox
Erlimpex
Bactirom
Sanbe
Bactoderm
Ikapharmindo
Bactoprim Combi
Combiphar
Bactraz
Otto
Bactricid
Bactrim/Bactrim Forte
Roche
Bactrizol
Corsa
Bactroban
GlaxoSmithKline Indonesia
Baliin Q10
Fortune Star
Balticin
Bamgetol
Mersifarma TM
Banadoz
Sandoz
Bantif Child
Caprifarmindo
Sanbe Vision
Baquinor/Baquinor Forte
Sanbe
Baraclude
Taisho/Bristol-Myers Squibb
Bartolium
Nufarindo
Barzepin
Novell Pharma
Batrafen
Sanofi Aventis
Batugin
Kimia Farma
Baxima
Sandoz
Baycuten-N
Bayer Healthcare
B-Beta
Ferron
Bd-GARD
Bebelac 1
Nutricia
Bebelac 3
Nutricia
Bebelac 4
Nutricia
Bebelac Complete
Nutricia
Bebelac EC
Bebelac FL
Nutricia
Bebelove 1
Nutricia
Bebelove 2
Nutricia
Bebelove FL
Nutricia
Becantex
Pharos
Bececar
Interbat
Becefort
Phapros
Beclomet Easyhaler
Actavis
Actavis
Beclov
Sanbe
Becombion Grow
Becombion Injection
Merck
Becombion Syrup/Drops/Forte
Becom-C
Sanbe
Becom-Zet
Sanbe
Beconase
GlaxoSmithKline Indonesia
Befozi
Bekamin C Forte
Kimia Farma
Bekarbon
Kimia Farma
Bellacid
Bellamox/Bellamox Forte
Bellapheen
Bellatram
Benacol
Kalbe Farma
Benacol DTM
Kalbe Farma
Benadryl
Pfizer
Benadryl CM
Pfizer
Benadryl DMP
Pfizer
Beniazide
Pembangunan
Benocetam
Bernofarm
Benocid
Bernofarm
Benodin
Bernofarm
Benofat
Bernofarm
Benofomin
Bernofarm
Benohist
Bernofarm
Benolicrol
Bernofarm
Benomet 300
Bernofarm
Benoson
Bernofarm
Benoson G
Bernofarm
Benoson M
Bernofarm
Benostan
Bernofarm
Benoviplex
Bernofarm
Benovit C
Bernofarm
Benovit M
Bernofarm
Benoxuric
Bernofarm
Benozym
Bernofarm
Benutrion VE
Sanbe
Benzolac
SDM Lab
Benzolac Cl
SDM Lab
Benzomid
SDM Lab
Benzoquin
SDM Lab
Bepanthen
Beprosalic
HOE
Beprosone
HOE
Berea
Zenith Pharma
Beriplast P Combi-Set
Berlicort
Berlifed
Berlison
Berlosid
Berloson-N
Bernesten
Berno Yeast
Bernofarm
Bernoflox
Bernofarm
Berocca Performance
Berodual
Boehringer Ingelheim
Berotec
Boehringer Ingelheim
Berry Vision
Sanbe Vision
Bersol
Bernofarm
Berthyco
Bernofarm
Berzymplex
Bernofarm
Bestalin
Lapi
Bestocol
Tanabe Indonesia
Beston
Tanabe Indonesia
Beta-Adalat
Bayer Healthcare
Betablok
Hexpharm Jaya
Beta-CE
Otto
Betaclav
Corsa
Betadine
Betadine Mouthwash
Betadine Shampoo
Betaferon
Bayer Healthcare
Betaflox
Betafort
Phapros
Betagentam
Betalans
Betalitik
Betam-Ophtal
Beta-One
Hexpharm Jaya
Betarhin
Betaserc
Abbott
Betasin
Otto
Betaslim
Betason
Kimia Farma
Betason-N
Kimia Farma
Betaver
Pyridam
Betiga
Solas
Betnovate-N
GlaxoSmithKline Indonesia
Betodermin
Mugi Labs
Betopic
Armoxindo Farma
Betoptima
Alcon
Betrion
Otto
Betrix
Bevalex
Molex Ayus
Bevita
Gracia Pharmindo
Bevitran
Landson
Bevizil
Sanbe
Bexce
Bexicom
Nufarindo
Bexicom Fit
Nufarindo
Biatron
Pharos
Bicolax
Armoxindo Farma
Bicrolid
Sanbe
Bidicef
Medikon
Biferce
Sanbe
Bifotik
Sanbe
Bilotec
Binapro
Puspa Pharma
Binomic
Pharos
Binotal
Bayer Healthcare
Binozyt
Sandoz
Bintapen
Hexpharm Jaya
Bioacne
Ikapharmindo
Biofarma
Bio-ATP
Phapros
Biobran
Ferron/Daiwa
Biocalcin
Bernofarm
Biocef
Otto
Biocepime
Otto
Biocream
Merck
BioCurkem
BioCurlam
BioCurliv
Biodasin
Promed
Biodiar
Sandoz
Biodroxil
Sandoz
Bio-E 200
Teguhsindo Lestaritama
Bioferron
Ikapharmindo
Biofos
Meprofarm
BioGaia Lozenge
Kalbe Farma
Biogesic
Biomedis/Probus
Bio-GI
Fahrenheit
Biolastin
Ikapharmindo
Biolincom
Otto
Biolite
Ikapharmindo
Biolysin
Bernofarm
Biolysin Kids
Bernofarm
Biolysin Smart
Bernofarm
Biomega
Graha Farma
Biomex
Actavis
Biomoist
Ikapharmindo
Bion 3
Bionam
Bion-C
Nicholas
Bionect
Combiphar/Fidia
Bionemi
Gracia Pharmindo
Bioneuron
Phapros
Bionutrion
Mugi Labs
Bion-W
Nicholas
Bioplacenton
Kalbe Farma
Bioplacenton Tulle
Kalbe Farma
Bioplan
Nufarindo
Bioprexum
Servier
Bioprexum Plus
Servier
Bio-Prolis
Bioprom
Otto
Bioquin
Ikapharmindo
Bioquinone
Puspa Pharma
Biorazon
Otto
Bio-Retin
Medikon
Biosan
Teguhsindo Lestaritama
Biosanbe
Sanbe
Pharos
Bio-Strath
Biostrum
Lapi
Biotamin
Sankyo
Biothicol
Sanbe
Biotriax
Sandoz
Biovit
Bernofarm
Bioxon
Otto
BioXtra
Kalbe Farma
Biozim
Otto
Bipro
Fahrenheit
Biscor
Dexa Medica
Bisoltussin
Boehringer Ingelheim
Bisolvon
Boehringer Ingelheim
Bisolvon Extra
Boehringer Ingelheim
Bisolvon Flu
Boehringer Ingelheim
Bisolvon Kids
Boehringer Ingelheim
Bisoprolol Hexpharm
Hexpharm Jaya
Dexa Medica
Bisovell
Novell Pharma
Bital
Solas
Sanbe Vision
Sanbe Vision
Bledstop
Caprifarmindo
Blenamax
Combiphar/Pharmachemie
Bleocin
Kalbe/Nippon Kayaku
Blephagel
Kalbe Vision
Blesifen
Caprifarmindo
Blistra
Pharos
BloodCare
Darya-Varia
Blopress
Takeda
Blopress Plus
Takeda
Blorec
Fahrenheit
Blue Cap
Tobbest Busindo/Catalysis SL
Tobbest Busindo/Catalysis SL
BMT
Kalbe Morinaga
BMT P-HP
Kalbe Morinaga
BMT Platinum
Kalbe Morinaga
BMT Soya
Kalbe Morinaga
Sanghiang Perkasa/Morinaga
bodrex
bodrex EXTRA
Bodrex Forte
bodrex Migra
bodrexin
bodrexin Demam
bodrexin Syrup
Bondi
Bondronat
Roche
Bonefos
Bayer Healthcare
Bonepatit 800
Bonic DS
Bonic Plus
Bonilav
Bon-One
Bonvit
Bonviva
Roche
Borraginol-N
Takeda
Borraginol-S
Takeda
Botox
Allergan
Brainact
Kalbe Farma
Brainolin
Dexa Medica
Brainvit
Bralifex
Sanbe Vision
Bralifex Plus
Sanbe Vision
Bralin
Bernofarm
Bravelle
Bravoderm-N
Bufa Aneka
Braxidin
Sanbe
Brazine
Solas
Breathy
Novell Pharma
Brenaris
Metiska Farma
Brenax
Sandoz
Brentan
Brexel
Kalbe Farma
Bricasma
AstraZeneca
Bricasma Expectorant
AstraZeneca
Brilinta
AstraZeneca
Broadced
Kalbe Farma
Bromifar/Bromifar Plus
Ifars
Bromika
Ikapharmindo
Brommer 30
Mersifarma TM
Bronchitin
Nufarindo
Broncholit
Nicholas
Bronchophylin
Darya-Varia
Bronchopront
Combiphar
Bronchosal
Ifars
Broncho-Vaxom
Actavis
Broncozol
Mugi Labs
Brondisal 2/Brondisal 4
Bronkris
Graha Farma
Bronsolvan
Kalbe Farma
Brospec
Prafa
Brospec 1000
Prafa
Broxal
Bernofarm
Brufen
Abbott
Bucain
Bernofarm
Budenofalk
Darya-Varia/Dr Falk
Bufabron
Bufa Aneka
Bufamoxy
Bufa Aneka
Bufect/Bufect Forte
Sanbe
Fahrenheit
Burnazin
Darya-Varia
Buscopan
Boehringer Ingelheim
Buscopan Plus
Boehringer Ingelheim
Buscotica
Buspar
Bristol-Myers Squibb
Butamidon
Otto
Buvanest 0.5%
Kalbe Farma
Kalbe Farma
Buventol Easyhaler
Actavis
Bycolen
Landson
Cado
Simex
Caduet
Pfizer
Caelyx
Cafergot
Novartis Indonesia
Cal-95
Lapi
Calacort
Galenium
Calapol
Sterling
Calbio
Pyridam
Calbon
Calcianta
Armoxindo Farma
CalciD
Calcidin
Otto
Calcidol
Kimia Farma
Calcifar Plus
Ifars
Calciflavone
Vitabiotics
Calcimega
Solas
Calcimex
Frisian Flag
Calcimex Vitagold
Frisian Flag
Calcimex Vitalize
Frisian Flag
Calcit
Calcium Ad
Armoxindo Farma
Ferron/Ebewe
Nufarindo
Calciumlevofolinat Ebewe
Ferron/Ebewe
calciviton
Calc-Os
Erlimpex
Caldece
Sanbe
Caldetri
Calix
Meprofarm
Calmin-AF
Combiphar
Calnat
Combiphar
Calnic
Gracia Pharmindo
Calnic Plus
Gracia Pharmindo
Caloma Plus
Novell Pharma
Calos
Fahrenheit
Calosbon
Teguhsindo Lestaritama
Calostrum
Meprofarm
Calplex
Calporosis D
Mersifarma TM
Calsan
Novartis Indonesia
Calsical
Teguhsindo Lestaritama
Calsiro
Nufarindo
Calsivas
Fahrenheit
CalSource
Novartis Indonesia
Caltrate 600 +D
Pfizer
Pfizer
Caltrax
Pyridam
Caltron
Pyridam
Caltum
Calvitos
Calvitran
Landson
Calvonin
Kalbe Farma
Cameloc
Dexa Medica
Camidexon
Camigesik
Campain
Harsen
Campto
Pfizer
Candacort
HOE
Candazole
HOE
Canderin
Dexa Medica
Candesartan TI
Takeda
Candipar
Pharmacore
Candistin
Pharos
candyvit-C
Canergy
Meprofarm
Canesten
Canesten Cream
Canesten Powder
Canicol
Caprifarmindo
Caprazol
Caprifarmindo
Caprenem
Caprifarmindo
Caprifim
Caprifarmindo
Capritazin
Caprifarmindo
Caprocef
Caprifarmindo
Caprol
Caproliv
Caprifarmindo
Capsinat
Caprifarmindo
Capsinat Injection
Caprifarmindo
Captensin
Kalbe Farma
Captopril Hexpharm
Hexpharm
Indo Farma
Captopril Landson
Landson
Capzacin Cream
Combiphar
Indo Farma
Carbloxal
Sandoz
Carboplatin DBL
Carboplatin Ebewe
Ferron/Ebewe
Carboplatin Kalbe
Kalbe Farma
Carbosin
Combiphar/Pharmachemie
Combiphar/Pharmachemie
Cardace
Sanofi Aventis
Cardiavit
Ikapharmindo
Cardicap
Caprifarmindo
Cardiject
Danpac Pharma
Cardio Aspirin
Bayer Healthcare
Cardiomin
Darya-Varia
Cardioplegia
Cardiotone
Pharos
Cardiover
Landson
Cardisan
Sanbe
Cardismo
Phapros
Cardivask
Kalbe Farma
Cardura
Pfizer
Cardyne
Pyridam
Cariamyl
Corsa/Sanofi-Synthelabo
Carmed
SDM Lab
Carni Plus
Ikapharmindo
Carniq
Kalbe Farma
Carniten
Solas
Carnon
Caronem
Pyridam
Carpiaton-25/Carpiaton-100
Fahrenheit
Car-Q
Kalbe Farma
Car-Q100
Kalbe Farma
Carsive
Landson
Cartiflex
Galenium
Cartin
Combiphar
Cartogen
Futamed
Cartos
Pyridam
Cartrilet
Fahrenheit
Casodex
AstraZeneca
Caspol
Hexpharm Jaya
Cataflam
Novartis Indonesia
Cataflam Drops
Novartis Indonesia
Cataflam Fast
Novartis Indonesia
Catalin
Takeda
Catanac
Catapres
Boehringer Ingelheim
Cataro
Pyridam
Cationorm
Kalbe Vision
Cavea
Pharos
Cavida
Cavit D3
Merck
Cavital
Pharos
Cazetin
Ifars
CDR
CDR Fortos
Cealb
Graha Farma
Althea Pharma
Althea Pharma
Cebelia Reinforced
Depigmenting
Althea Pharma
Cebex
Otto
Cebion
Merck
Cedantron/Cedantron Syrup
Cedocard
Darya-Varia/Nycomed
Ceelin
Medifarma
Cefabiotic
Bernofarm
Cefacef
Caprifarmindo
Cefadroxil Hexpharm
Hexpharm
Indo Farma
Cefadroxil Soho
Cefarin
Gracia Pharmindo
Cefarox
Gracia Pharmindo
Cefat
Sanbe
Cefaxon
Kimia Farma
Cefazol
Kalbe Farma
Indo Farma
Cefazolin OGBdexa
Dexa Medica
Cefdime
Promed
Cefepime Hexpharm
Hexpharm Jaya
Cefika
Ikapharmindo
Cefila
Lapi
Cefim
Lapi
Cefinov
Novell Pharma
Cefir
Fahrenheit
Cefixime Hexpharm
Hexpharm Jaya
Dexa Medica
Medikon
Cefizox
Kalbe Farma
Cefmer 1
Mersifarma TM
Cefnos
Pharos
Cefobactam DI
Sanbe
Cefobet
Cefobid
Pfizer
Cefoject
Cefomax
Simex
Cefoperazone Yarindo
Yarindo Farmatama
Cefophar
Pharos
Cefor
Meiji
Ceforim
Sanbe
Cefotaxime Hexpharm
Hexpharm
Indo Farma
Cefovell
Novell Pharma
Cefpirome Hexpharm
Hexpharm Jaya
Cefpirome Phapros
Phapros
Cefradol
Ferron
Cefratam
Dexa Medica
Cefriex
Novell Pharma
Cefrin
Dexa Medica
Cefrom
Sanofi Aventis
Contents
Salicylic acid 2%, sulfur precipitated 4%
Lamivudine
Lamivudine
5-fluorouracil
Permethrin
Amlodipine besylate
Paracetamol 500 mg, thiamine HCl 50 mg, pyridoxine HCl 100 mg, cyanocobalamin 100
mcg
Clarithromycin
Per mL Vit A 2,000 IU, vit B1 2 mg, vit B2 3 mg, vit B6 2 mg, vit B12 2 mcg, vit D3 400 IU,
nicotinamide 20 mg, l-lysine HCl 25 mg, d-panthenol 5 mg
Aripiprazole
Aripiprazole
Aripiprazole
Aripiprazole
Cefpirome sulfate
Cefixime
Zafirlukast
Quinapril HCl
Captopril
Fosinopril Na
Captopril
Per L NaCl 6 g, anhydrous Na acetate 2.28 g, KCl 300 mg, CaCl2 dihydrate 200 mg
Losartan K
Acetylcysteine
Acetylspiramycin
Ranitidine
Nopoxamine lauryl sulfate 2.5 mg, Al amino acetate 250 mg, galactane sulfate 200 mg
Acyclovir
Lansoprazole
Per tab/5 mL liqd Mg(OH)2 200 mg, dried Al(OH)3 gel 200 mg, simethicone 20 mg.
Per caplet Co-amoxiclav: Amoxycillin 500 mg, clavulanic acid 125 mg. Per 5 mL dry syr
Co-amoxiclav: Amoxycillin 125 mg, clavulanic acid 31.25 mg. Per 5 mL forte dry syr Coamoxiclav: Amoxycillin 250 mg, clavulanic acid 62.5 mg
Zoledronic acid
Diclofenac K
Ranitidine HCl
Acarbose
Disodium clodronate
Cefepime HCl
Per Actal tab Creamaline spray dried powd 360 mg [equiv to Al(OH)3 216 mg]. Per Actal
Plus tab Creamaline spray dried powder 360 mg [equiv to Al(OH)3 216 mg], Mg(OH)2
monohydrate [equiv to Mg(OH)2 150 mg], simethicone 25 mg
Atorvastatin Ca
Amlodipine besylate
Glimepiride
Alprazolam
Tocilizumab
Nanocrystalline Ag
Per 5 mL Pseudoephedrine HCl 30 mg, guaiphenesin 100 mg, triprolidine HCl 1.25 mg,
ethanol 6.93% v/v
Per Actimmune 250 caplet Echinacea 250, potent herbs, multivit. Per Actimmune 600
caplet Echinacea 600 mg, potent herbs, multivit
Glucosamine HCl 750 mg, chondroitin sulfate 250 mg, MSM 250 mg, vit C 50 mg
Risedronate Na
Risedronate Na
Carboplatin
Pioglitazone
Nadifloxacin
Acyclovir
Per 0.3 mL (6 drops) Na fluoride 0.5 mg, l-lysine HCl 25 mg, vit A 2,500 iu, vit D 400 iu, vit
B1 0.6 mg, vit B2 0.6 mg, vit B6 0.5 mg, vit B12 1.5 mcg, niacinamide 6 mg, d-panthenol
2.5 mg
Per 0.3 mL Vit A 1,500 iu, vit B1 0.6 mg, vit B2 0.5 mg, vit B3 5 mg, vit B5 2.5 mg, vit B6
0.5 mg, vit B12 1.5 mcg, vit D 400 iu
Nifedipine
Na hyaluronate
Per mL Vit A 5,000 iu, vit D 500 iu, vit B1 2 mg, vit B2 3 mg, vit B6 2 mg, vit B12 2 mcg,
nicotinamide 20 mg, D-panthenol 5 mg, L-lysine HCl 25 mg
Metformin HCl
Per mL Vit A 5,000 iu, vit B1 2 mg, vit B2 3 mg, vit B6 2 mg, vit B12 2 mcg, vit D 500 iu,
nicotinamide 20 mg, panthenol 5 mg, lysine HCl 25 mg
Fe gluconate 250 mg, manganese sulfate 200 mcg, copper sulfate 200 mcg, vit C 50 mg,
folic acid 1,000 mcg, vit B12 7.5 mcg, sorbitol 25 mg
Carbazochrome Na sulfonate
Adrenaline
Doxorubicin HCl
Carbazochrome Na sulfonate
Methylprednisolone aceponate
Desloratadine
Dimethicone
Isoflurane
Everolimus
Folic acid 1,000 mcg, vit B1 100 mg, vit B6 100 mg, vit B12 100 mcg, DHA powd 60 mg,
amino acid 5 mg, ginger extr 50 mg
Oxymetazoline HCl
Cilostazol
Cilostazol
Influenza virus surface antigen inactivated
Anagrelide HCl
Ticlopidine HCl
Ofloxacin
Ofloxacin
Attapulgite 600 mg, pectin 50 mg
Cafedrine HCl 100 mg, theodrenaline HCl 5 mg
Phenylbutazone
Per 5 mL Vit A 4,000 IU, vit B1 2.5 mg, vit B2 2.5 mg, vit B6 0.75 mg, nicotinamide 15 mg,
panthenol 5 mg, vit C 60 mg, vit D 200 IU, Fe 3.6 mg. Per mL Vit A 3,600 IU, vit B1 1.2
mg, vit B2 1.8 mg, vit B6 0.3 mg, nicotinamide 15.8 mg, panthenol 1 mg, vit C 60 mg, vit
D 666 IU
Vit C 500 mg, niacinamide 100 mg, Ca pantothenate 20 mg, vit B1 15 mg, vit B2 10 mg,
vit B6 5 mg, vit B12 4 mcg
Vit E 30 mg, vit C 500 mg, folic acid 0.4 mg, vit B1 15 mg, vit B2 15 mg, nicotinamide 100
mg, vit B6 20 mg, vit B12 12 mcg, Ca pantothenate 20 mg, Zn 22.5 mg
Per 100 g Fat 25 g, protein 10.8 g, carbohydrate (maltodextrin) 58.6 g, linoleic acid 3.19
g, linolenic acid 400 mg, vit A 428 mcg-RE, vit D 5.36 mcg, vit E 5.2 mg, vit K 30.6 mcg,
vit B1 0.4 mg, vit B2 0.44 mg, vit B3 4.24 mg, vit B5 4.16 mg, vit B6 0.28 mg, vit B9 64
mcg, vit B12 1.12 mcg, vit C 69.8 mg, biotin 9.1 mcg, choline 40 mg, inositol 28.6 mg,
taurine 26.3 mg, L-carnitine 6.4 mg, Ca 357 mg, P 208 mg, Mg 42 mg, Fe 4.3 mg, Zn 3.2
mg, manganese 101 mcg, copper 0.3 mg, iodine 54.4 mcg, Na 170 mg, K 510 mg, Cl 314
mg, selenium 8 mcg, fluoride 30 mcg, nucleotides 10.9 mg, LA/ALA=8, Ca/P=1.7,
casein:whey=40:60. Energy: 503 kCal
a-lipoic acid
a-lipoic acid (ALA) 300 mg, folic acid 400 mcg, cyanocobalamin (vit B12) 100 mcg
a-lipoic acid
Human albumin
Clindamycin HCl
Sulfacetamide Na
Human albumin
Human albumin
Human albumin.
Human albumin
Human albumin
Per 0.8 mL Alco drops Pseudoephedrine HCl 7.5 mg. Per 5 mL Alco Plus syr
Pseudoephedrine HCl 30 mg, brompheniramine maleate 2 mg. Per 5 mL Alco Plus DMP syr
Pseudoephedrine HCl 30 mg, brompheniramine maleate 2 mg, dextromethorphan HBr 10
mg
Ciprofloxacin HCl
Spironolactone
Indapamide hemihydrate
Glipizide
Ranitidine HCl
Donepezil HCl
a-lipoic acid 300 mg, biotin 0.03 mg, chromium picolinate 0.2 mg
Pemirolast K
Alendronate Na trihydrate
Dexamethasone 0.5 mg, dexchlorpheniramine maleate 2 mg
Per tab Triprolidine HCl 2.5 mg, pseudoephedrine HCl 60 mg. Per 5 mL Triprolidine HCl
1.25 mg, pseudoephedrine HCl 30 mg
Allopurinol
Loratadine
Desloratadine
Betamethasone Na phosphate
Coenzyme Q10
Cytarabine
Diclofenac K
Alprazolam
Alinamin Fursultiamine HCl. Alinamin-F Fursultiamine HCl (& vit B2 5 mg for tab).
Cilostazol
Melphalan
Ethanol
Per 5 mL Glyceryl guaiacolate 50 mg, Na citrate 180 mg, diphenhydramine HCl 12.5 mg,
phenylpropanolamine HCl 12.5 mg, alcohol 5%
Loratadine
Allopurinol
Allopurinol
Loratadine
Allopurinol
Allopurinol
Allopurinol
Lodoxamide
Finasteride
Vit A 5,000 IU, vit C 100 mg, vit D 100 IU, vit E 10 IU, vit K 85 mcg, thiamine 1.2 mg,
riboflavin 1.2 mg, vit B6 2 mg, folic acid 800 mcg, vit B12 1.3 mcg, Ca 128 mcg, Fe 20
mg, phosphorus 100 mg, iodine 150 mcg, Mg 200 mg, Zn 20 mg, copper 1.5 mg, DHA 50
mg
Amikacin sulfate
Alendronate Na
Minoxidil
Donepezil HCl
Mefenamic acid
Per caplet Paracetamol 500 mg, phenylpropanolamine HCl 12.5 mg, chlorpheniramine
maleate 2 mg, dextromethorphan HBr 15 mg. Per 5 mL syr Paracetamol 125 mg,
phenylpropanolamine HCl 3.125 mg, chlorpheniramine maleate 0.5 mg,
dextromethorphan HBr 3.75 mg
Terfenadine
Gabapentin
Betamethasone valerate
Povidone-iodine
Povidone-iodine
Per 5 mL Diphenhydramine HCl 13.5 mg, ammonium Cl 131.5 mg, alcohol 5%
Paracetamol
Cyproheptadine HCl
Loperamide HCl
Paracetamol
Alprazolam
Alprazolam
Per 5 mL Vit A 4,000 iu, vit D 300 iu, vit B1 3 mg, vit B2 2 mg, vit B6 1 mg, vit B12 5 mcg,
vit C 50 mg, niacinamide 20 mg, Ca pantothenate 5 mg, L-lysine HCl 200 mg
Ketoprofen
Per tab Mg carbonate & Al(OH)3 co-precipitate 250 mg, Ca carbonate 50 mg, caffeine 7.5
mg, diastase 7.5 mg, chlorpheniramine maleate 1 mg, scopolamine HBr 0.05 mg. Per 5
mL susp Al oxide 219 mg, Mg oxide 54 mg, hyoscyamine HBr 51 mcg, atropine sulfate 9.5
mcg, hyoscine HBr 3 mcg
Per chewable tab/5 mL susp Al(OH)3 dried gel 200 mg, Mg(OH)2 200 mg, simethicone 20
mg.
Orciprenaline sulfate
Per 200 mg/50 mg Lopinavir 200 mg, ritonavir 50 mg. Per 100 mg/25 mg Lopinavir 100
mg, ritonavir 25 mg
Alprazolam
Cefadroxil monohydrate
Allylestrenol
Donepezil HCl
Glimepiride
Per 1/250 mg Glimepiride 1 mg, metformin HCl 250 mg. Per 2/500 mg Glimepiride 2 mg,
metformin HCl 500 mg
Ampicillin trihydrate
Per g Al subacetate 35 mg, hydrocortisone acetate 2.5 mg, lidocaine HCl 50 mg, Zn oxide
180 mg
Ambroxol HCl
Ambroxol HCl
Ampicillin trihydrate
Amlodipine besylate
Amlodipine maleate
Loperamide HCl
a-Ketoisoleucine Ca salt 67 mg, a-Ketoleucine Ca salt 101 mg, a-Ketophenylalanine Ca
salt 68 mg, a-Hydroxymethionine Ca salt 59 mg, a-Ketovaline Ca salt 86 mg, L-tryptophan
23 mg, L-threonine 53 mg, L-histidine 38 mg, L-tyrosine 30 mg, L-lysine acetate 105 mg
Per L Glucose 75 g, total free amino acids 30 g, total nitrogen 4.7 g, essential/nonessential amino acids 1.44 g, branched-chain amino acids 30% w/w. Energy: 420 kCal
High content of branched-chain amino acids 45% & low content of methionine,
phenylalanine & tryptophan
High conc of branched chain amino acid & low conc of aromatic amino acid (no tyrosine),
Na, Cl, other important amino acids
Per sachet Protein 13.5 g, fat (rice oil) 3.5 g, carbohydrate 32.35 g, L-isoleucine 1.92 g, Lleucine 2.04 g, L-valine 1.6 g, other important amino acids, vits & minerals. Energy: 210
kCal.
Aminophylline
a-keto isoleucine Ca salt 67 mg, a-keto leucine Ca salt 101 mg, a-keto phenylalanine Ca
salt 68 mg, a-keto valine Ca salt 86 mg, a-hydroxy methionine Ca salt 59 mg, L-lysine
acetate 105 mg, L-threonine 53 mg, L-tryptophan 23 mg, L-histidine 38 mg, L-tyrosine 30
mg, total nitrogen 36 mg, total Ca 50 mg
Amino acids
Amino acids
Amino acids
Amikacin sulfate
Per L Total free amino acids 100 g, nitrogen 15.7 g, Na 2 meq, acetate 120 meq
Per 1,000 mL Amino acid 7.2% (BCAA 45.8%), L-leucine 14 g, L-isoleucine 9 g, L-valine 10
g, L-lysine acetate 7.1 g, L-threonine 3.5 g, L-tryptophan 2.5 g, L-methionine 3 g, Lphenylalanine 5 g, L-cysteine 1 g, L- tyrosine 0.5 g, L-arginine 4.5 g, L-histidine 3.5 g, Lalanine 2.5 g, L-proline 3 g, L-serine 3 g, L-aspartic acid 1 g, L-glutamic acid 1 g.
Osmolarity: 592 mOsm. Energy: 288 kCal
Amlodipine besylate
Amlodipine besylate
Amlodipine besylate
Amlodipine besylate
Amlodipine besylate
Amlodipine besylate
Amlodipine besilate
Per 1,000 mL Amino acid 5% (BCAA 16.4%) (L-isoleucine 3.2 g, L-leucine 2.4 g, L-lysine, Lmalate 3.83 g, L-methionine 3 g, L-phenylalanine 4 g, L-threonine 2 g, L-tryptophan 1 g, Lvaline 3.2 g, L-arginine HCl 7.5 g, L-histidine 1 g, L-alanine 6 g, glycine 14 g, L-proline 2 g,
L-malic acid 0.56 g, d-sorbitol 50 g), sorbitol 5%, vit B2, vit B3, vit B6, vit C, Na 35 meq, K
25 meq, Mg 10 meq, acetate 35 meq, malate 22 meq, Cl 38 meq. Osmolarity: 1286
mOsm/L. Energy: 600 kCal.
Amoxicillin trihydrate
Per captab Co-amoxiclav: Amoxycillin 500 mg, clavulanic acid 125 mg. Per 5 mL syr Coamoxiclav: Amoxycillin 125 mg, clavulanic acid 31.25 mg. Per 5 mL forte syr Coamoxiclav: Amoxycillin 250 mg, clavulanic acid 62.5 mg.
Amoxycillin trihydrate
Amoxicillin trihydrate
Amoxicillin trihydrate
Amoxicillin trihydrate
Amoxicillin
Amoxycillin
Ampicillin trihydrate
Triamcinolone
Per 5 mL Acetaminophen 120 mg, guaifenesin 25 mg, phenylpropanolamine HCl 3.5 mg,
chlorpheniramine maleate 0.5 mg
Per drag Paracetamol 500 mg, dextromethorphan HBr 15 mg, chlorpheniramine maleate 1
mg, phenylpropanolamine HCl 15 mg. Per 5 mL syr Paracetamol 120 mg,
dextromethorphan HBr 3.5 mg, chlorpheniramine maleate 0.5 mg, phenylpropanolamine
HCl 3.5 mg
Diosmin 450 mg, hesperidin 50 mg
Ibuprofen
Paracetamol 200 mg, salicylamide 200 mg, caffeine 50 mg, chlorpheniramine maleate 1
mg
Clomipramine HCl
Per 5 mL Dextromethorphan HBr 5 mg, guaifenesin 25 mg, pseudoephedrine HCl 7.5 mg,
chlorpheniramine maleate 1 mg
Methampyrone 500 mg, diazepam 2 mg
Mefenamic acid
Vit A 2,500 iu, vit B1 0.6 mg, vit B2 phosphate 0.5 mg, vit B6 0.5 mg, vit B12 1.5 mcg, vit
D 500 iu, niacinamide 5 mg, Ca pantothenate 2.5 mg
Cefuroxime (Caplet: Axetil; inj: Na)
Roxithromycin
Cefadroxil monohydrate
Per FC tab Co-amoxiclav: Amoxicillin trihydrate 500 mg, K clavulanate 125 mg. Per 5 mL
Forte dry susp Co-amoxiclav: Amoxicillin trihydrate 250 mg, K clavulanate 62.5 mg
Medroxyprogesterone acetate
Per Andalan PIL KB active tab Levonorgestrel 0.15 mg, ethinylestradiol 0.03 mg. Per
Andalan Fe active tab Levonorgestrel 0.15 mg, ethinylestradiol 0.03 mg plus placebo tab
contains Fe fumarate 75 mg
Tramadol HCl
Isothipendyl HCl
Fluoxetine HCl
Activated colloidal attapulgite 650 mg, pectin 65 mg
Cyproterone acetate
Mesterolone
Folic acid
Folic acid
Clindamycin HCl
Midazolam
Ketamine HCl
Flumazenil
Ramipril
Sertraline HCl
Cefixime
Mg(OH)2 400 mg, dried Al(OH)3 gel 400 mg, simethicone 100 mg
Ketoconazole
Ketoconazole
Estradiol 1 mg, drospirenone 2 mg
Trimetazidine diHCl
Losartan K
Loratadine
Ranitidine HCl
Loratadine
Metronidazole
Per 100 g Anmum powd Protein 32.8 g, carbohydrate 45.1 g, lactose =22 g, fat 12.3 g,
linoleic acid 0.8 g, a-linolenic acid 0.2 g, food fibre 6.4 g, vit A 640 mcg, vit D3 6.7 mcg,
vit C 80 mg, vit B1 180 mcg, vit B2 1.7 mg, vit B6 230 mcg, pantothenic acid 3 mg, folic
acid 900 mcg, vit B12 3.2 mcg, biotin 32 mcg, choline 130 mg, Ca 1,330 mg, phosphorus
860 mg, Fe 20 mg, Mg 110 mg, Zn 3.6 mg, iodine 94 mcg, Na 410 mg, K 1,350 mg, Cl
1,060 mg. Energy: 420 kCal. Per 100 g Anmum chocolate powd Protein 27.3 g,
carbohydrate 51.9 g, fat 10.3 g, linoleic acid 0.7 g, a-linolenic acid 0.2 g, food fibre 7 g, vit
A 530 mcg, vit D3 5.4 mcg, vit C 66 mg, vit B1 130 mcg, vit B2 1.3 mg, vit B6 190 mcg,
pantothenic acid 2 mg, folic acid 740 mcg, vit B12 2.9 mcg, biotin 28 mcg, choline 110
mg, Ca 1,090 mg, phosphorus 750 mg, Fe 17 mg, Mg 120 mg, Zn 3.4 mg, iodine 77 mcg,
Na 340 mg, K 1,340 mg, Cl 900 mg. Energy: 410 kCal.
Per 32 g Total fat 7 g, protein 7 g, carbohydrate 17 g, Na 55 mg, vit A 120 mcg, vit C 19
mg, vit D3 2 mcg, vit E 1.4 mg, vit K1 8 mcg, vit B1 160 mcg, vit B2 352 mcg, vit B3
1,340 mcg, vit B6 160 mcg, folic acid 17 mcg, vit B12 0.7 mcg, Ca 210 mg, Fe 1.9 mg,
phosphorus 140 mg, Mg 16 mg, Zn 1 mg, iodine 27 mcg, linoleic acid 1,216 mg, linolenic
acid 128 mg, DHA 2.6 mg, arachidonic acid 2.6 mg, gangliosides 2.1 mg, whey protein 4
g, a-lactalbumin 480 mg, sialic acid 72 mg, biotin 5.4 mcg, pantothenic acid 480 mcg, K
260 mg, Cl 130 mg, copper 58 mcg. Energy: 160 kCal.
Per 32 g Total fat 6 g, protein 7 g, carbohydrate 16 g, Na 60 mg, vit A 130 mcg (440 iu),
vit C 13 mg, vit D 1.9 mcg (77 iu), vit E 1.4 mg (2.1 iu), vit B1 154 mcg, vit B2 384 mcg,
vit B3 1,280 mcg, vit B6 128 mcg, folic acid 22 mcg, vit B12 0.7 mcg, Ca 320 mg, Fe 2.6
mg, Mg 18 mg, Zn 1.3 mg, iodine 16 mcg, linoleic acid 800 mg, linolenic acid 96 mg, DHA
1.9 mg, arachidonic acid 1.9 mg, ganglioside 2.1 mg, whey protein 4 g, a-lactalbumin 416
mg, sialic acid 68 mg. Energy: 150 kCal.
Per 100 kCal Protein 2.6 g, whey protein 1.6 g, alpha- lactalbumin (alpha-protein) 176.5
mg, taurine 6.3 mg, nucleotides 4.9 mg, fat 5.5 g, carbohydrate 11 g, lactose 10.5 g,
water 0.5 g, linoleic acid 588.2 mg, linolenic acid 58.8 mg, DHA 7.8 mg, arachidonic acid
11.8 mg, lipid complex 0.9 mg, vit A 92.2 mcg, -carotene 25.5 mcg, vit D 1.2 mcg, vit E
1 mg, vit K 7.6 mcg, vit B1 98 mcg, vit B2 176.5 mcg, vit B3 1,058.8 mcg, vit B5 647.1
mcg, vit B6 58.8 mcg, folic acid 11.6 mcg, vit B12 0.6 mcg, vit C 11.6 mg, biotin 2.2 mcg,
choline 17.6 mg, Ca 96.1 mg, phosphorus 64.7 mg, Mg 12.4 mg, Fe 1.7 mg, manganese
15.3 mcg, copper 82.4 mcg, iodine 82.4 mcg, Na 36.5 mg, K 111.8 mg, Cl 96.1 mg.
Energy: 100 kCal.
Per 33 g Total fat 8 g, protein 5 g, carbohydrate 18 g, Na 75 mg, vit A 5 mcg, vit C 19 mg,
vit D3 2 mcg/82 iu, vit E 2.2 mg/3.2 iu, vit K1 16 mcg, vit B1 132 mcg, vit B2 296 mcg, vit
B3 1,612 mcg, vit B6 132 mcg, folic acid 18 mcg, vit B12 1 mcg, Ca 181 mg, Fe 2.4 mg,
phosphorus 135 mg, Mg 21 mg, Zn 1.3 mg, iodine 32 mcg, manganese 25 mcg, linoleic
acid 855 mg, linolenic acid 99 mg, DHA 13 mg, arachidonic acid 13 mg, lipid complex 1.9
mg, whey protein 2.7 g, a-lactalbumin 329 mg, taurine 10.5 mg, nucleotides 8.2 mg, carotene 43 mcg, biotin 3.2 mcg, choline 30 mg, pantothenic acid 1,283 mcg, K 191 mg,
Cl 161 mg, copper 135 mcg. Energy: 160 kCal.
Per 46 g Total fat 5 g, saturated fat 2.5 g, trans fat, cholesterol 13 mg, linoleic acid
(omega 6) 0.3 g, protein 13 g, total carbohydrate 23 g, fiber 3.4 g, sugar 10 g, Na 170
mg, K 550 mg, vit A 360 mcg, vit B3 8.5 mg, vit C 39 mg, vit D3 2.5 mcg, vit B1 0.7 mg,
vit B2 1.3 mg, vit B3 8.5 mg, vit B5 3.1 mg, vit B6 0.8 mg, vit B9 250 mcg, vit B12 1.4
mcg, Ca 500 mg, Fe 11 mg, Mg 51 mg, phosphorus 396 mg, Zn 1.5 mg, iodine 56 mcg, alinolenic acid (omega 3) 0.08 g, DHA 25 mg, sialic acid 94 mg, lactose 6.3 g, biotin 14
mcg, choline 359 mg, Cl 398 mg. Energy: 190 kCal.
Per 37.5 g Total fat 4.5 g, saturated fat 2.5 g, cholesterol 10 mg, linoleic acid (omega 6)
0.3 g, protein 12 g, total carbohydrate 17 g, fiber 2.5 g, Na 130 mg, K 520 mg, vit A 360
mcg, vit C 39 mg, vit D3 2.5 mcg, vit B1 0.7 mg, vit B2 1.2 mg, vit B3 8.5 mg, vit B5 2.6
mg, vit B6 0.8 mg, vit B9 250 mcg, vit B12 1.4 mcg, Ca 500 mg, Fe 7.4 mg, Mg 40 mg,
phosphorus 316 mg, Zn 1.4 mg, iodine 56 mcg, a-linolenic acid (omega 3) 0.1 g, DHA 25
mg, sialic acid 66 mg, lactose 4.8 g, biotin 8.4 mcg, choline 322 mg, Cl 42 mg. Energy:
160 kCal.
Per 40 g Total fat 5 g, saturated fat 2.5 g, trans fat 6 g, cholesterol 13 mg, linoleic acid
(omega 6) 0.3 g, protein 13 g, carbohydrate 24 g, sugar 10 g, Na 170 mg, K 550 mg, vit A
240 mcg, vit C 30 mg, vit D3 2.5 mcg, vit B1 94 mcg, vit B2 0.7 mg, vit B5 0.7 mg, vit B6
1 mg, folic acid 340 mcg, vit B12 1 mcg, Ca 500 mg, Fe 7.5 mg, Mg 52 mg, phosphorus
337 mg, Zn 1.6 mg, iodine 35 mcg, linolenic acid 0.09 g, DHA 25 mg, gangliosides 4.2
mg, fiber 3 g, sialic acid 98 mg, lactose 9 g, biotin 13 mcg, choline 46 mg, Cl 403 mg.
Energy: 190 kCal.
Per 37.5 g Total fat 4.5 g, saturated fat 2 g, trans fat 4 g, cholesterol 10 mg, linoleic acid
(omega 6) 0.3 g, protein 12 g, carbohydrate 18 g, sugar, Na 135 mg, K 530 mg, vit A 240
mcg, vit C 30 mg, vit D3 2.5 mcg, vit B1 56 mcg, vit B2 0.9 mg, vit B5 1.1 mg, vit B6 1.1
mg, folic acid 340 mcg, vit B12 0.8 mcg, Ca 500 mg, Fe 75 mg, Mg 39 mg, phosphorus
374 mg, Zn 1.6 mg, iodine 35 mcg, linolenic acid 0.09 g, DHA 25 mg, gangliosides 3.4
mg, fiber 2.5 g, sialic acid 80 mg, lactose 7 g, biotin 9 mcg, choline 41 mg, Cl 320 mg.
Energy: 160 kCal.
Norethisterone
Glimepiride
Ketoprofen
Fluoxetine HCl
Per 5 mL syr Psidii folium extr 100 mg, Curcuma domestica rhizoma extr 50 mg, Piper
betle folia 50 mg, Cimicifuga racemosa rhizome extr equiv to 20 mg root & rhizome
Methampyrone
Metamizole Na
Metamizole
Dithranol
Lactobacillus algae ferment, glyceril polymethacrylate, palmitoyl oligopeptide,
phenoxyethanol, methylparaben, lactoferin, hydrolysed wheat protein, thioxanthine
Famotidine
Piracetam
Mg oxide 300 mg, Mg carbonate 50 mg, Na bicarbonate 100 mg, Ca carbonate 150 mg,
bismuth subcarbonate 100 mg
-carotene 6 mg, vit C 100 mg, vit E 25 mg
Cilostazol
Sertraline
Fluoxetine HCl
Per drag Paracetamol 500 mg, dextromethorphan HBr 15 mg, chlorpheniramine maleate 1
mg, phenylpropanolamine HCl 12.5 mg. Per 5 mL syr Paracetamol 250 mg,
dextromethorphan HBr 7.5 mg, chlorpheniramine maleate 1 mg, phenylpropanolamine
HCl 6.25 mg
Lycopene 2 mg, grapeseed extr 40 mg, green tea extr 50 mg, -carotene 6 mg, vit B3 20
mg, vit B6 25 mg, vit B12 6 mcg, vit C 100 mg, vit E 25 mg, Zn 15 mg, selenium 50 mcg
Metamizole Na
Per cap Psidii folium extr 150 mg, Curcuma domestica rhizoma extr 50 mg, Piper betle
folia 50 mg, Cimicifuga racemosa rhizome extr 25 mg, Areca catechu 15 mg
Ticlopidine HCl
Diclofenac free acid
Paclitaxel
Alprazolam
Curcuminoid 2 mg, -carotene 10% 4 mg, vit B1 3 mg, vit B2 2 mg, vit B6 5 mg, vit B12 5
mcg, vit D 100 IU, dexpanthenol 3 mg, Ca pidolate 300 mg, fructooligosaccharides 300
mg
Cyproheptadine HCl
Per 5 mL syr Vit A 5,000 IU, vit B1 3 mg, vit B2 2 mg, vit B6 6 mg, vit B12 5 mcg, vit C 50
mg, vit D 400 IU, nicotinamide 20 mg, lysine HCl 250 mg, d-pantothenol 5 mg, l-glutamic
acid 25 mg. Per 0.6 mL Vit A 2,000 IU, vit C 30 mg, vit D 400 IU, vit B1 1 mg, vit B2 1.2
mg, vit B6 1 mg, vit B12 2 mcg, nicotinamide 10 mg, pantothenol 5 mg, lysine HCl 25 mg
Insulin glulisine
Diethylpropion HCl 75 mg, vit B1 5 mg, vit B2 4 mg, vit B6 2 mg, nicotinamide 30 mg
Desonide
Pregabalin
Irbesartan
Silymarin 150 mg, turmeric 12.5 mg, a- lipoic acid 50 mg, pantothenic acid 5 mg, vit C
125 mg, vit E 50 iu, vit B1 0.75 mg, vit B2 0.85 mg, vit B6 1 mg, vit B12 3 mcg,
niacinamide 10 mg
Glucosamine sulfate 500 mg, chondroitin sulfate 25 mg, MSM 200 mg, vit C 100 mg
Ca (carbonate, hydroxyapatite, citrate) 250 mg, Mg (oxide, amino acid chelate) 100 mg,
vit D3 100 iu, Zn 3.75 mg, vit B6 1 mg, copper 200 mcg, manganese 0.8 mg, isoflavone
2.5 mg, boron 0.4 mg, silicon 200 mcg
Acetylsalicylic acid
Diclofenac K
Leflunomide
Irbesartan
Sulbutiamine
Amoxicillin trihydrate
Diphenhydramine HCl
Vit B12
Etoricoxib
Vit A 0.8 mg, vit B1 1.5 mg, vit B2 1.6 mg, vit B6 2.2 mg, vit B12 2.5 mcg, vit C 100 mg,
vit D 0.01 mg, vit E 10 mg, vit K 0.055 mg, folic acid 1 mg, Fe fumarate 90 mg,
nicotinamide 17 mg, Ca lactate 250 mg, Zn 15 mg, iodine 0.15 mg, Mg 6 mg, biotin 0.03
mg, selenium 0.03 mg
Pamidronate disodium
Norepinephrine
Ibuprofen
Donepezil HCl
Meloxicam
Anastrozole
Aripiprazole
Fondaparinux Na
Trihexyphenidyl HCl
Levofloxacin anhydrate
Royal jelly 6 mg, lyophilized ginseng powd 50 mg, vit A 5,000 iu, vit C 150 mg, vit E 10
mg, vit D 400 iu, vit B1 5 mg, vit B2 5 mg, vit B6 10 mg, vit B12 5 mcg, niacinamide 100
mg, pantothenate K 10 mg, folic acid 100 mcg, copper 0.25 mg, iodine 0.05 mg,
phosphorus 60 mg, manganese 0.25 mg, Mg 0.375 mg, K 0.25 mg, Zn 0.05 mg, rutin 1.25
mg, Ca 1.6 mg, Fe 30 mg
Nimesulide
Exemestane
Metamizole Na 300 mg, vit B1 100 mg, vit B6 50 mg, vit B12 0.1 mg, vit E 30 iu
Ethambutol HCl
Trihexyphenidyl HCl
Artemether
Carteolol
Clopidogrel
Ibuprofen
Diacerein
Vit B6 3 mg, vit C 500 mg, Zn 20 mg, -carotene 4.5 mg, vit B12 3 mcg, vit E 200 IU,
selenium 50 mcg, lecithin 175 mg
Tenoxicam
Meloxicam
Glucosamine 500 mg, chondroitin sulfate 200 mg, MSM 200 mg, Zn 5 mg
Glucosamine 100 mg, chondroitin sulfate 75 mg, MSM 300 mg
Glucosamine HCl 250 mg, chondroitin sulfate 200 mg, vit C 25 mg, Zn 2.5 mg,
manganese 250 mcg, Mg 5 mg
Glucosamine HCl 500 mg, chondroitin sulfate 400 mg, MSM 350 mg, vit C 50 mg,
selenium 12.5 mcg, Zn 2.5 mg, manganese 1 mg
Diacerein
Clobazam
Mefenamic acid
Mefenamic acid
Tranexamic acid
Acetylsalicylic acid
Piperazine hexahydrate
Astaxanthin
Piperazine hexahydrate
Vit B1 50 mg, vit B2 25 mg, vit B6 10 mg, vit B12 5 mcg, vit C 175 mg, nicotinamide 100
mg, Ca pantothenate 25 mg, folic acid 0.5 mg
Per 5 mL Vit B1 8.33 mg, vit B2 4.16 mg, vit B6 1.67 mg, vit B12 8.33 mcg, vit C (as Na
ascorbate) 83.33 mg, nicotinamide 8.33 mg, pantothenol 3.33 mg
Per 5 mL DHA 32 mg, curcuma extr 2 mg, vit A 2,400 IU, vit D3 200 IU, vit C 60 mg, vit B1
4 mg, vit B2 1.2 mg, vit B6 1.2 mg, vit B12 4 mcg, nicotinamide 16 mg, Ca pantothenate
6 mg, choline bitartrate 12 mg, inositol 12 mg, Ca gluconate 300 mg, Ca hypophosphite
20 mg, Na hypophosphite 20 mg, L-lysine HCl 200 mg
Povidone-iodine
Per L Na 130 meq, K 4 meq, Cl 109 meq, Ca 3 meq, acetate 28 meq, anhydrous dextrose
50 g
Per chewtab 400 Magaldrate anhydrous 400 mg, simethicone 40 mg. Per chewtab 800
Magaldrate anhydrous 800 mg, simethicone 40 mg. Per 5 mL susp Magaldrate anhydrous
400 mg, simethicone 30 mg
Mefenamic acid
Vit C
Salbutamol
Acetylsalicylic acid
Aspirin
Acetylsalicylic acid
Salbutamol sulfate
Natural astaxanthin
Natural astaxanthin
Natural astaxanthin 0.07%.
Natural astaxanthin 0.02%, collagen 0.5%.
Ephedrine HCl 12.5 mg, theophylline 125 mg
Acetylsalicylic acid
Natural astaxanthin
Astaxanthin
Tipepidine hibenzate
Alprazolam
Procaterol HCl
Lorazepam
Per chewable tab Al(OH)3 300 mg, Mg(OH)2 300 mg, dimethicone 50 mg. Per 5 mL susp
Al(OH)3 300 mg, Mg(OH)2 300 mg, dimethicone 50 mg
Atorvastatin Ca
Atorvastatin Ca
Atorvastatin
Atracurium besylate
Atracurium besilate
Diclofenac Na
Meloxicam
Ipratropium Br
Per 625 mg FC tab Amoxicillin 500 mg, clavulanic acid 125 mg. Per 1 g FC tab Amoxicillin
875 mg, clavulanic acid 125 mg. Per 5 mL susp Amoxicillin 125 mg, clavulanic acid 31.25
mg. Per 5 mL Forte susp Amoxicillin 250 mg, clavulanic acid 62.5 mg
Per '500' vial Amoxycillin Na 500 mg, clavulanic acid 100 mg. Per '1000' vial Amoxycillin
Na 1000 mg, clavulanic acid 200 mg.
Moclobemide
Co-amoxiclav: Amoxycillin 500 mg, clavulanic acid 125 mg
Azelaic acid
Fluticasone furoate
Per 2 mg/500 mg Rosiglitazone maleate 2 mg, metformin HCl 500 mg. Per 4 mg/500 mg
Rosiglitazone maleate 4 mg, metformin HCl 500 mg
Rosiglitazone maleate
Bevacizumab
Moxifloxacin HCl
Per 6 g sachet Malic acid 700 mg, glucosamine HCl 800 mg, L-arginine HCl 800 mg,
glycine 333 mg, glycyrrhizinic acid 33.3 mg, Zn sulfate 5 mg, Ca pantothenate 3 mg,
pyridoxine 0.6 mg, folic acid 133 mcg, cyanocobalamin 0.5 mcg, Cistus incanus 125 mg
Chloroquine phosphate
Levocetirizine diHCl
Dutasteride
Danazol
Azithromycin dihydrate
Brinzolamide
Azithromycin
-carotene 5,000 IU, vit C 500 mg, vit E 100 IU, selenium 20 mcg, Zn 8 mg
Azithromycin dihydrate
Per tab Ethambutol HCl 250 mg, INH 100 mg, vit B6 5 mg. Per Forte tab Ethambutol HCl
500 mg, INH 200 mg, vit B6 10 mg
Ethambutol
Ciprofloxacin HCl
Cefpirome sulfate
Mupirocin
Per tab Co-trimoxazole: Trimethoprim 80 mg, sulfamethoxazole 400 mg. Per 5 mL syr Cotrimoxazole: Trimethoprim 40 mg, sulfamethoxazole 200 mg. Per forte caplet Cotrimoxazole: Trimethoprim 160 mg, sulfamethoxazole 400 mg
Per 400 mg/80 mg tab Sulfamethoxazole 400 mg, trimethoprim 80 mg. Per 5 mL of 200
mg/40 mg susp Sulfamethoxazole 200 mg, trimethoprim 40 mg. Per 800 mg/160 mg Forte
caplet Sulfamethoxazole 800 mg, rimethoprim 160 mg
Per Adult tab Co-trimoxazole: Trimethoprim 80 mg, sulfamethoxazole 400 mg. Per 5 mL
syr Co-trimoxazole: Trimethoprim 40 mg, sulfamethoxazole 200 mg. Per forte tab Cotrimoxazole: Trimethoprim 160 mg, sulfamethoxazole 800 mg
Per adult tab Co-trimoxazole: Trimethoprim 80 mg, sulfamethoxazole 400 mg. Per forte
caplet Co-trimoxazole: Trimethoprim 160 mg, sulfamethoxazole 800 mg. Per 5 mL syr Cotrimoxazole: Trimethoprim 40 mg, sulfamethoxazole 200 mg
Mupirocin
Coenzyme Q10 30 mg, safflower oil 181.7 mg, purified fish oil (contains DHA) 5 mg, vit E
5 mg, folic acid 0.12 mg, vit B6 1 mg, nicotinamide 1 mg, vit B12 1 mcg
Gentamicin sulfate
Carbamazepine
Cefpodoxime proxetil
Ciprofloxacin
Ciprofloxacin HCl
Entecavir
Flunarizine
Oxcarbazepine
Ciclopiroxolamine
Per 30 mL Strobilanthes crispus leaf extr 0.3 g, Sonchus arvensis leaf extr 3 g
Cefotaxime Na
Per g Dexamethasone 0.4 mg, clotrimazole 10 mg
Bisoprolol fumarate
Lactoferrin 100 mg, colostrum bovine 100 mg, Echinacea angustifolia 50 mg, vit C 50 mg,
Zn picolinate 10 mg
Per 100 g Protein 10.8 g, fat 25 g, carbohydrate 58.8 g, moisture =2.7 g, linolenic acid
3,650 mg, a-linolenic acid 365 mg, arachidonic acid 51.8 mg, DHA 25.9 mg, fiber 1.5 g,
fructo-oligosaccharide 1.5 g, lactoferrin 48.9 mg, vit A 440 mcg, -carotene 200 mcg, vit
D3 6.1 mcg, vit E 12 mg a-TE, vit K1 33 mcg, vit B1 0.4 mg, vit B2 0.89 mg, vit B3 3.6 mg,
vit B5 2,700 mcg, vit B6 0.29 mg, vit B9 75 mcg, vit B12 1.8 mcg, vit C 61 mg, biotin 13
mcg, choline 100 mg, inositol 20 mg, L-carnitine 7 mg, taurine 36 mg, Ca 310 mg,
phosphorus 170 mg, Mg 32 mg, Fe 5 mg, Zn 3.2 mg, manganese 48 mcg, copper 315
mcg, selenium 10 mcg, iodium 71 mcg, Na 135 mg, K 445 mg, Cl 300 mg
Per 235 mL Total fat 6 g, saturated fat 1.5 g, cholesterol 15 mg, linoleic acid 338 mg,
protein 6 g, carbohydrate 28 g, fiber 1 g, soluble fiber 1 g, sugar 24 g, lactose 18 g,
sucrose 4 g, Na 75 mg, K 300 mg, vit A 25%, vit D3 40%, vit E 30%, vit K1 40%, vit C
40%, vit B1 40%, vit B2 70%, vit B3 35%, vit B5 40%, vit B6 40%, vit B9 40%, vit B12
80%, Ca 45%, P 45%, Mg 30%, Fe 40%, Zn 45%, iodine 45%, selenium 30%, probiotic FOS
& GOS 1.4 g, DHA 9 mg, AA 9 mg, phospholipid 68 mg, a-linoleic acid 52 mg, choline 24
mg, taurine 3.4 mg, L-carnitine 3.3 mg, biotin 5.9 mcg, inositol 12 mg, Cl 200 mg, copper
155 mcg. Energy: 190 kCal
Per 235 mL Total fat 6 g, saturated fat 2.5 g, cholesterol 20 mg, linolenic acid 104 mg,
protein 7 g, carbohydrate 28 g, fiber 1 g, soluble fiber 1 g, total sugar 23 g, lactose 18 g,
sucrose 4 g, fructose 1 g, Na 90 mg, K 380 mg, vit A 30%, vit D3 45%, vit E 30%, vit C
40%, vit B1 45%, vit B2 40%, vit B3 30%, vit B5 20%, vit B6 35%, vit B9 30%, vit B12
30%, Ca 35%, P 35%, Mg 10%, Fe 45%, Zn 35%, iodium 40%, selenium 45%, prebiotic
FOS 0.14 g, prebiotic GOS 1.3 g, DHA 9 mg, AA 66 mg, a-linoleic acid 35 mg, choline 23
mg, L-carnitine 2.9 mg, biotin 6.5 mcg, inositol 16 mg, Cl 251 mg, copper 161 mg. Energy:
190 kCal
Per 100 g Vegetable fat 25.5 g, linoleic acid 3.7 g, a-linolenic acid 0.37 g, protein 11.2 g,
casein 4.5 g, whey protein 6.7 g, carbohydrate 58.9 g, lactose 33.7 g, dextrin (including
glucose) 25.2 g, moisture 2 g, vit, minerals, taurine, L-carnitine. Energy: 510 kCal.
Per 100 g Carbohydrate 55.9 g, fat 27.3 g, protein 12.4 g, moisture =3 g, vit A 633 mcg,
-carotene 197 mcg, vit D3 10 mcg, vit E 5.5 mg-a-TE, vit K1 36 mcg, vit B1 0.41 mg, vit
B2 1 mg, niacinamide 3.1 mg, pantothenic acid 2.1 mg, vit B6 0.34 mg, folic acid 52 mcg,
vit B12 1 mcg, biotin 10 mcg, vit C 52 mg, L-carnitine 11 mg, choline 67 mg, inositol 23
mg, taurine 31 mg, L-cystine HCl 170 mg, Na 160 mg, K 465 mg, Cl 335 mg, phosphorus
205 mg, Fe 6.7 mg, Zn 5.2 mg, copper 410 mcg, manganese 90 mcg, iodium 52 mcg
Per 100 mL Protein 1.4 g, fat 3.4 g, linoleic acid 474 mg, a-linolenic acid 50 mg, DHA 6.7
mg, AA 6.7 mg, phospholipid 42 mg, carbohydrate 7.8 g, lactose 7 g, fiber 0.55 g, fructooligosaccharides 0.04 g, galacto-oligosaccharides 0.36 g, L-carnitine 1.7 mg, taurine 5.2
mg, vit A 63 mcg-RE, -carotene 25 mcg, vit D3 0.84 mcg, vit E 1.3 mg a-TE, vit K1 6.4
mcg, vit B1 63 mcg, vit B2 159 mcg, vit B3 0.53 mg, vit B5 0.46 mg, vit B6 53 mcg, vit B9
13 mcg, vit B12 0.38 mcg, vit C 14 mcg, biotin 3.3 mcg, choline 16 mg, inositol 6.5 mg,
Ca 52 mg, P 29 mg, Mg 6.1 mg, Fe 1.1 mg, Zn 0.72 mg, manganese 9.5 mcg, copper 44
mcg, selenium 1.6 mcg, iodine 13 mcg, Na 12 mg, K 82 mg, Cl 50 mg. Energy: 70 kCal
Per 100 mL Total fat 6 g, linoleic acid 833 mg, protein 5 g, carbohydrate 17 g, fiber 1 g,
soluble fiber 1 g, lactose 14 g, Na 60 mg, K 230 mg, vit A 45%, vit C 75%, vit D3 55%, vit
E 50%, vit K 95%, vit B1 30%, vit B2 80%, vit B3 25%, vit B5 50%, vit B6 30%, vit B9 40%,
vit B12 100%, Ca 40%, P 40%, Mg 30%, Fe 25%, iodine 30%, Zn 30%, selenium 25%,
fructo-oligosaccharides 0.08 g, galacto-oligosaccharides 0.73 g, DHA 12 mg, AA 12 mg,
phospholipid 81 mg, a-linolenic acid 87 mg, choline 34 mg, taurine 10 mg, L-carnitine 4.9
mg, biotin 5.9 mcg, inositol 14 mg, Cl 146 mg, copper 96 mcg. Energy: 140 kCal
Per 100 mL Protein 1.7 g, fat 3.6 g, carbohydrate 7.5 g, moisture =3 g, linolenic acid 555
mg, a-linolenic acid 53 mg, AA 7.3 mg, DHA 7.3 mg, vit A 63 mcg-RE, vit D3 0.83 mcg, vit
E 0.94 mg a-TE, vit K1 3.4 mcg, vit B1 41 mcg, vit B2 92 mcg, vit B3 0.29 mg, vit B5 0.291
mg, vit B6 32 mcg, vit B9 7 mcg, vit B12 0.1 mcg, vit C 9.4 mg, biotin 1.1 mcg, choline
7.5 mg, inositol 3 mg, L-carnitine 1.3 mg, taurine 3.8 mg, Ca 44 mg, P 24 mg, Mg 4.5 mg,
Fe 0.53 mg, Zn 0.52 mg, manganese 9.4 mcg, copper 43 mcg, iodium 7.5 mcg, Na 23 mg,
K 53 mg, Cl 41 mg. Energy: 69 kCal
Rebamipide
Citicoline
Per 5 mL Thiamine HCl 5 mg, riboflavin sodium phosphate 2 mg, nicotinamide 20 mg,
pyridoxol HCl 2.5 mg, vit B12 3 mcg, vit C 60 mg, vit D3 1,000,000 iu/g, vit D 400 iu, Dpantothenyl alcohol 3 mg, inulin 500 mg, tricalcium phosphate 100 mg
Per 2 mL amp Vit B1 10 mg, vit B2 4 mg, nicotinamide 40 mg, d(+) pantothenol 6 mg, vit
B6 4 mg, vit B12 8 mcg, d(+) biotin 0.5 mg
Per 10 mL Vit A 4,000 IU, vit B1 1.4 mg, vit B2 1.7 mg, vit B3 18 mg, vit B6 0.7 mg, vit C
35 mg, vit D 400 IU, vit E 3 mg, cod liver oil 200 mg
Per 5 mL Vit B1 5 mg, vit B2 2 mg, vit B3 20 mg, vit B5 3 mg, vit B6 2.5 mg, vit B12 3
mcg, L-lysine HCl 375 mg
Per 5 mL Becombion syr Vit B1 5 mg, vit B2 2 mg, vit B3 20 mg, vit B5 3 mg, vit B6 2.5
mg, vit B12 3 mcg. Per mL Becombion drops Vit B1 2.5 mg, vit B2 1 mg, vit B3 10 mg, vit
B5 1.5 mg, vit B6 1 mg, vit B12 2 mcg, D-biotin 0.125 mg, ethanol 1.57%. Per Becombion
Forte sugar-coated tab Vit B1 15 mg, vit B2 15 mg, vit B3 50 mg, vit B5 25 mg, vit B6 10
mg, vit B12 10 mcg, D (+) biotin 0.15 mg
Per FC caplet Vit B1 50 mg, vit B2 25 mg, vit B6 10 mg, vit B12 5 mcg, vit C 500 mg,
nicotinamide 100 mg, pantothenic acid 18.4 mg
Vit E 30 IU, vit C 750 mg, vit B1 15 mg, vit B2 15 mg, vit B6 20 mg, vit B12 12 mcg, folic
acid 400 mcg, pantothenic acid 20 mg, Zn 22.5 mg, niacin 100 mg
Beclomethasone dipropionate
Fe sulfate 80 mg, folic acid 500 mcg, Zn sulfate monohydrate 61.8 mg
Vit C
Activated charcoal
Amoxicillin trihydrate
Per Bellamox caplet Co-amoxiclav: Amoxicillin trihydrate 500 mg, clavulanate K (equiv w/
clavulanate acid) 125 mg. Per 5 mL Bellamox syr Co-amoxiclav: Amoxicillin trihydrate 125
mg, clavulanate K (equiv w/ clavulanate acid) 31.25 mg. Per 5 mL Bellamox Forte syr Coamoxiclav: Amoxicillin trihydrate 250 mg, clavulanate K (equiv w/ clavulanate acid) 62.5
mg
Per drag Belladonna total alkaloid 0.1 mg, ergotamine tartrate 0.3 mg, phenobarb 20 mg
Tramadol HCl
Per 5 mL Diphenhydramine HCl 12.5 mg, ammon Cl 100 mg, K guaiacolsulfonate 30 mg,
menthol 1 mg, ethanol 4%
Per 5 mL Dextromethorphan HBr 7.5 mg, diphenhydramine HCl 12.5 mg, ammon Cl 100
mg, K guaiacolsulfonate 30 mg, ethanol 4%
Diphenhydramine HCl
Per 5 mL Diphenhydramine HCl 12.5 mg, ammon Cl 125 mg, Na citrate 50 mg, menthol 1
mg, alcohol 5%
Per 5 mL Diphenhydramine HCl 5 mg, dextromethorphan HBr 7.5 mg, phenylephrine HCl
5 mg
Indomethacin
Povidone-iodine
Sucralfate
Metformin HCl
Pheniramine maleate
Mg trisilicate 300 mg, Al(OH)3 gel 300 mg, papaverine HCl 10 mg, chlordiazepoxide HCl 5
mg, vit B1 2 mg, vit B2 1 mg, vit B6 500 mcg, vit B12 10 mcg, nicotinamide 5 mg
Cimetidine
Betamethasone
Betamethasone valerate 0.1%, gentamicin sulfate 0.1%
Benzoyl peroxide
Monobenzone
Dexpanthenol
Betamethasone dipropionate 0.5 mg, salicylic acid 30 mg
Betamethasone dipropionate
Ambroxol HCl
Per tab/5 mL Al(OH)3 dried gel 261.44 mg, Mg(OH)2 200 mg, dimethicone 40 mg
Clotrimazole
Primary dried yeast 100 mg, vit B1 2 mg, vit B2 2 mg, vit B6 2 mg, vit B12 2 mcg,
niacinamide 15 mg, Ca pantothenate 5 mg
Ciprofloxacin
Per film-coated tab Vit B1 7.5 mg, vit B2 8.5 mg, vit B3 50 mg, vit B5 23 mg, vit B6 10
mg, vit B12 10 mcg, vit C 500 mg, biotin 150 mcg, folic acid 400 mcg, Mg 100 mg, Ca 100
mg, Zn 10 mg, ginseng extr 50 mg. Per effervescent tab Vit B1 15 mg, vit B2 15 mg, vit
B3 50 mg, vit B5 23 mg, vit B6 10 mg, vit B12 10 mcg, vit C 500 mg, biotin 150 mcg, folic
acid 400 mcg, Mg 100 mg, Ca 100 mg, Zn 10 mg, ginseng extr 50 mg
Per actuation Ipratropium Br 0.021 mg, fenoterol HBr 0.05 mg
Fenoterol HBr
Per tab Bilberry dry extr 80 mg, retinol 1,600 IU, vit E 40 mg, -carotene 5 mg. Per
Dispersible tab Bilberry dry extr 40 mg, retinol 800 IU, vit E 20 mg, -carotene 2.5 mg
Clobetasol propionate
Mecobalamin
Pancreatin 112.5 mg, ox bile 30 mg, dimethylpolysiloxane 25 mg, vit B1 10 mg, vit B2 5
mg, vit B6 5 mg, vit B12 5 mcg, niacinamide 10 mg, Ca pantothenate 5 mg
Hydroxyzine diHCl
Atenolol
Povidone-iodine
Povidone-iodine
Povidone-iodine
Povidone iodine
Interferon -1b
Ofloxacin
Per 5 mL Vit B1 1 mg, vit B2 1.2 mg, vit B6 1.4 mg, vit B12 1.4 mcg, d-pantothenol 5 mg,
niacinamide 13 mg, vit C 45 mg, -carotene 4.2 mg, vit D 10 mcg
Per mL Betamethasone dihydrogen phosphate disodium 1 mg, gentamicin sulfate 5 mg
Lansoprazole
Ambroxol HCl
Betamethasone dihydrogen phosphate disodium
Bisoprolol fumarate
Cetirizine diHCl
Betahistine diHCl
Per FC caplet Chitosan 250 mg, Garcinia cambogia extr 250 mg, L-carnitine 50 mg,
chromium picolinate 50 mcg, vit C 25 mg
Betamethasone
Betamethasone valerate 0.1%, neomycin sulfate 0.5%
Betahistine mesylate
Per g Salicylic acid 5 mg, Zn oxide 10 mg, menthol 5 mg, triclosan 1 mg, Al chlorohydrate
30 mg
Betamethasone valerate 0.1%, neomycin sulfate 0.5%
Betamethasone valerate
Betamethasone valerate
Betaxolol HCl
Vit B1 disulfide 100 mg, vit B6 HCl 200 mg, vit B12 200 mcg
Ceftriaxone
Per Bexce caplet Vit B1 15 mg, vit B2 10 mg, vit B6 5 mg, vit B12 10 mcg, vit C 500 mg,
Ca pantothenate 20 mg, nicotinamide 100 mg. Per 5 mL Bexce syr Vit B1 10 mg, vit B2 6
mg, vit B6 10 mg, vit B12 10 mcg, vit C 100 mg, panthenol 10 mg, nicotinamide 50 mg.
Per mL Bexce Plus drops Vit A 3,000 iu, vit B1 1 mg, vit B2 1.2 mg, vit B6 0.8 mg, vit C 50
mg, nicotinamide 16 mg, vit B12 3 mcg, panthenol 5 mg, vit D 400 iu, vit E 10 iu
Per Bexicom caplet Vit B1 15 mg, vit B2 10 mg, vit B6 10 mg, vit B12 100 mcg, vit C 500
mg, vit E 20 mg, Ca pantothenate 20 mg, niacinamide 50 mg. Per Bexicom-Z caplet Vit B1
15 mg, vit B2 15 mg, vit B6 20 mg, Ca pantothenate 20 mg, nicotinamide 100 mg, vit B12
12 mcg, folic acid 400 mcg, vit C 750 mg, vit E 30 IU, Zn 22.5 mg
Vit B1 mononitrate 15 mg, vit B2 10 mg, vit B6 10 mg, vit B12 100 mcg, vit C 500 mg, vit
E 20 mg, Ca pantothenate 20 mg, nicotinamide 50 mg, L-carnitine tartrate 100 mg
Metronidazole
Bisacodyl
Clarithromycin
Cefadroxil monohydrate
Vit C
Cefoperazone Na
Azithromycin
Ampicillin
ATP 20 mg, vit B1 100 mg, vit B6 200 mg, vit B12 200 mcg, vit E 30 mg
Arabinoxylan derivatives
Per 5 mL Vit A 3,000 iu, vit B1 3 mg, vit B2 2 mg, vit B6 1 mg, vit B12 5 mcg, vit C 30 mg,
vit D3 600 iu, niacinamide 20 mg, Ca gluconate 300 mg, Ca hypophosphite 10 mg, Ca
pantothenate 5 mg, Na hypophosphite 10 mg, Ca glycerophosphate 100 mg
Cefotaxime Na
Cefepime
Cefadroxil monohydrate
Natural vit E
Fe fumarate equiv to Fe 5 mg, ascorbic acid 50 mg, folic acid 250 mcg, cyanocobalamin
10 mcg
Per 5 mL Echinacea extr 250 mg, curcuminoid 2 mg, fructooligosaccharide 300 mg,
taurine 100 mg, Phyllanthus niruri extr 25 mg
Lactobacillus reuteri prodentis
Paracetamol
Lincomycin HCl
Per chewable tab Vit A 1,500 IU, vit B1 1.4 mg, vit B2 1.6 mg, vit B6 1.6 mg, vit B12 3 mg,
vit C 60 mg, vit D3 400 IU, vit E 5 mg, niacinamide 10 mg, Ca pantothenate 3 mg, L-lysine
HCl 100 mg
Arachidonic acid 60 mg, DHA 20 mg, vit A 1,500 iu, vit B1 1 mg, vit B2 0.8 mg, vit B6 0.8
mg, vit B12 3 mcg, vit C 50 mg, vit D3 400 iu, D-panthenol 3 mg, niacinamide 10 mg, Llysine HCl 100 mg
Per film-coated caplet Methampyrone 500 mg, vit B1 50 mg, vit B6 100 mg, vit B12 100
mg
Vit B1 100 mg, vit B6 200 mg, vit B12 300 mcg
Hyaluronic acid
Fe fumarate 360 mg, folic acid 1.5 mg, vit B12 15 mcg, vit C 75 mg, vit D3 400 IU, Ca
carbonate 200 mg
Per drag Vit B1 disulfide 100 mg, vit B6 200 mg, vit B12 200 mcg. Per 3 mL amp Vit B1
100 mg, vit B6 100 mg, vit B12 1,000 mcg, lidocaine HCl 15 mg
Per 5 mL Vit B1 1 mg, vit B2 2 mg, vit B6 2 mg, vit B3 6 mg, vit D3 100 iu, vit E 3 mg, Ca
pantothenate 3 mg, Ca hypophosphite 150 mg, lysine HCl 200 mg
a-arbutin 3%, L-ascorbic acid 2-glucoside 2%, disodium edetate, Na metabisulfite, Na
citrate, hydroxyethyl cellulose, methyl hydroxybenzoate, propylene glycol, glycerol, aloe
vera gel, polydimethylsiloxanic, citric acid, ethanol
Propolis extr
Cefpirome
Hydroquinone
Per softcap Co-enzyme Q10 100 mg, L-carnitine 500 mg, vit E 100 IU, soya bean oil 323.1
mg
Cefoperazone
Dry bilberry extr 100 mg, Tribulus terrestris extr 100 mg, natural -carotene 5 mg
Tribulus terrestris L
Fe gluconate 250 mg, manganese sulfate 200 mcg, copper sulfate 200 mcg, vit C 50 mg,
folic acid 1 mg, cyanocobalamin w/ intrinsic factor 7.5 mcg, sorbitol 25 mg
Per mL Tetanus antitoxin 1,500 IU, phenol 2.5 mg
Per mL Agkistrodon rhodostoma =10 LD50, Bungarus fasciatus =25 LD50, Naja sputatrix
=25 LD50, phenol 2.5 mg
Roxithromycin
Per tab Plasmolysed herbal yeast, corn starch. Per liqd Plasmolysed herbal yeast, malt
extr, natural honey, orange juice
Colostrum bovine 300 mg, DHA 200 mg, cod liver oil 10 mg, lysine HCl 200 mg, vit A
2,000 IU, vit D 200 IU, vit B1 0.6 mg, vit B2 0.15 mg, vit B6 0.6 mg, vit B12 1.5 mcg,
nicotinamide 5 mg, dexpanthenol 2.5 mg, Zn picolinate 5 mg
Benfotiamine
Thiamphenicol
Ceftriaxone Na
Per 5 mL Vit A 5,000 iu, vit B1 3 mg, vit B2 1 mg, vit C 50 mg, vit D3 1,000 iu,
niacinamide 20 mg
Ceftriaxone diNa
Per oral gel Polyglyceryl methacrylate, maltitol, sorbitol, xylitol, aqua, glucose,
hydroxyethylcellulose, colostrum, K thiocyanate, glucose oxidase, lactoperoxidase,
lysozyme, lactoferrin, Aloe barbadensis leaf powd. Per mouthspray Aqua, xylitol,
hydroxyethylcellulose, sorbitol, maltitol, Na benzoate, Na methylparaben, K sorbate, KCl,
citric acid, NaCl, Na propylparaben, dipotassium phosphate, Na monofluorophosphate,
saccharin Na, CaCl2, lactoperoxidase, colostrum, MgCl2. Per toothpaste Sorbitol, silica,
glycerin, xylitol, Na monofluorophosphate, lactoperoxidase, colostrum, lactoferrin,
lysozyme, aqua. Per mouthwash Aqua, propylene glycol, xylitol, Na monofluorophosphate,
poloxamer, colostrum, lactoferrin, lysozyme, lactoperoxidase, aloe barbadensis powd
Ceftazidime pentahydrate
Bisoprolol fumarate
Bisoprolol fumarate
Dextromethorphan HBr
Bromhexine HCl
Per 5 mL Bromhexine HCl 4 mg, paracetamol 150 mg, chlorpheniramine maleate 2 mg,
phenylephrine HCl 5 mg
Bromhexine HCl
Bisoprolol fumarate
Bisoprolol
Bisoprolol fumarate
Bisoprolol hemifumarate
Methylergometrine maleate
Bleomycin
Bleomycin HCl
Nicardipine HCl
Crataegus oxyacantha (hawthorn) 50 mg, ginkgo biloba 5 mg, garlic oil 150 mg, Melissa
officinalis (lemon balm) 10 mg, Morinda citrifolia (noni) 30 mg, vit E 30 IU
Candesartan cilexetil
Carvedilol
Per Blue Cap cream Zn pyrithione 0.2%, moisture base 50 g. Per Blue Cap shampoo Zn
pyrithione 1%, menthol 0.25%. Per Blue Cap spray Zn pyrithione 0.2%, isopropyl
myristate.
Hydrolyzed vegetable protein 111 mg, fumaric acid 36 mg, vit C 10 mg, lettuce extr 150.5
mg, Ca pantothenate 1 mg, vit B6 0.33 mg, folic acid 33 mcg, vit B12 0.16 mcg, green tea
extr 7.5 mg, blueberry extr 334 mg, Zn sulphate 10 mg
Per 100 g Protein 11 g, fat 27 g, carbohydrate 57.1 g, linoleic acid 3 g, a-linolenic acid 0.4
g, DHA 30 mg, choline 80 mg, arachidonic acid (AA) 30 mg, taurine 40 mg, phospholipids
230 mg, inositol 50 mg, L-carnitine 10 mg, lactoferrin 50 mg, lactulose 300 mg, vit A
1,800 IU, vit C 65 mg, vit D 350 IU, vit E 8.8 IU, vit K 25 mcg, vit B1 0.4 mg, vit B2 0.7 mg,
vit B3 4.2 mg, vit B5 3 mg, vit B6 0.3 mg, vit B9 100 mcg, vit B12 1.5 mcg, biotin 10 mcg,
-carotene 45 mcg, Na 160 mg, K 540 mg, Ca 650 mg, phosphorus 210 mg, Mg 45 mg, Fe
6 mg, manganese 30 mcg, selenium 7 mcg, Zn 3.3 mg, iodine 65 mcg, Cl 330 mg. Energy
515 kCal
Per 100 g Protein 11.7 g, fat 27 g, carbohydrate 56 g, carnitine 10 mg, taurine 40 mg,
cystein 200 mg, nucleotide 20 mg, arachidonic acid (AA) 100 mg, DHA 50 mg, a-linolenic
acid 400 mg, linoleic acid 3 g, phospholipids 600 mg, lactulose 300 mg, vit A 1,800 IU, vit
D 352 IU, vit E 8.8 IU, vit K 25 mcg, vit B1 0.4 mg, vit B2 0.7 mg, vit B3 4.2 mg, vit B5 3
mg, vit B6 0.3 mg, vit B9 100 mcg, biotin 10 mcg, choline 80 mg, inositol 50 mg, Ca 380
mg, phosphorus 210 mg, Mg 45 mg, Fe 6 mg, Zn 3.3 mg, manganese 45 mcg, copper 320
mcg, iodine 65 mcg, Na 160 mg, K 540 mg, Cl 330 mg, selenium 7 mcg. Energy 514 kCal
Per 100 g Protein 11 g, fat 27 g, carbohydrate 57.1 g, linoleic acid 3 g, a-linolenic acid 0.4
g, DHA 50 mg, choline 80 mg, arachidonic acid (AA) 100 mg, taurine 40 mg, phospholipid
230 mg, a-lactalbumin 1.8 g, inositol 50 mg, L-carnitine 10 mg, nucleotide 20 mg,
lactoferrin 50 mg, cystein 0.2 g, lactulose 300 mg, vit A 1,800 IU, vit C 100 mg, vit D 350
IU, vit E 8.8 IU, vit K 25 mcg, vit B1 0.4 mg, vit B2 0.7 mg, vit B3 4.2 mg, vit B5 3 mg, vit
B6 0.3 mg, vit B9 100 mcg, vit B12 1.5 mcg, biotin 10 mcg, -carotene 45 mcg, Na 160
mg, K 540 mg, Ca 380 mg, phosphorus 210 mg, Mg 45 mg, Fe 6 mg, manganese 30 mcg,
selenium 7 mcg, Zn 3.3 mg, iodine 65 mcg, Cl 330 mg. Energy 515 kCal
Per 100 g Protein 12.6 g, fat 27 g, carbohydrate 55.5 g, ash 2.2 g, moisture 2.7 g,
lactoferrin 50 mg, -carotene 45 mcg, lactulose 300 mg, mucin 10 mg, taurine 20 mg, vit,
minerals. Energy: 515 kCal
Paracetamol 600 mg, caffeine 50 mg
Paracetamol 350 mg, ibuprofen 200 mg, caffeine 50 mg
Per caplet Paracetamol 500 mg, pseudoephedrine HCl 30 mg, dextromethorphan HBr 12
mg. Per 5 mL syr Paracetamol 150 mg, pseudoephedrine HCl 10 mg, dextromethorphan
HBr 4 mg
Per caplet Paracetamol 500 mg, pseudoephedrine HCl 30 mg, glyceryl guaiacolate 50 mg,
bromhexine HCl 8 mg. Per 5 mL syr Paracetamol 150 mg, pseudoephedrine HCl 10 mg,
glyceryl guaiacolate 50 mg, bromhexine HCl 2.6 mg
Paracetamol
Paracetamol 350 mg, propyphenazone 150 mg, caffeine 50 mg
Acetylsalicylic acid 80 mg
Paracetamol
Paracetamol 100 mg, pseudoephedrine HCl 7.5 mg, glyceryl guaiacolate 20 mg,
bromhexine HCl 2 mg, chlorpheniramine maleate 0.5 mg
Per 5 mL Pseudoephedrine HCl 7.5 mg, chlorphenamine maleate 0.5 mg
Ibandronic acid
Disodium clodronate
Microcrystalline hydroxyapatite
Glucosamine HCl 250 mg, chondroitin sulfate 400 mg, vit C 100 mg, vit E 10 mg,
manganese 0.25 mg, Zn 2.5 mg, Ca 100 mg, selenium (yeast) 5 mcg
Glucosamine HCl 750 mg, chondroitin sulfate 200 mg, MSM 200 mg
Glucosamine HCl 500 mg, isoflavone 50 mg
Alfacalcidol
MSM 300 mg, chondroitin sulfate 200 mg, glucosamine sulfate 250 mg, vit B1 5 mg, vit
B6 25 mg, Mg 0.5 mg, selenium 6 mcg
Ibandronic acid
Citicoline
Citicoline
Per 5 mL Colostrum bovine 300 mg, DHA 250 mg, arachidonic acid 50 mg, -carotene 4
mg, vit B1 0.5 mg, vit B2 0.5 mg, vit B6 0.5 mg, nicotinamide 5 mg, vit B12 1 mcg,
dexpanthenol 3 mg, vit D 100 IU, Ca citrate 250 mg
Tobramycin
Citicoline
Cinnarizine
NaCl
Piracetam
Terbutaline sulfate
Ticagrelor
Ceftriaxone disodium
Per Bromifar caplet Bromhexine HCl. Per Bromifar Plus tab Bromhexine HCl 8 mg,
guaiphenesin 100 mg. Per Bromifar Plus syr Bromhexine HCl 4 mg, guaiphenesin 100 mg
Ambroxol
Per 5 mL Ephedrine HCl 8 mg, glyceryl guaiacolate 50 mg, paracetamol 200 mg,
chlorpheniramine maleate 2.5 mg
Carbocisteine
Theophylline
Ambroxol HCl
Salbutamol sulfate
Ambroxol HCl
Salbutamol
Bromhexine HCl
Theophylline
Ceftriaxone disodium
Ceftriaxone disodium
Ambroxol HCl
Ibuprofen
Bupivacaine HCl
Budesonide
Theophylline
Amoxicillin
Ibuprofen
Bupivacaine
Silver sulfadiazine
Hyoscine-N-butylbromide
Hyoscine-N-butylbromide
Buspirone HCl
Bupivacaine
Bupivacaine
Salbutamol
Per 5 mL Paracetamol 125 mg, glyceryl guaiacolate 30 mg, ammon Cl 90 mg, Na citrate
50 mg, chlorpheniramine maleate 2 mg
Ca carbonate 400 mg, Mg 75 mg, vit C 1,000 mg, vit D3 50 IU, vit B6 3,000 mcg, Zn 2,500
mcg
Amlodipine besylate, atorvastatin Ca (crystalline form)
Coral Ca 500 mg, natural soy isoflavone 20 mg, vit D3 200 IU, vit K1 25 mcg, Mg 100 mg,
Zn 5 mg, boron 1 mg
Hydrocortisone acetate
Paracetamol
Ca citrate 300 mg, vit D3 50 IU, isoflavone 50 mg, Zn 5 mg, Mg 15 mg, manganese 2 mg,
vit C 25 mg
Nifedipine
Per tab Dibasic Ca phosphate 200 mg, Ca lactate 100 mg, vit C 25 mg, vit D3 100 IU. Per
3 mL syr Dibasic Ca phosphate 200 mg, Ca gluconate 200 mg, d-panthenol 3 mg, vit A
2,000 IU, vit B1 2 mg, vit B2 750 mcg, vit B6 300 mcg, vit B12 3 mcg, vit C 25 mg, vit D3
400 IU, nicotinamide 6 mg, folic acid 100 mcg.
Per 5 mL Vit B12 5 mcg, vit B1 3 mg, vit B2 1.25 mg, vit B6 0.5 mg, vit C 50 mg, vit A
3,000 iu, vit D 400 iu, nicotinamide 10 mg, Ca pantothenate 5 mg, Ca 77 mg, phosphorus
25 mg, DHA 10 mg, lysine 125 mg
Ca hydrogen phosphate dihydrate 500 mg, vit D3 200 IU
Per tab Isoflavone 50 mg (including genisteine & diadzeine from soy isoflavone 40% 125
mg), elemental Ca 300 mg, elemental Mg 75 mg, vit D3 200 IU
Dibasic Ca phosphate 500 mg, DHA 100 mg, omega-3 fatty acids 20 mg, thiamine HCl 2
mg, pyridoxine HCl 1.5 mg, cyanocobalamin 5 mcg, vit D3 400 IU, nicotinamide 10 mg
Per 30 g Fat 0.1 g, carbohydrate 17 g, protein 8 g, vit A, vit D3, vit E, vit K1, vit C, Ca,
phosphorus, Mg, Fe, vit B1, vit B2, niacin, vit B6, folic acid, vit B12, Zn, iodine, selenium,
Na. Energy: 100 kCal.
Per 30 g (Plain) Total fat 2 g, protein 8 g, total carbohydrate 16 g, fiber 1 g, Na 120 mg, K
370 mg, vit A 793 iu, vit D3 122 iu, vit E 5.1 mg, vit C 19 mg, vit B1 0.4 mg, vit B2 0.5
mg, niacin 5 mg, vit B6 0.5 mg, folic acid 102 mcg, vit B12 1.5 mcg, Ca 600 mg,
phosphorus 265 mg, Mg 46 mg, Fe 4 mg, Zn 1.4 mg, iodine 8 mcg, selenium 3.2 mcg.
Energy: 110 kCal. Per 35 g (Cokelat) Total fat 2 g, protein 7 g, total carbohydrate 22 g,
fiber 2 g, Na 105 mg, K 400 mg, vit A 756 iu, vit D3 149 iu, vit E 6.3 mg, vit C 24 mg, vit
B1 0.4 mg, vit B2 0.6 mg, niacin 5.6 mg, vit B6 0.5 mg, folic acid 100 mcg, vit B12 1.6
mcg, Ca 600 mg, phosphorus 238 mg, Mg 55 mg, Fe 4.3 mg, Zn 1.1 mg, iodine 8.2 mcg,
selenium 2.5 mcg. Energy: 130 kCal.
Per 30 g (Plain) Total fat 1 g, protein 8 g, total carbohydrate 17 g, fiber 2 g, Na 115 mg, K
380 mg, vit A 708 iu, vit D3 121 iu, vit E 5 mg, vit C 21 mg, vit B1 0.4 mg, vit B2 0.5 mg,
niacin 4.4 mg, vit B6 0.5 mg, folic acid 105 mcg, vit B12 1.5 mcg, Ca 500 mg, phosphorus
241 mg, Mg 54 mg, Fe 4.2 mg, Zn 1 mg, iodine 7.8 mcg, selenium 3.3 mcg. Energy: 110
kCal. Per 35 g (Cokelat) Total fat 2.5 g, protein 7 g, total carbohydrate 22 g, fiber 2 g, Na
100 mg, K 400 mg, vit A 748 iu, vit D3 148 iu, vit E 6.2 mg, vit C 23 mg, vit B1 0.4 mg, vit
B2 0.6 mg, niacin 5.6 mg, vit B6 0.5 mg, folic acid 100 mcg, vit B12 1.6 mcg, Ca 505 mg,
phosphorus 219 mg, Mg 54 mg, Fe 4.2 mg, Zn 1 mg, iodine 8.1 mcg, selenium 2.5 mcg.
Energy: 130 kCal
Calcitriol
Ca gluconate 50 mg, dicalcium phosphate 150 mg, vit A 300 IU, vit D 100 IU
Ca folinate
Ca lactate
L-leucovorin
Per 6 g sachet Ca 500 mg, vit C 500 mg, vit D 100 iu, vit K 60 mcg, Mg 20 mg,
manganese 1 mg, Zn 10 mg
Oyster shell providing elemental Ca 500 mg, vit D 125 IU
Vit B6 15 mg, vit C 1,000 mg, vit D 300 IU, Ca carbonate 625 mg (equiv to elemental Ca
250 mg)
Ca hydrogen phosphate anhydrate 500 mg, cholecalciferol 133 IU
Per 5 mL Ca pidolate 300 mg, curcuminoid 2 mg, fructo-oligosaccharide 300 mg, vit A
2,000 iu, vit D3 100 iu, vit B1 3 mg, vit B2 2 mg, vit B6 5 mg, vit B12 5 mcg
Vit A 5,000 iu, vit D 400 iu, vit C 100 mg, vit B1 10 mg, vit B2 2.5 mg, vit B6 15 mg, vit
B12 4 mcg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 0.4 mg, Fe fumarate
90 mg, Ca lactate 250 mg, iodine 0.1 mg
Ca carbonate (equiv to 500 mg elemental Ca)
Ca
Per caplet Ca 400 mg, vit D3 200 IU. Per 5 mL oral susp Ca 200 mg, vit D3 200 IU
Cod liver oil 200 mg, vit A 120 IU, vit D3 17 IU, omega-3 fatty acids, EPA 16 mg, DHA 14
mg, vit E 5 mg, vit B12 1 mcg, folic acid 0.3 mg, vit B6 0.6 mg, Ca 40 mg, Mg 25 mg, Fe
4.76 mg
Ca carbonate (equiv to elemental Ca 500 mg)
Per 5 mL Colostrum bovine 300 mg, DHA 200 mg, cod liver oil 10 mg, lysine HCl 200 mg,
vit A 2,000 mg, vit D2 200 IU, vit B1 0.6 mg, vit B2 0.15 mg, vit B6 0.6 mg, vit B12 1.5
mcg, nicotinamide 5 mg, dexpanthenol 2.5 mg, Zn picolinate 5 mg, Ca gluconate 300 mg,
Ca hypophosphite 20 mg
Coral Ca 500 mg, soy fiber germ (natural soy isoflavone) 20 mg, vit D3 200 IU, vit K1 25
mcg, Zn 5 mg, Mg 100 mg, boron 1 mg
Calporosis D 500 Ca carbonate 500 mg, vit D 100 IU. Calporosis D 800 Ca carbonate 800
mg, vit D 300 IU
Amlodipine besylate
Milk Ca 1,042 mg (equiv to Ca 250 mg), vit C 1,000 mg, vit D 300 IU, vit B6 15 mg
Ca carbonate (equiv to elemental Ca 600 mg) 1,500 mg, vit D3 200 IU, Mg 40 mg, Zn 7.5
mg, copper 1 mg, manganese 1.8 mg, boron 250 mcg
Ceftazidime pentahydrate
Per 5 mL Vit A 1,500 iu, vit D 300 iu, Ca 150 mg, Mg 30 mg, Zn 5 mg, folic acid 100 mcg,
fructo-oligosaccharide 500 mg
Isoflavone
Meloxicam
Dexamethasone Na phosphate
Tramadol HCl
Piroxicam
Clotrimazole
Candesartan cilexetil
Candesartan cilexetil
Fluconazole
Nystatin
Vit C
Per FC tab L-carnitine fumarate 500 mg, a-lipoic acid 100 mg, coenzyme Q10 30 mg, vit
B1 3 mg, vit B2 3 mg, vit B6 2 mg, vit B12 3 mcg, vit C 50 mg
Clotrimazole
Clotrimazole
Clotrimazole
Thiamphenicol
Lansoprazole
Meropenem
Cefepime
Cetirizine HCl
Cefpirome
Pantoprazole
Silybin phosphatidylcholine complex 70 mg, Schizandrae fructus extr 135 mg, Curcuma
domestica C95 extr equiv to curcuminoid 25 mg, Liquiritae radix extr 135 mg, choline
bitartrate 150 mg, vit B6 2 mg
Co-amoxiclav (amoxicillin & clavulanic acid). Per 500 mg FC caplet Amoxicillin 500 mg,
clavulanic acid 125 mg. Per 5 mL dry syr Amoxicillin 125 mg, clavulanic acid 31.25 mg.
Per 5 mL Forte dry syr Amoxicillin 250 mg, clavulanic acid 62.5 mg
Captopril
Captopril
Captopril
Captopril
Capsaicin
Carbamazepine
Carvedilol
Carboplatin
Carboplatin
Carboplatin
Carboplatin
Ramipril
Vit B6 2 mg, folic acid 400 mcg, vit C 100 mg, vit E 40 iu, vit B12 100 mcg.
Amlodipine besylate
Dobutamine HCl
Acetylsalicylic acid
Vit B6 25 mg, vit B12 25 mcg, folic acid 500 mcg, natural vit E 400 IU.
Dobutamine HCl
Verapamil HCl
Amlodipine besylate
Isosorbide 5-mononitrate
Amlodipine besylate
Doxazosin mesylate
Diltiazem HCl
Heptaminol acefyllinate
Urea
L-carnitine 250 mg, choline bitartrate 25 mg, inositol 25 mg, Dl-methionine 25 mg, vit B6
5 mg, nicotinamide 3 mg, Zn amino acid chelate 3 mg, Mg amino acid chelate 3 mg,
manganese amino acid chelate 1.5 mg.
Coenzyme Q10 30 mg, L-carnitine fumarate 500 mg
Meropenem trihydrate
Spironolactone
Nicardipine HCl
Glucosamine K sulfate
Ticlopidine HCl
Bicalutamide
Diclofenac K
Diclofenac resinate
Diclofenac K
Pirenoxine Na
Diclofenac K
Clonidine HCl
Microencapsulated tricalcium phosphate 546 mg (equiv to Ca 200 mg), vit C 25 mg, vit
D3 100 IU, vit B6 20 mg
Light mineral oil 0.5% w/w, heavy mineral oil 0.5% w/w, glycerol, tyloxapol, poloxamer
188, tris-hydrochloride, tromethamine, cetalkonium chloride
Ca hydrogen phosphate dihydrate 500 mg, cholecalciferol 133 IU
Per 5 mL Ca gluconate 250 mg, Ca glycerophosphate 100 mg, vit A 2,000 IU, vit D 400 IU,
vit B1 1.05 mg, vit B2 1.2 mg, vit B6 1.05 mg, vit B12 4.5 mcg, vit C 60 mg, niacinamide
13.5 mg, pantothenol 7.5 mg, lysine HCl 200 mg
Nystatin
Ca (in Ca carbonate 625 mg) 250 mg, vit B6 15 mg, vit C 1,000 mg, vit D 300 iu
Human albumin
Vit B1 mononitrate 15 mg, vit B2 10 mg, vit B6 5 mg, vit B12 5 mcg, vit C 500 mg,
nicotinamide 100 mg, Ca pantothenate 20 mg.
Per tab Na ascorbate 112.5 mg, vit C 100 mg. Drops Vit C.
Isosorbide dinitrate
Per 5 mL syr Ascorbic acid 100 mg. Per mL drops Na ascorbate 100 mg
Cefalexin monohydrate
Cefixime
Cefadroxil monohydrate
Cefadroxil
Cefadroxil
Cefotaxime Na
Cefixime
Cefadroxil monohydrate
Ceftriaxone Na
Cefazolin Na
Cefazolin
Cefazolin Na
Ceftazidime pentahydrate
Cefepime
Cefixime trihydrate
Cefixime
Ceftizoxime
Cefepime HCl
Cefpirome
Cefixime
Cefixime
Cefixime
Ceftizoxime
Cefpirome sulfate
Cefpirome
Cefoperazone
Cefoperazone Na
Cefoperazone
Cefoperazone Na
Cefoperazone, sulbactam
Cefoperazone Na
Cefotaxime Na
Cefotaxime Na
Cefotaxime Na
Cefotaxime Na
Cefpirome
Cefpirome sulfate
Cefotiam HCl
Ceftriaxone
Cefpirome
Cefpirome
Indications
In combination w/ other antiretroviral agents for the treatment of HIVinfected adults & childn.
Classic hemophilia A.
Treatment of scabies.
Resp tract infections, acute otitis media, skin & skin structure
infections.
Listed in Dosage.
Listed in Dosage.
Infections of lower resp tract, complicated upper & lower urinary tract,
skin & soft tissue. Bacteriaemia/septicaemia. Infections in neutropenic
& immunocompromised patients.
Uncomplicated UTI caused by E. coli & P. mirabilis, otitis media caused
by H. influenzae, Moraxella catarrhalis; uncomplicated
cervical/urethral gonorrhea caused by Neisseria gonorrhoeae.
Prophylaxis & chronic treatment of asthma in adult & childn =12 yr.
HTN.
Upper & lower resp tract infections, UTI, skin & soft tissue infections,
pelvic inflammatory disease, septicemia, osteomyelitis, post-op
infections.
Acne vulgaris.
Cleanser for acne prone & oily skin.
Listed in Dosage.
DM in combination w/ diet.
Listed in dosage.
Insulin-requiring DM.
Listed in Dosage.
Diabetic neuropathy.
Supplement for DM.
Listed in Dosage.
Alco drops & Alco Plus syr Symptomatic relief of sneezing & nasal
congestion due to flu. Alco Plus DMP syr Relief of cough w/ sneezing &
nasal congestion due to flu.
Essential HTN.
Adjunct therapy for simple & complex partial seizures & secondary
generalized tonic-clonic seizures in patients not satisfactorily
controlled w/ antiepileptics.
Vit supplement.
Type 2 DM inadequately controlled by diet, physical exercise & wt
reduction alone. May be used in combination w/ metformin or insulin.
Amino acid supply in hypoproteinemia, malnutrition & pre- &/or postop condition.
Provision of amino acids in patients w/ acute or chronic renal failure &
during hypoproteinemia, malnutrition, pre- & post-op.
Treatment of gm+ve & -ve infections eg upper & lower resp tract,
GUT, skin & soft tissue, bone infections, gonorrhea, dental abscess
(adjunct to surgical management).
Resp tract, GUT, skin & soft tissue infection due to susceptible gm+ve
& gm-ve organisms.
Listed in Dosage.
Relief of moderate to severe pain, esp colic & post-op when the
combination w/ tranquilizer is needed.
Infection of lower resp tract, urinary tract, soft tissue, bone & joint, O
& G infection, gonorrhoea, septicaemia & meningitis. Prophylaxis
against infection in abdominal, pelvic, orthopaedic, cardiac,
pulmonary, esophageal & vascular surgery when there is increased
risk from infection.
Upper & lower resp tract, skin & soft tissue, GUT infections, bone &
joint & other infections (septic abortion, peripheral & intra-abdominal
sepsis, post-op infections).
Antidepressant.
Essential HTN.
Treatment & prophylaxis of angina pectoris & MI. Fever colds, postvaccination pain, toothache, muscle pain & neuralgia.
Schizophrenia.
Listed in Dosage.
Listed in Dosage.
Help enhance collagen formation, reduce pain & repair joint function.
Maintain healthy joints.
Moisturizes & reduces the sensitivity of inflamed tissue & helps relieve
burning, itching & pain by protecting from further irritation. Enhances
healing process of the skin.
Adjunct to diet for the reduction of elevated total cholesterol, LDLcholesterol, apolipoprotein B & triglycerides in primary
hypercholesterolaemia, combined (mixed) hyperlipidaemia &
heterozygous & homozygous familial hypercholesterolaemia when
response to diet & other nonpharmacological measures are
inadequate.
Adjunct to diet for the reduction of elevated total cholesterol, LDL
cholesterol, apolipoprotein B & triglycerides in patients w/ primary
hypercholesterolemia, combined or mixed hyperlipidemia,
heterozygous & homozygous familial hypercholesterolemia when diet
response & nonpharmacological measures are inadequate. Prevention
of CV complications.
Adjunct to diet for the reduction of elevated total cholesterol, LDLcholesterol, apo B & triglycerides in patients w/ primary
hypercholesterolemia, combined (mixed) hyperlipidemia,
heterozygous & homozygous familial. Hypercholesterolemia when
response to diet & other non-pharmacological measure are
inadequate.
Supportive treatment of muscular, heart, skin, ear & eye diseases.
Short-term symptomatic treatment of acute exacerbation of OA. Longterm symptomatic treatment of RA (chronic polyarthritis).
Upper & lower resp tract infections, GUT, skin & soft tissue infections,
pelvic inflammatory diseases, septic abortion & other infections eg
osteomyelitis.
Dry acne & protect skin from sun rays.
Treatment of the symptoms of allergic rhinitis in adult, adolescent =12
yr & childn 6-11 yr.
Listed in Dosage.
Mild to moderate upper & lower resp tract, skin & soft tissue
infections; non-gonococcal urethritis & cervicitis due to Chlamydia
trachomatis.
Upper & lower resp tract infections; bacterial pneumonia; UTI &
pyelonephritis; intra-abdominal infections; bacterial septicaemia; skin,
soft tissue, bone & joint infections, gonococcal infections. Prophylaxis
of post-op infection in patients undergoing abdominal or pelvic
surgery. Prophylaxis of post-op sepsis in termination of pregnancy or
caesarean section.
Listed in Dosage.
Infections of lower resp tract, complicated upper & lower urinary tract,
skin & soft tissue. Bacteraemia/septicaemia. Infections in neutropenic
& immunocompromised patients.
Acute primary skin infections eg impetigo, folliculitis, furunculosis.
Listed in Dosage.
Gastric ulcers in combination w/ offensive factor inhibitors (protonpump inhibitors, anticholinergic, H2-antagonist) & gastritis.
Upper resp tract including ENT & lower resp tract infections; skin &
soft tissue, urogenital tract & post-op infections.
Adjunctive treatment for diaper rash, minor wound, dry skin, sunburn,
skin irritation caused by x-ray or light.
Relief of the inflammatory manifestations of hyperkeratolic & dry
corticosteroid-responsive dermatoses.
Listed in Dosage.
Vit supplement.
Eczema including atopic, infantile, stasis & discoid eczema & prurigo.
Vit supplement.
Infections of the lower resp tract, skin & soft tissue, GUT, intraabdominal, bone & joint. Bacteremia, septicemia & meningitis.
Complicated upper & lower UTI, lower resp tract infection, skin & soft
tissue infection, intra-abdominal infections, severe or complicated
gynecological infections, septicemia; empiric treatment in febrile
neutropenia.
Keeps skin moisture; used on face & neck to whiten & brighten skin;
helps conceal smooth lines on the face.
Sepsis, meningitis, infection of the lower resp tract, UTI, skin & soft
tissue infection, bone infection, intra-abdominal infections,
septicaemia, gonorrhoea, peri-op surgical prophylaxis.
Oral gel: Provides long-lasting comfort & helps maintain a healthy
balance in the mouth. Mouthspray: Provides a moisturizing barrier
over dry mouth surfaces, lips & throat. Helps improve moisture
balance, maintain fresh breath & promote oral health. Toothpaste:
Helps reduce the presence of unwanted bacteria, gently & safely
maintaining mouth's natural balance. Mouthwash: Helps reduce the
build up of unwanted bacteria & encourages a balanced oral
environment.
HTN.
Cancer of the skin, head & neck, esophageal, uterine cervix. Malignant
lymphoma. Pleural effusions.
HTN & heart failure & impaired left ventricular systolic function.
Essential HTN.
Special infant formula for babies 0-6 mth to reduce risk of allergy.
Special infant formula for babies 0-6 mth w/ cow's milk allergy, lactose
intolerance & galactosemia.
FC tab & inj Treatment of metastatic bone disease; to reduce the risk
of skeletal complications of malignant disease including
hypercalcemia, pain, the need for radiotherapy against painful bonce
lessions & impending fractures, & decrease the risk for fractures. Inj
Treatment of tumour-induced hypercalcemia.
Osteoporosis.
Osteoarthritis, prevention of joint/cartilage damage.
Maintenance of healthy joints.
Relief of menopausal symptoms & maintenance of healthy bones.
Moisten dry & inflamed nasal membrane due to cold, allergy, low
moisture, minor nose bleeds & other minor nasal irritation.
Resp tract, GIT, GUT, skin & soft tissue infections due to susceptible
gm+ve & gm-ve microorganisms.
Mild to moderate pain eg primary dysmenorrhoea, toothache or postextraction dental pain, post-op pain, headache; mild to moderate pain
symptom in rheumatic disease, muscle pain & sprain; fever reduction.
Prevents & reduces the risk of osteoporosis in men & women. Relieves
premenopausal & menopausal symptoms.
Ca supplement.
Listed in Dosage.
Adult =16 yr: Lower resp tract (pneumonia & bronchopneumonia), skin
& skin structure, intra-abdominal (peritonitis, biliary tract infection),
severe or complicated gynecological infections; septicemia; empiric
treatment in febrile neutropenia. Childn 2 mth-<16 yr: Severe
pneumonia, empiric treatment in febrile neutropenia, complicated
upper (pyelonephritis) & lower UTI.
Upper & lower resp tract, GUT, skin & soft tissue, bone & joint, dental
& other infections eg septic abortion, puerperal & intra-abdominal
sepsis.
HTN, angina.
Listed in Dosage.
Acute & chronic treatment of signs & symptoms of RA, osteoarthritis &
ankylosing spondylitis. Management of pain & primary
dysmenorrhoea, when prompt pain relief is desired.
For face, neck & hand usage eg chloasma, freckles, age spots,
hyperpigmentation post-inflammation, pre- & post-laser intervention,
pre- & post-peeling, post liqd nitrogen therapy.
Resp tract, skin & soft tissue & GUT infection, osteomyelitis, arthritis,
septicaemia, peritonitis, puerperal sepsis.
Listed in Dosage.
Upper & lower resp tract infections, UTI, peritonitis, cholecystitis &
other intra-abdominal infections, septicemia, meningitis, skin & soft
tissue infections, bones & joints infections, pelvic inflammatory
disease, endometritis, gonorrhea & other infection of the genital tract.
Adult =16 yr: Infections of lower resp tract, complicated upper & lower
urinary tract, skin & skin structure, severe or complicated
gynecological infections; septicemia; febrile neutropenia. Childn 2
mth-16 yr: Empiric treatment in febrile neutropenia; severe
pneumonia.
Listed in Dosage.
Upper & lower resp tract infection & UTI, peritonitis, cholecystitis,
cholangitis, other intra-abdominal infections, skin & soft tissue
infections.
Serious lower resp tract infection, skin, urinary tract, bone & joint,
intra-abdominal, gonorrheal, bacterial septicaemia, peri-op surgical
prophylaxis, infections of the kidneys, meningitis.
Lower resp tract infection, UTI, skin & soft tissue infections,
bacteremia/septicemia, severe infections; infections in neutropenic
patients.
Dosage
Adult & adolescent =30 kg 300 mg (two 150-mg tab) once daily or 150 mg twice daily. Childn >3 m
weighing 21-30 kg tab in the morning & 1 tab in the evening, 14-21 kg tab twice daily.
Adult 100 mg once daily. Treatment discontinuation may be considered when HBe & HBs antigen
seroconversion occurs.
Mild hemorrhage & prophylaxis 10 IU/kg as single-dose IV. Moderate hemorrhage 15-25 IU/kg IV. If
repeated doses of 10-15 IU/kg 8-12 hrly may be given. Severe hemorrhage Initially 40-50 IU/kg IV.
Maintenance: 20-25 IU/kg 8-12 hrly. Surgery Pre-op dose: 50 IU/kg IV. To maintain hemostatic levels
repeated infusions may be necessary 6-12 hrly initially & for 10-14 days until healing is complete.
Use for single dose. Apply throughout the skin from head up to toes, especially the inner lobe of th
the bottom fold & finger gaps. Leave medication on for 8-12 hrs. Recommended to apply at night t
wash the next day.
Individualized dosage.
HTN & angina 5 mg once daily, may be increased to a max of 10 mg once daily.
Abbotic filmtab Adult 500 mg twice daily in severe infections. Legionella pneumophila infection 500
twice daily for 4 wk. Abbotic Granule dry syr Childn 7.5 mg/kg body wt 12 hrly for 5-10 days. Dose
increased to a max of 500 mg 12 hrly. Abbotic XL filmtab 500-1000 mg 24 hrly for 7-14 days.
Schizophrenia Adult 10 or 15 mg once daily. Adolescent 13-17 yr Initially 2 mg/day then, titrated to
mg/day followed by a target dose of 10 mg/day. Doses are titrated in a 2-day interval. Bipolar disor
Adult 30 mg once daily. Childn & adolescent 10-17 yr Initially 2 mg/day then, titrated to 5 mg/day f
by a target dose of 10 mg/day. Doses are titrated in a 2-day interval. Adjunctive treatment for patie
taking antidepressants 2-5 mg/day. Adjunctive therapy for major depressive disorder 2-15 mg/day.
dose gradually up to 5 mg/day at not <1-wk interval.
Acute agitated schizophrenia & bipolar disorder 9.75 mg or 1.3 mL. Max of 3 x 9.75 mg/day.
Irritability associated w/ autistic disorder Children & adolescents 6-17 yr Initially 2 mg/day then, inc
5 mg/day w/ subsequent increases of 10-15 mg/day if needed. Adjust dose gradually up to 5 mg/da
<1 wk interval. Doses are individualized according to tolerability & response.
Maintenance for acute schizophrenia & bipolar disorder 10 or 15 mg once daily. Max of 30 mg/day.
Adjunctive therapy for major depressive disorder Initial dose: 2-5 mg/day. Max of 15 mg/day.
Complicated upper & lower UTI, skin & soft tissue infections 1 g. Lower resp tract infections 1 or 2 g
Bactericaemia/septicaemia & infections in neutropenic patients 2 g. All doses are given 12 hrly.
Cap Adult & childn weighing =30 kg 50-100 mg twice daily. Severe or intractable infections May be
increased up to 200 mg twice daily. Dry syr Childn 1.5-3 mg/kg twice daily. Severe or intractable in
May be increased up to 6 mg/kg twice daily. Cervical/urethral gonorrhea 400 mg as single dose.
Initially 12.5 mg 2-3 times daily, may increase up to 25 mg 2-3 times daily.
Initially 50 mg daily, may be increased to 100 mg daily. To be given 1-2 times daily.
Resp tract 1 tab daily (preferably at night). Paracetamol toxication (accidental or non-accidental) E
dose: 140 mg/kg body wt. 10 hr after toxication: 70 mg/kg body wt every 4 hr for 1-3 days. Uropath
iso & cyclophosphamide 1 g 4 times daily.
Relief of pain 1-2 tab 4-6 hrly. Max: 8 tab/day. Patient w/ CrCl <30 mL/min Not more than 2 tab 12 h
Adult Herpes simplex 200 mg 5 times daily 4 hrly w/o night dose for 5 days, may be increased to 4
daily. Suppression of herpes simplex in immunocompetent patients 200 mg 4 times daily 6 hrly. Pro
of herpes simplex in immunocompromised patients 200 mg 4 times daily 6 hrly. Doses may be incr
400 mg in severe immunocompromised patients (post-bone marrow transplant) or indigestion. Her
zoster 800 mg 5 times daily 4 hrly w/o night dose for 5 days. Childn Treatment & prophylaxis of her
simplex in immunocompromised patients Childn =2 yr Adult dose, <2 yr adult dose. Severe rena
dysfunction (CrCl 10 mL/min) 200 mg twice daily 12 hrly. Herpes zoster in patients w/ severe renal
dysfunction 800 mg twice daily 12 hrly. Herpes zoster in patients w/ moderate renal dysfunction (C
25 mL/min) 800 mg 3 times daily.
Apply 5 times daily 4 hrly w/o night dose. Duration of treament: 5 days, may be continued until 10
Duodenal ulcer & reflux oesophagitis 30 mg once daily for 4 wk. Benign gastric ulcer30 mg once da
wk.
Adult & childn >12 yr 1 caplet 3 times daily. Childn 7-12 yr 2 tsp dry syr or 1 tsp forte dry syr, 3 tim
2-7 yr 1 tsp dry syr or tsp forte dry syr, 3 times daily.
Treatment of osteoporosis in postmenopausal women & men; treatment & prevention of glucocortic
induced osteoporosis in women & men 5 mg as a single IV infusion for =15 min once a yr. Patients
recent low-trauma hip fracture Loading dose of vit D 50,000-125,000 IU orally or IM is recommende
to 1st Aclasta infusion. Paget's disease 5 mg as single IV infusion.
1 cap daily.
Adult Initially 5 mg 3-4 times daily. Max: 40 mg 3-4 times daily. Childn Initially 0.2 mg/kg body wt in
times daily, may be increased to max 0.8 mg/kg body wt/day but not >20 mg daily.
Tab/Caplet Peptic ulcer 150 mg 2 times daily. Zollinger-Ellison syndrome 150 mg 2 times daily. Seve
Up to 6 g/daily. Amp IM 50 mg/2 mL 6-8 hrly. IV intermittent bolus 50 mg (2 mL) 6-8 hrly.
According to individual response. Initially 50 mg, then adjust to 100 mg. Max: 100-200 mg. Doses a
taken 3 times daily. May be increased after 4-8 wk.
Treatment of hypercalcemia due to malignancy 2,400 or 3,200 mg daily depending on patient's res
which may be reduced gradually to 1,600 mg. Treatment of osteolysis due to malignancy 1,600 mg
may be increased to max 3,200 mg if necessary. Single infusion: 1,500 mg diluted in 500 mL of Na
glucose 5% soln to be given as IV infusion over a 4-hr period. Multiple infusion: 300 mg/day diluted
mL soln to be given as IV infusion over a period of 2 hr until normocalcemia is achieved or to max o
days.
Adult 1 g IM/IV 12 hrly. Mild to moderate UTI 500 mg-1 g IV/IM 12 hrly. Mild to moderate infection e
UTI 1 g IV/IM 12 hrly. Severe infection 2 g IV 12 hrly. Very severe to life-threatening infection 2 g IV
Duration of therapy: 7-10 days or greater for severe infections.
Initially =10 mg once daily, adjusted at =4-wk intervals. Max: 80 mg once daily. Primary
hypercholesterolemia & combined or mixed hyperlipidemia 10 mg daily for 2 wk & up to 4 wk for m
response. Homozygous familial hypercholesterolemia 80 mg. Heterozygous familial hypercholester
Childn 10-17 yr 10 mg daily. Max: 20 mg daily.
Initially 5 mg daily, may be increased to 10 mg daily. Elderly & patients w/ hepatic insufficiency Init
mg once daily.
Initially 1 mg/day once daily. Daily dose may be increased at stepwise manner w/ 1-2 wk intervals b
each step to 1 mg/day-2 mg/day-3 mg/day-4 mg/day & in exceptional cases, 4 mg/day. Max: 6 mg/
Adult 0.25-0.5 mg 3 times daily, may be increased at intervals of 3-4 days in divided doses. Max: 4
Elderly & debilitated patients, severe liver dysfunction 0.25 2-3 times daily, may be increased grad
8 mg/kg body wt, but not <480 mg, IV infusion once every 4 wk.
Childn 1-5 yr 1 single inj, 6-12 mth 2 inj at 1-mth interval followed by a booster 12 mth after the 2n
infant <6 mth 3 inj at 1-mth interval followed by a booster 12 mth after the 3rd dose.
Adult & childn >12 yr 5 mL, 6-12 yr 2.5 mL, 2-6 yr 1.25 mL. To be taken 3 times daily.
Adult & childn >12 yr 5 mL, 6-12 yr 2.5 mL, 2-6 yr 1.25 mL. To be taken 3 times daily.
Adult & childn >12 yr 5 mL, 6-12 yr 2.5 mL, 2-6 yr 1.25 mL. To be taken 3 times daily.
MI Patients in whom Treatment Can be Started within 6 hr After Symptom Onset Initially 15 mg IV b
then 50 mg IV infusion over the 1st 30 min, followed by 35 mg infusion over 60 min until max of 10
Patients <65 kg Initially 15 mg IV bolus & 0.75 mg/kg body wt over 30 min (max: 50 mg) followed
mg/kg infusion over 60 min (max: 35 mg). 3-hr dose regimen: 10 mg IV bolus then 50 mg IV infusio
the 1st hr, followed by 10 mg infusion over 30 min until max dose of 100 mg over 3 hr. Max: 1.5 m
patient <65 kg. Pulmonary embolism 10 mg IV bolus over 1-2 min then 90 mg IV infusion over 2 hr
1.5 mg/kg in patient <65 kg. Acute ischaemic stroke 0.9 mg/kg (max: 90 mg) infused over 60 min
of total dose as initial IV bolus. Initiate therapy w/in 4.5 hr after onset of symptoms.
1 tab once mthly for 12 mth only. To be taken on the same date each mth.
Monotherapy: Recommended dose: 10 mg. Adults (previously untreated) 400 mg/m2 IV as a single
administered in 15-60 min. Renal failure CrCl 41-59 mL/min 250 mg/m2 as a single dose, CrCl 16-4
mL/min 200 mg/m2 as a single dose.
Adult 2 mL once wkly for 5 consecutive wk, administered by inj in the cavity of the knee joint.
Recommended dose: 60-75 mg/m2 as a single IV dose for 21 days. Alternative dose: 20 mg/m2 wk
mg/m2 each successive days repeated every 4 wk to decrease toxicity. In combination w/ other
myelosuppressive drugs 30-40 mg/m2 every 3-4 wk. In combination w/ non-myelosuppressive drug
mg/m2 every 3-4 wk.
Adult & childn =12 yr 5 mg, 6-11 yr 1 tsp (2.5 mg in 5 mL), 1-5 yr tsp (1.25 mg in 2.5 mL). All do
be taken once daily.
Spray Adult & childn >6 yr 2-3 spray in each nostril 2 times daily. Drops 2-3 drops in each nostril 2
daily.
W/o dressing/sterile gauze Apply 3-4 times daily. W/ dressing/sterile gauze Apply more frequently.
Treatment duration: 7 days.
Adult 100 mg twice daily.
Adult 75 mg once daily. Unstable angina or non-Q-wave MI 300 mg, then continued to 75 mg once
Adult & childn from 36 mth 0.5 mL IM or deep SC inj. Childn <9 yr receiving vaccine for the 1st tim
2nd dose after an interval at least 4 wk.
Initially, 0.5 mg 4 times daily or 1 mg twice daily for at least 1 wk. Dose may be increased by not m
than 0.5 mg/day in any 1 wk. Max dose: 10 mg/day or 2.5 mg as a single dose.
Tab UTI 100-400 mg twice daily for 1-10 days. Severe & complicated infections Up to 600 mg daily
days. Resp tract infections 200-400 mg twice daily. Uncomplicated gonococcal urethritis & cerviciti
(including PPNG infections) 200-600 mg as single dose. Non-gonococcal urethritis 400 mg daily in s
divided doses for 9 days. Skin & soft tissue, O&G infections, bacterial enteritis 400 mg daily for 7 d
Adult 6-10 drops twice daily. Childn Decrease adult dose.
Syr: Adult & childn >3 yr 1 tsp, <3 yr tsp. To be taken daily. Drops: Childn 1-3 yr 16 drops daily, <
drops daily.
IV infusion only. Hypoproteinemia in acutely ill patient Adult 50-75 g at 2 mL/min. Shock Initially 20
mL/min. Total dose should not exceed 2 g/kg body wt in the absence of active bleeding. Severe bur
dose: 20-80 g daily at 1 mL/min.
Adult Serious infection: 150-300 mg 6 hrly. More severe infection: 300-450 mg 6 hrly.
Local haemostasis Apply conc directly. Burns 1:3 to 1:8 dilutions of conc. Extensive burns Diluted c
alone or coating of Albothyl gel or gauze pad over affected area. Vag supp To be inserted into the v
Gel Intravag application every other day.
Individualized dosage.
Individualized dosage.
Alco drops Childn 2-5 yr 0.8 mL 3 times daily. Alco Plus syr/Alco Plus DMP syr Adult & childn >12 yr
Childn 6-12 yr 2.5 mL, 2-5 yr 1.25 mL. To be taken 3 times daily.
Adult Initially 5 mg/day in the evening before bedtime for 1 mth then may be increased up to 10 m
daily.
Adult 1 tab. Childn 6-12 yr tab, 2-6 yr tab. To be taken 3-4 times daily.
Adult & childn =12 yr 1 tab once daily. Childn 6-12 yr, body wt >30 kg 1 tab once daily, body wt <3
tab once daily.
Adult & adolescents (=12 yr) 10 mL (5 mg). Childn 6-11 yr 5 mL (2.5 mg), 1-5 yr 2.5 mL (1.25 mg).
doses to be taken once daily.
Initially 1-2 drops/hr in the morning & every 2 hr in the evening. Reduce to 1 drop 4 hrly & then to
4 times daily.
1 cap 1-2 times daily.
Adult 1-2 tsp. Childn 7-12 yr 1-1 tsp, 2-6 yr -1 tsp. Infant - tsp. To be taken 3-4 times daily
Adult & childn =12 yr 1 tab or 10 mL (2 tsp) daily. Childn 2-12 yr >30 kg body wt 10 mg (2 tsp) dai
kg 5 mg (1 tsp) daily.
Gargle 10 mL 2-3 times daily or as needed. Spray 3 times or as needed to the affected area. Oral g
1 or 2 drops to cover whole mouth ulcer or lesion, 3-4 times daily.
1 caplet daily.
IM 15 mg/kg body wt daily in divided doses 8 or 12 hrly. Neonate & premature infant Initially 10 mg
body wt daily followed by 15 mg/kg body wt daily in divided doses 12 hrly. Max of 1.5 g daily. Max d
of treatment: 10 days. IV infusion 500 mg in 200 mL of normal saline soln or 5% dextrose soln to b
w/in 30 min to 1 hr (in adult & childn) or 1-2 hr (infant).
Caplet Adult 1 caplet. Childn 6-12 yr caplet. Syr Childn 6-12 yr 2 tsp. All doses to be taken 3 time
Adult & childn >12 yr 900-1,800 mg/day. Day 1: 300 mg once daily. Day 2: 300 mg twice daily. Day
mg 3 times daily. The dose may be increased to 1,200 mg/day in 3 equally divided doses & if neces
further titration can occur using increments of 300 mg/day in 3 divided doses. Max: 2,400 mg/day.
w/ renal failure CrCl >60 mL/min 400 mg 3 times daily, 30-60 mL/min 300 mg twice daily, 15-30 m
300 mg once daily, <15 mL/min 300 mg every other day. Hemodialysis patients Initially 300-400 m
Maintenance dose: 200-300 mg 4 hr after hemodialysis.
Anxiety 0.25-0.5 mg 3 times daily. Geriatric patients or in the presence of debilitating disease 0.25
times daily.
100 mg/day by deep IM but may be increased to 200 mg in severe cases. The duration of administ
can range from 5-10 days & may be continued through oral or rectal routes.
Chewable tab 1-2 tab between meals & at bedtime. Susp 1-2 tsp between meals & at bedtime.
Adult: Therapy-naive patients Lopinavir 400 mg/ritonavir 100 mg (2 tab of 200/50 mg tab) twice da
lopinavir 800 mg/ritonavir 200 mg (4 tab of 200/50 mg tab) once daily. Therapy-experienced patien
Lopinavir 400 mg/ritonavir 100 mg twice daily. Concomitant use w/ efavirenz, nevirapine, amprena
nelfinavir Dose may be increased to lopinavir 500 mg/ritonavir 125 mg (2 tab of 200/50 mg tab & 1
100/25 mg tab) twice daily. 100/25 mg Childn Based on BSA =1.4 m2 4 tab, 0.9 to <1.4 m2 3 tab,
<0.9 m2 2 tab. Based on body wt >35 kg 4 tab (may use 2 tab, 200/50 mg tab); >25 to 35 kg 3 ta
kg 2 tab. Concomitant use w/ efavirenz, nevirapine, nelfinavir or amprenavir Based on BSA =1.7 m
=1.2 to <1.7 m2 4 tab, =0.8 to <1.2 m2 3 tab, =0.6 to <0.8 m2 2 tab. Based on body wt >45 kg 5
>30 kg-45 kg 4 tab (may use 2 tab, 200/50 mg tab), >20-30 kg 3 tab, 15-20 kg 2 tab. All doses are
twice daily.
Adult 0.25-0.5 mg 3 times daily. Geriatric or debilitated patients 0.25 mg 3 times daily.
Threatened abortion 1 tab 3 times daily for 5-7 days. May be extended if necessary. Habitual abort
tab daily after pregnancy is diagnosed, continue for =1 mth after the critical period. Threatened pr
labour individualized dosage. Max 40 mg daily.
5 mg once daily before bedtime for 1 mth. After 1 mth, doses may be increased to 10 mg once dail
daily dose: 10 mg.
1-8 mg daily. Initial dose & dose titration: 1 mg once daily. Daily dose may be increased at intervals
wk, & carried out stepwise as follows: 1 mg-2 mg-3 mg-4 mg-6 mg, & in exceptional cases, 8 mg.
1-8 mg daily. Initial dose & dose titration: 1 mg once daily. Daily dose may be increased at intervals
wk, & carried out stepwise as follows: 1 mg-2 mg-3 mg-4 mg-6 mg, & in exceptional cases, 8 mg.
Adult & childn >20 kg 250-500 mg 4 times daily. Childn <20 kg 50-100 mg/kg/day in 4 divided dos
Gonococcal urethritis 3.5 g ampicillin w/ 1 g probenecid as a single dose.
HTN & angina Initially 5 mg once daily, may be increased to max dose of 10 mg. Chronic stable or
vasospastic angina 5-10 mg. Small, fragile, elderly or patient w/ hepatic insufficiency Initially 2.5 m
daily.
Adult Initially 5 mg once daily. Max: 10 mg.
Chronic kidney insufficiency GFR 5 & 50 mL/min 4-8 film-coated caplet 3 times daily.
Adult Usual dose: 500 mL infused via peripheral vein. Max: 2,500 mL/day. Infusion rate: 500 mL/12
slowed in elderly & critically ill patients.
Patients w/ 70 kg body wt 1,000-1,500 mL daily by infusion rate of 2 mL/kg body wt/hr or 45 drops/
Chronic renal insufficiency 4-8 caplet. Compensated retention 4-6 caplet. Decompensated retention
caplet. Doses are to be taken 3 times daily.
Adult For internal disorders or pre-surgical protein deficiency 500 mL IV drip infusion over 4-6 hr. Re
hrly for 5-7 days. For post-surgical impairment of protein synthesis 500 mL over 4-6 hr following dr
infusion of Darrow's soln & 10% sugar soln. Repeat at 24-hr intervals for 5-7 days.
IM Neonates Initially 10 mg/kg/day, followed by 7.5 mg/kg 12 hrly. Max: 15 mg/kg/day or 1.5 g/day.
Duration of therapy: 7-10 days. IV Infusion Adult & childn 500 mg in 100-200 mL of 0.9% NaCl or 5%
Dextrose soln infused over 30-60 min. Infants Adult dose infused over 1-2 hr.
Adult Central vein infusion: 1000 mL/day. Peripheral vein infusion: 500 mL/day.
Adult Usual dose: Chronic renal failure 200 mL/day via peripheral vein w/ infusion rate of 100 mL o
min (25 drops/min) or 400 mL/day via central vein by TPN. Acute renal failure 600 mL/day via centr
by TPN. >300 kCal of non-protein cal/g of nitrogen should be administered for efficiency of amino a
utilization. Childn, elderly, seriously ill patients Individualized dosage via slow infusion.
Initially 5 mg once daily. Max: 10 mg once daily. Elderly or patient w/ hepatic impairment Initially 2
once daily.
HTN 5 mg once daily. Max: 10 mg/day. Elderly, fragile patients, or w/ impaired liver function Initially
once daily. Chronic stable angina or vasospastic angina 5-10 mg daily.
HTN Initially 5 mg once daily. Max: 10 mg daily. Fragile, elderly patients or patients w/ liver insuffici
Initially 2.5 mg once daily. Chronic stable & vasospastic angina 5-10 mg once daily.
HTN 5 mg once daily, then may be increase to max dose of 10 mg/day. Chronic stable or vasospast
angina 5-10 mg.
Adult Internal disorder of presurgical protein deficiency Usual dosage: 500 mL by IV drip infusion ov
hr (20-30 drops/min) simultaneously or followed by drip infusion of Darrow's soln 1000 mL over 4 h
100 drops/ min) & followed by drip infusion of a 10% sugar soln 500 mL over 2 hr (60-80 drops/min
op impairment of protein synthesis Usual dosage: 500 mL by IV drip infusion over 4-6 hr (20-30 dro
following drip infusion of Darrow's soln 1000 mL over 4 hr (60-100 drops/min).
Treatment of infection Adult & childn >40 kg Usual dosage: Severe infections: 875 mg 12 hrly or 50
times daily. Childn <40 kg 125 mg 3 times daily. More severe infections: 250 mg 3 times daily. Gon
g as single dose. Renal impairment: Mild (CrCl >30 mL/min) No change in dose. Moderate (CrCl 10mL/min) Max: 500 mg twice daily. Severe (CrCl <10 mL/min) Max: 500 mg daily. Ped susp Severe o
recurrent otitis media Childn 3-10 yr 750 mg twice daily for 2 days as an alternative course of treat
Adult 250-500 mg 8 hrly. Childn 20 mg/kg body wt daily in divided doses 8 hrly. Severe infection: D
may be doubled. Acute gonorrhoea 2-3 g as single dose.
Cap/Dispersible tab Adult & childn =20 kg 250-500 mg 8 hrly. Childn <20 kg 20-40 mg/kg 8 hrly in
doses. Syr Childn >8 kg 125-250 mg 8 hrly. Paed drops All indications except infections of lower res
Childn =6 mth 6-8 kg 0.5-1 mL 8 hrly, =6 kg 0.25-0.5 mL 8 hrly. Infections of lower resp tract Child
mth 6-8 kg 1-1.5 mL 8 hrly, =6 kg 0.5-1 mL 8 hrly. Inj Adult 250-500 mg IM 8 hrly. 500 mg-1 g IV/in
hrly in severe infections. Childn 35-100 mg/kg body wt/day IM in divided doses or up to 100 mg/kg
wt/day IV/infusion in divided doses 6 hrly over 30-min infusion. Typhoid & paratyphoid Adult 4 g da
divided doses for 14-21 days. Childn 100 mg/kg body wt/day in divided doses for 14-21 days. Typh
carrier states 3-4 g daily in divided doses for min of 1 mth. Gonorrhea Single dose of 3 g + 1 g prob
Uncomplicated UTI Single dose of 3 g. Syphilis 250 mg 6 hrly for 4 wk up to 5 mth. Severe or recurr
lower resp tract infection 3 g twice daily. Dental abscess 3 g twice daily 8 hrly. Otitis media Adult &
3-10 yr 750 mg 2 times daily for 2 days.
Adult & Childn =12 yr 4-48 mg/day. Childn <12 yr 416 mcg-1.7 mg/kg body wt/day.
Chronic venous disease 2 caplet daily. Acute hemorrhoidal attacks 6 caplet for the 1st 4 days, then
daily for 3 days, 2 caplet thereafter. Chronic hemorrhoids 2 caplet daily.
Adult 1 caplet, if pain persist, followed by 1 cap 6-8 hrly. Max: 4 caplet daily.
Adult & adolescent =16 yr Initially 2 caplet/day & as needed in not <6 hr dose interval. Max dose:
caplet/day.
Caplet Adult & childn >12 yr 250 mg 2 times daily, may be increased up to 500 mg 2 times daily. In
childn =12 yr 125 mg 2 times daily. Uncomplicated UTI 125-250 mg 2 times daily. Uncomplicated
gonococcal urethritis 1 g as a single dose. Otitis media Childn =2 yr 250 mg, <2 yr 125 mg. To be t
times daily. Inj Adult 750 mg-1.5 g 8 hrly IM or IV for 5-10 days. If necessary, may increase to 3-6 g
hrly. Childn & infant >3 mth 50-100 mg/kg/day 6-8 hrly, severe & serious infections: 100 mg/kg/da
& joint infections 150 mg/kg/day 8 hrly (not exceeding max dosage of adult). Bacterial meningitis 2
mg/kg/day IV 6-8 hrly.
Adult 150 mg twice daily, morning & evening. Childn >4 yr 5-8 mg/kg body wt daily in 2 divided do
not for >10 days.
Adult & childn >40 kg 1-2 g daily in 2 divided doses. Childn <40 kg 25 mg/kg/body wt daily in 2 div
doses.
FC tab Adult & childn >12 yr Mild to moderate infections tab 3 times daily. Severe infections 1 ta
times daily. Dry susp Childn 31.25 mg/kg body wt daily in divided doses every 8 hr. >6 yr 5 mL 3 ti
daily; 1-6 yr 2.5 mL 3 times daily; <1 yr 1 mL 3 times daily.
Folic acid deficiency Initially 0.25-1 mg/day. Maintenance: 0.25-0.5 mg/day. Supplement in pregnan
lactation 0.5-1 mg/day. Megaloblastic anemia 0.5-1 mg/day.
Adult 150-300 mg 6 hrly. Severe infection: 300-450 mg 6 hrly. Childn >1 mth Usually 8-16 mg/kg b
wt/day. Severe infection: 16-20 mg/kg body wt/day. To be taken in 3-4 divided doses.
IM Pre-op med Adult 0.07-0.1 mg/kg. Elderly & debilitated patients 0.025-0.05 mg/kg to be adminis
min before induction of anesth. IV Basal sedation Initially 2.5 mg 5-10 min pre-op. Severe illness In
1.5 mg. Max total dose: 3.5 mg. Induction of anesth & conscious sedation 10-15 mg.
Induction IV Initially 1-4.5 mg/kg (dose rarely exceed to 2 mg/kg). To be administered over at least
IM Initially 6.5-10 mg/kg.
Initially 2.5 mg once daily, may be increased by doubling the dose at intervals of 2-3 wk. Usual
maintenance dose is 2.5-5 mg daily, max dose of 10 mg daily.
Cap/caplet Adult & childn >30 kg 50-100 mg twice daily, may be increased to 200 mg twice daily f
severe cases. Dry syr 1.5-3 mg/kg body wt twice daily. Typhoid fever in childn 10-15 mg/kg body w
2 wk.
1-8 mg daily. Initial dose & dose titration: 1 mg once daily, may be increased at intervals of 1-2 wk
stepwise as follows: 1 mg, 2 mg, 3 mg, 4 mg, 6 mg & in exceptional cases, 8 mg.
Drag Adult 1 drag. Syr Adult 2 tsp. Childn 6-12 yr 1 tsp. To be taken 3-4 times daily.
Adult Initially 100-150 mg daily in 2-3 divided doses. Pain management & OA Max dose: 150 mg/da
Max dose: 225 mg/day. Ankylosing spondylitis Max dose: 125 mg/day. Migraine Initially 50 mg at th
signs of an impending attack. In cases where pain relief w/in 2 hr after the 1st dose is not sufficient
may be repeated. Further doses may be taken 4-6 hrly, if needed. Max dose: 200 mg/day.
Adult 1-2 sugar-coated tab daily. Prevention of motion sickness sugar-coated tab 1 hr before trav
when necessary. Childn 6-12 yr adult dose.
Childn 7-12 yr 5 mL 2 times daily, 1-6 yr 5 mL once daily, 6 mth-1 yr 2.5 mL once daily.
Syr Adult & childn >5 yr 1-2 tsp once daily. Childn 2-5 yr 1 tsp once daily. Drops Childn 1-3 yr 0.6 m
daily, <12 mth 0.3 mL once daily.
Individualized dosage. Vial Administer by SC infusion pump or by IV. OptiSet Administer by SC inj.
Initially 75 mg twice daily. May be increased to 150 mg twice daily at 3-7 daily interval. Max: 300 m
daily.
150 mg once daily, may be increased to 300 mg daily. Elderly Initially 75 mg.
Angina pectoris & MI 1 tab once daily. Fever colds, post-vaccination pain, toothache, muscle pain &
neuralgia Adult 4-6 tab, childn 5-12 yr 2-3 tab, 1-4 yr 1 tab. To be taken 3-4 times daily.
Adult 100-150 mg daily. Milder cases & childn >14 yr 75-100 mg daily. Daily dose should be given i
divided doses.
Adult >18 yr Loading dose: 100 mg once daily for 3 days. Maintenance: RA 10 or 20 mg once daily.
Psoriatic arthritis 20 mg once daily.
Adult 2 tab/day.
Adult 250-500 mg. Childn up to 10 yr 125 mg. To be taken 3 times daily.
OA, chronic musculoskeletal pain 60 mg once daily. Analgesia acute pain associated w/ dental surg
mg once daily.
2 tab daily.
Acute hemorrhoidal attacks 6 tab daily for the 1st 4 days, then 4 tab daily for the next 3 days, 2 ta
thereafter. Chronic hemorrhoids 2 tab daily.
Dilute 4 mL in 1L of 5% dextrose soln or 5% dextrose-NaCl soln. Initially 2-3 mL/min via IV infusion.
Maintenance: 0.5-1 mL/min.
Adult 400 mg 3-4 times daily. Analgesia 200-400 mg 3-4 times daily.
Adult & childn >12 yr 1 tab 3 times daily, childn 6-12 yr 1 tab twice daily (morning & evening). Max
duration of therapy: 3 wk.
5 mg daily, may be increased to 10 mg/day following 1 mth clinical assessment.
Adult & elderly Mild to moderate Alzheimer's disease Initially 5 mg/day in the evening (prior to reti
Dose can be increased to 10 mg/day after at least 1 mth of clinical assessment of treatment at 5 m
Max: 10 mg/day. Severe Alzheimer's disease 10 mg/day, only after daily dose of 5 mg for 4-6 wk. If
tolerated, reduce to 5 mg.
OA 7.5 mg once daily, may be increased to 15 mg once daily. RA 15 mg once daily, may be reduced
mg once daily. Patient w/ kidney failure Max: 7.5 mg once daily.
Prevention of VTE for orthopaedic & abdominal surgery 2.5 mg once daily by SC inj 6 hr post-op. Th
treatment should be continued at least 5-9 days post-op. Treatment of UA/NSTEMI 2.5 mg once dai
inj continued for up to 8 days or until hospital discharge. Treatment of STEMI 2.5 mg once daily. The
dose is administered IV & subsequent doses are by SC inj, continued for up to 8 days or until hospi
discharge. Prevention of VTE for the patients at risk of thromboembolic complications 2.5 mg once
SC inj treatment should be given 6-14 days. Treatment of DVT & PE Patients w/ >100 kg body wt 10
50-100 kg body wt 7.5 mg, <50 kg body wt 5 mg. The treatment should be continued for at least 5
until adequate oral anticoagulations is established (INR 2-3). Doses are to be taken once daily by S
Parkinsonism 1st day: 1 mg. 2nd day: 2 mg w/ further increase of 2 mg daily at 3-5 days interval, u
mg daily in 3-4 divided doses. Some patients may require total dose of 12-15 mg daily. Drug-induce
parkinsonism 5-15 mg daily, advisable to initiate therapy w/ single 1 mg dose. Patient >65 yr Smal
doses required.
Patients w/ normal kidney function Acute exacerbation of chronic bronchitis 500 mg/day for 7 days
Community-acquired pneumonia 500 mg/day for 7-14 days. Acute maxillary sinusitis 500 mg/day f
days. Skin infections 500 mg/day for 7-10 days. Complicated UTI 250 mg/day for 10 days. Acute
pyelonephritis 250 mg/day for 10 days. Patients w/ CrCl 20-49 mL/min Initially 500 mg followed by
mg/day, CrCl 10-19 mL/min Initially 500 mg followed by 250 mg/48 hr; Haemodialysis Initially 500
followed by 250 mg/2 days; CAPD Initially 250 mg, followed by 250 mg/2 days.
1 cap daily.
Adults Day 1: 160 mg once daily; Day 2-5: 80 mg/kg once daily. Childn >8 kg Day 1: 3.2 mg/kg onc
Day 2-5: 1.6 mg/kg once daily.
Adult 75 mg once daily. Unstable angina 300 mg, then reduce to 75 mg once daily.
Tab Initially 1200 mg daily. Maintenance: 600-800 mg daily. To be taken in 3-4 divided doses. Syr Ad
tsp 3-4 times daily. Childn 8-12 yr 2 tsp, 3-7 yr 1 tsp, 1-2 yr tsp. All doses to be taken 3-4 times d
Adult 20-30 mg daily. Elderly 10-20 mg daily in divided doses. Childn >3 yr 10-15 mg daily.
1 tsp daily.
Childn >6 yr 1 tbsp twice daily; <6 yr -1 tbsp twice daily.
Individualized dosage.
Adult & childn >14 yr Initially 500 mg, followed by 250 mg 6 hrly.
Adult 1-2 tab 3-4 times daily. Childn -1 tab up to 2 times daily.
1 caplet daily.
1 cap daily.
Tab Adult 2-4 mg, childn 6-12 yr 2 mg, 2-6 yr 1-2 mg. Syr Adult 5-10 mL, childn 6-12 yr 5 mL, 2-6 y
mL. All doses are to be taken 3-4 times daily.
Cap 1 cap daily. Syr Adult & elderly 2 tsp once daily. Childn <12 yr 0.1 mg/kg body wt.
1 cap daily.
Apply twice daily on the face.
Apply twice daily on the face.
1 tab daily. MI may be increased to 300 mg/day. Transient ischemic attack May be increased to 100
mg/day.
1 cap daily.
1 softcap daily.
Anxiety 0.25-0.5 mg 3 times daily. Geriatric patients or in the presence of debilitating disease 0.25
times daily.
Adult 50 mcg twice daily. Childn >6 yr 25 mcg (or 5 mL syr) twice daily; <6 yr 1.125 mcg or 0.2-0.2
body wt twice daily.
Chewable tab Adult 1-2 tab, childn 6-12 yr -1 tab. Oral susp Adult 1-2 tsp, childn 6-12 yr -1 tsp.
taken 3-4 times daily.
Usual dose: 10 mg once daily. Range: 10-80 mg once daily. Primary hypercholesterolemia & combin
mixed hyperlipidemia 10 mg daily for 2 wk & up to 4 wk for max response. Homozygous familial
hypercholesterolemia 80 mg. Heterozygous familial hypercholesterolemia in ped patients 10-17 yr
daily. Max: 20 mg daily. Dose adjustment should be made at =4 wk intervals.
Apply to affected area 3 times daily & massage gently into the skin.
10-80 mg daily.
Initially 10 mg once daily at range of 10-80 mg once daily. Primary hypercholesterolemia & combin
(mixed) hyperlipidemia 10 mg once daily for 2 wk & up to 4 wk for max response. Homozygous fam
hypercholesterolemia 80 mg. Heterozygous familial hypercholesterolemia Childn 10-17 yr Recomm
starting dose: 10 mg daily. Max: 20 mg daily. Adjust dose at =4 wkly intervals.
Usual dose: 10 mg once daily. Range Dose: 10-80 mg. Hypercholesterolemia & combined (mixed)
hyperlipidemia atorvastatin 10 mg once daily for 2 wk. Max response: 4 mg. Homozygous familial
hypercholesterolemia 80 mg. Childn (10-27 yr) Heterozygous familial hypercholesterolemia 10 mg
Max: 20 mg daily. Dose adjustments should be made at =4 wk interval.
Tab 2-3 tab 3 times daily. Amp: IM/SC 1 amp once a day; IV 1 amp once a day injected slowly at 10
min rate or when mixed w/ 10-20 mL of isotonic or hypertonic glucose inj.
RA 15 mg daily, may be reduced to 7.5 mg daily. OA 7.5 mg daily, may be increased to 15 mg daily
15 mg/day. Initially, 7.5 mg daily for patients w/ increased risk of adverse reactions.
Metered-dose inhaler/metered aerosol Adult & childn =12 yr 2 puffs 4 times daily. Total daily dose:
puffs. Inhalant soln Adult, elderly & adolescents >14 yr 0.4-2 mL (8-40 drops). Childn 6-14 yr 0.4-1
20 drops). Doses to be taken 3-4 times daily.
Adult Mild to moderate infections 250/125 mg 3 times daily or 500/125 mg 2 or 3 times daily or 87
mg twice daily. Severe infections (including chronic & recurrent UTI & those of lower resp tract) 2 x
mg 3 times daily or 1-2 x 500/125 mg 3 times daily or 875/125 mg 3 times daily. Childn up to 12 yr
soft tissue & recurrent tonsillitis 20/5 to 40/10 mg/kg body wt/day. Otitis media, sinusitis, lower res
infections & UTI 40/10 to 60/15 mg/kg body wt/day. Doses should be taken 3 times daily.
After cleansing the face, apply thoroughly over the face affected by acne; only by then, loose powd
applied.
Adult & adolescent =12 yr Initially 2 sprays in each nostril. Maintenance dose: 1 spray in each nost
Childn 6-11 yr Initially 1 spray in each nostril, may be increased to 2 sprays in each nostril, then 1
each nostril once adequate control of symptoms is achieved. All doses are to be taken once daily. In
route only.
Initial dose should be given over 90-min infusion; 2nd dose over 60-min infusion & all subsequent d
over 30-min infusion. Metastatic colorectal cancer (mCRC) 5 or 10 mg/kg body wt as an IV infusion
every 2 wk, or 7.5 or 15 mg/kg body wt given once every 3 wk. Locally recurrent or metastatic tripl
negative breast cancer (mBC) 10 mg/kg of body wt given every 2 wk or 15 mg/kg of body wt given
every 3 wk as an IV infusion.
0.5 mL for each inj, IM. Primary vaccination: 1 sinlge dose of vaccine followed by a booster 6 mth la
childn, or 6-12 mth later for adult >16 yr.
Adult 1-2 sachet daily. May be given before or during cancer treatment (surgery, radio- & chemothe
Adult & childn >12 yr tab 2-3 times daily to be increased to 1 tab 3 times daily if required.
Adult 4 mg. Childn >12 yr 2-4 mg, 6-12 yr 2 mg, 2-6 yr 1-2 mg. To be taken 3-4 times daily.
Endometriosis 200-600 mg/day in 2 divided doses. Initially 200 mg, if necessary 600 mg/day. Conti
therapy uninterrupted for 3-6 mth, may be extended to 9 mth. Menorrhagia 200 mg daily for 12 wk
Fibrocystic breast disease Start w/ 50 mg daily, can be increased up to 100 mg/day in 2 divided do
Adult Mild to moderate infection in pulmonary disease, pneumonia, pharyngitis, tonsillitis, skin & so
infections Day 1: 500 mg as a single dose, Days 2-5: 250 mg once daily. Total dose of 1 g. Non-gon
urethritis & cervicitis 1 g as a single dose.
Cap Upper & lower resp tract, mild & moderate skin infections 500 mg as single dose on the 1st da
followed by single dose of 250 mg for 2.5 days. Non-complicated urethritis & non-gonorrheal cervic
caused by Chlamydia trachomatis 1 g as single dose. Syr Adult 500 mg/day for 3 days. Alternative
For 5 days administration: 1st day: 500 mg/day, 2nd-5th day: 250 mg/day. Childn 10 mg/kg body w
3 days. Alternative dose: For 5 days administration: 1st day: 10 mg/kg body wt/day, 2nd-5th day: 5
body wt/day.
Initial treatment & prophylaxis: A single dose of 15 mg/kg body wt/day ethambutol w/ 300 mg/day
Repeat treatment after 2-mth initial phase: A single dose of 25 mg/kg body wt/day ethambutol w/ 3
mg/day INH.
15-25 mg/kg body wt as single dose 24 hrly.
Tab Adult & childn >30 kg 375-750 mg twice daily. Childn <30 kg 25-50 mg/kg/day in 2 divided dos
Uncomplicated gonorrhoea 2.25 g as a single dose + probenecid 1 g concomitantly. Inj Adult 1.5-12
in divided doses every 6-8 hr up to a max of 4 g/day of sulbactam. Childn, infant & neonates 150
mg/kg/day in divided doses every 6-8 hr. Prophylaxis of surgical infections 1.5-3 g upon induction o
anesth. May be repeated every 6-8 hr.
UTI 250 mg twice daily. May be increased to 500 mg twice daily in severe infections. Resp tract, bo
joint, skin & soft tissue infections 500 mg twice daily, may be increased to 750 mg twice daily. GIT
infections 500 mg twice daily. Acute gonorrhoea 250 mg as a single dose. Acute osteomyelitis 750
twice daily.
Complicated upper & lower UTI, skin & soft tissue infections 1 g. Lower resp tract infections 1 or 2 g
Bacteraemia/septicaemia & infections in neutropenic patients 2 g. All doses are given 12 hrly.
Adult & childn Apply up to 3 times daily for up to 10 days.
Adult 2-4 g daily daily in 2 divided doses 12 hrly. Max: 4 g/day Severe or intractable infection May b
increased up to 8 g/day. Childn 40 mg/kg body wt/day in equally divided doses 6-12 hrly. Severe or
intractable infection May be increased up to 160 mg/kg body wt/day.
Adult tab Adult & childn >12 yr 2 tab. Gonorrhea 5 tab. Syr Childn 6-12 yr 10 mL, 6 mth-5 yr 5 mL,
mth 2.5 mL. Forte tab Adult & childn >12 yr 1 tab. Gonorrhea 2 tab. All doses to be taken twice dai
Apply 3-4 times daily to the affected areas. May be covered by sterile gauze, if needed.
Epilepsy Adult & childn >12 yr Initially 200 mg 2 times daily. Dosage may be increased at intervals
until 200 mg 3-4 times daily. Childn 12-15 yr Max: 1,000 mg/day, >15 yr Max: 1,200 mg/day. Adult
mg/day. Maintenance 800-1,200 mg/day. Childn 6-12 yr Initially 100 mg 2 times daily, increased w/
1 wk to 3-4 times daily until the optimum dosage is reached. Maintenance 400-800 mg/day. Trigem
neuralgia Initially 100 mg 2 times daily. Dosage may be increased to 200 mg 2 times daily until fre
pain. Max: 1,200 mg/day. Maintenance: 400-800 mg/day.
Acute community acquired pneumonia 200 mg/12 hr for 14 days. Total daily dose: 400 mg. Uncom
gonorrhea (men & women) & rectal gonococcal infections (women) 200 mg as a single dose. Skin &
structure infections 400 mg/12 hr for 14 days. Total daily dose: 800 mg. Pharyngitis &/or tonsillitis 1
mg/12 hr for 10 days. Total daily dose: 200 mg. Uncomplicated UTI 100 mg/12 hr for 1 wk. Total da
200 mg.
Childn 7-12 yr 10 mL, 2-6 yr 5 mL. All doses are to be taken 3 times daily.
Corneal ulcer 1st day: 2 drops every 15 min for 1st 6 hr then 2 drops every 30 min for remainder o
2nd day: 2 drops hrly. 3rd-14th day 2 drops 4 hrly. Conjunctivitis 1-2 drops 2 hrly for 2 days & 1-2 d
hrly for next 5 days.
Oral UTI Mild/moderate: 250 mg twice daily. Severe infections: 500 mg twice daily. Resp tract, skin
tissues, bone & joints infections Mild/moderate: 500 mg twice daily. More severe complications: 75
twice daily. GIT infections 500 mg twice daily. Acute osteomyelitis Dosage should not be <750 mg t
daily. IV infusion Uncomplicated renal infection, lower & upper UTI 100 mg twice daily. Other infecti
mg twice daily. Acute gonorrhoea & uncomplicated cystitis in women 100 mg as a single dose in wo
Nucleoside-naive treatment adult & adolescent =16 yr Chronic hepatitis B virus infection 0.5 mg on
Hepatitis B viremia while receiving lamivudine or w/ known lamivudine-resistance mutations 1 mg
daily.
Adult Monotherapy Initially 300 mg/day. Maintenance: 600-1,200 mg/day. Polytherapy Initially 300
Maintenance: 900-3,000 mg/day. Childn >5 yr Mono- or polytherapy 10 mg/kg body wt/day. Mainte
30 mg/kg/day. Dose may be increased by 5-10 mg/kg body wt/day if seizures remain uncontrolled.
Apply 2 times daily.
Initially 5 mg once daily may be increased to 10-20 mg once daily. Patients w/ bronchospastic, liver
(hepatitis or cirrhosis) & renal disorders (CrCl <40 mL/min) Initially 2.5 mg once daily.
Acute or chronic infection 1-2 cap daily. Supportive treatment of cancer 2 cap 3 times daily.
Gastric ulcer & gastritis Adult 1 tab 3 times daily in the morning, in the evening & before bedtime.
Consciousness due to head injury or brain surgery 100-500 mg IM/IV 1-2 times daily. Consciousnes
disturbances in acute cerebral infarction stage 1,000 mg IV once daily for 2 consecutive wk. Hemip
after cerebral apoplexy 1,000 mg IV once daily for 4 consecutive wk, continue for 4 wk if patient sh
clinical improvement.
Childn >5 yr 1 tsp (5 mL), infant 1-12 mth tsp (2.5 mL).
Childn >12 yr 2 tsp (10 mL), 6-12 yr 1 tsp (5 mL), 1-6 yr tsp (2.5 mL). Doses are to be taken onc
Childn >12 yr 2 tsp (10 mL), 6-12 yr 1 tsp (5mL), 1-6 yr tsp (2.5 mL). Doses are to be taken once
Becombion syr Adult 1 tsp (5 mL) twice daily. Childn >12 yr 1 tsp (5 mL) twice daily, 6-12 yr 1 tsp (
daily, 1-6 yr tsp (2.5 mL) daily. Becombion oral drops 1-3 yr 10 drops (0.5 mL) twice daily, 6-12 m
drops (0.5 mL) daily, <6 mth Dosage according to the physician. Becombion Forte sugar-coated tab
daily.
Caplet Adult & childn >12 yr Mild to moderate infection: 250 mg. Severe infections: 500 mg. To be
times daily. Syr/Forte syr Childn 7-12 yr 250 mg, 2-7 yr 125 mg, 9 mth-2 yr 62.5 mg. To be taken 3
daily. Dosage may be doubled in severe infections.
2.5 g IV infusion (corresponding to 50 mL/kg body wt/day). Infusion rate: 2-5 mL/kg body wt/hr or 2
drops/kg body wt/min (60 drops=1g0.1 g).
Wash & dry affected area. Apply sparingly to the affected areas & rub twice daily, morning & eveni
directed.
Cream & oint Apply a thin film to cover completely the affected area, once or twice daily, morning
Topical soln Wash & dry affected area. Apply sparingly to the affected area & rub twice daily. Treatm
should not be continued for >4 wk w/o patients re-evaluation.
Tab Adult & childn >12 yr 2 tab 3 times daily then reduce to 1 tab after 2-3 days. Childn 5-12 yr 1 t
times daily. Syr Adult & childn >12 yr 2 tsp. Childn 5-12 yr 1 tsp; 2-5 yr tsp. Doses to be taken 3
daily.
Adult & childn >6 yr Acute asthma episodes: 2 actuations. In more severe cases, if breathing has n
noticeably improved after 5 min, 2 further actuations may be taken. Intermittent & long-term treat
2 actuations, max: 8 actuations/day (average of 1-2 actuations 3 times daily).
Inhaler Acute asthma episodes 1 puff. If breathing has not improved after 5 min, a 2nd puff may be
Prophylaxis of exercise-induced asthma 1-2 puffs/administration up to max: 8 puffs/day. Bronchial a
other conditions w/ reversible airways narrowing 1-2 puffs/administration up to max: 8 puffs/day. In
soln Adult & adolescents >12 yr Acute asthma episodes 0.5 mL (10 drops). Severe cases: 1-1.25 m
drops). Particular severe cases: Up to 2 mL (40 drops). Prophylaxis of exercise-induced asthma 0.5
drops) up to 4 times daily. Bronchial asthma & other conditions w/ reversible airways narrowing 0.5
drops) up to 4 times daily. Childn 6-12 yr (22-36 kg body wt) 0.25-0.5 mL (5-10 drops). Severe case
(20 drops). Particular severe cases: 1.5 mL (30 drops). Prophylaxis of exercise-induced asthma 0.5
drops) up to 4 times daily. Bronchial asthma & other conditions w/ reversible airways narrowing 0.5
drops) up to 4 times daily. Childn <6 yr (<22 kg body wt) 50 mcg/kg body wt/dose (5-20 drops) up
times daily.
Tab 1 tab 2-3 times daily. Dispersible tab Adult 1-2 tab 2-3 times daily. Childn 6-12 yr 1 tab 3 times
6 yr tab 3 times daily.
Adult 25 mg 3 times daily, if required 100 mg daily, childn >6 yr 50-100 mg daily divided into 3-4 d
<6 yr 50 mg daily divided into 3-4 doses. Sedative Adult 50-100 mg. Childn 0.6 mg/kg/day.
1 cap daily.
Duodenal ulcer & recurrent gastric ulcer 30 mg once daily for 4-8 wk. Reflux/erosive oesophagitis 3
once daily for 8 wk.
Initially 1-2 drops/hr during the day & every 2 hr at night. Reduce to 1 drop 4 hrly & then to 1 drop
times daily.
Usual dose: 5-10 mg once daily. Patients w/ marked kidney, liver or lung diseases 2.5 mg daily.
Tab Adult & childn =12 yr 10 mg daily. Syr Adult & childn >12 yr 10 mL once daily. Childn 6-12 yr 1
once daily or 5 mL 12 hrly, 2-6 yr 5 mL once daily or 2.5 mL 12 hrly. Drops Adult & childn >12 yr 1
daily. Childn 6-12 yr 1 mL once daily or 0.5 mL 12 hrly, 2-6 yr 0.5 mL once daily or 0.25 mL hrly.
Apply 2-3 times daily until acute phase is over, then apply once daily.
Adult & childn >12 yr 1-2 g IV once daily. Max: 4 g daily. Peri-op infection prophylaxis 1 g as a singl
-2 hr pre-op. Infant & childn <12 yr 50-75 mg/kg/day in 2 divided doses. Max: 4 g daily. Meningits
mg/kg/day in 2 divided doses.
Adult 1 tsp 3 times daily. Childn 6-12 yr 1 tsp 2 times daily, 1-6 yr 1 tsp once daily, 6 mth-1 yr ts
daily.
Trichomoniasis Adult 2 g daily in a single dose or 500 mg twice daily for 7 days. To prevent re-infec
partner should be treated simultaneously w/ the same dose. Childn 15 mg/kg body wt/day in 3 divi
doses for 7-10 days. Intestinal amoebiasis Adult 750 mg 3 times daily for 5-10 days. Hepatic amoe
500-750 mg 3 times daily for 5-10 days. Childn 35-50 mg/kg body wt/day in 3 times daily for 10 da
Giardiasis Adult 2 g once daily for 3 days or 250-500 mg 3 times daily for 5-7 days. Childn 15 mg/k
wt in 3 divided doses for 5-7 days. Anaerobe infection Adult 7.5 mg/kg body wt 6 hrly, (Max: 4 g da
7-10 days.
Adult 2-3 tab. Up to 6 tab may be taken for complete evacuation of the colon. Childn 1-2 tab.
Pharyngitis/tonsillitis 250 mg 12 hrly for 10 days. Acute maxillary sinusitis 500 mg 12 hrly for 14 da
Lower resp tract infections 250-500 mg 12 hrly for 7-14 days. Uncomplicated skin & skin structure
12 hrly for 7-14 days.
Childn 6 mth to 5 yr 1 tab once daily for 10 days even if diarrhea has stopped. Infant <6 mth tab
daily for 10 days even if diarrhea has stopped.
Adult & elderly STD due to Chlamydia trachomatis 1000 mg as a single dose orally. Adult =16 yr 15
in a 3-day (500 mg/day) or 5-day regimen (500 mg as a single dose on day 1 then 250 mg/day on d
5).
After the skin has been cleansed, apply thinly 2 or 3 times a day.
=10,000 IU via IM/IV inj depends on severity.
Adult & childn >12 yr 1 g IM/IV 2 hrly. Surgical prophylaxis 1-2 g given 30-60 min pre-op. Gonorrho
g/day IM. Uncomplicated infections 1 g IM/IV 12 hrly. Moderate to severe infections 1-2 g IM/IV 8 hr
may be increased to 2 g IV 6-8 hrly if necessary. Life-threatening infections 2 g IV 4 hrly. Neonates
=12 yr 50-100 mg/kg body wt/day in 2-4 divided doses.
Mild to moderate UTI 500 mg-1 g IM/IV 12 hrly. Other mild to moderate infections 1 g IM/IV 12 hrly.
infections 2 g IV 12 hrly. Very severe or life-threatening infections 2 g IV 8 hrly.
Adult Serious infection 150-300 mg 6 hrly. More severe infection 300-450 mg 6 hrly. Childn Serious
infection 8-16 mg/kg body wt/day in 3-4 divided doses. More severe infection 16-20 mg/kg body wt
3-4 divided doses.
Adult 2 tab after initial bowel movement & 2 tab after subsequent bowel movement. Max daily dos
tab. Childn 6-12 yr adult dose. Max daily dose: 6 tab.
1 cap daily.
Adult 500 mg 3-4 times daily. Childn >1 mth 30-60 mg/kg body wt daily in 3-4 divided doses.
Apply once daily for 2 wk, may increase to twice daily after 2 wk.
Apply evenly on the skin or face, after washed w/ soap & cleansed w/ toner, in the morning & night
1 cap daily.
Inj IM inj daily until acute symptoms disappears. Drag 1-2 drag 3 times daily.
HTN Initially 5 mg once daily in the morning, may be increased to 10 mg once daily after 1 mth of
treatment. Elderly Initially 2.5 mg then 5 mg after 1 mth, may further increased to 10 mg dependin
renal function. Symptomatic heart failure Initially 2.5 mg in the morning, may be increased to 5 mg
daily after 2 wk. Stable CAD Initially 5 mg once daily for 2 wk, may be increased to 10 mg once dai
Elderly Initially 2.5 mg once daily for 1 wk then 5 mg once daily the next wk, may further increased
mg once daily.
1 tab daily.
Complicated UTI, skin & soft tissue infections 1 g 12 hrly. Lower resp tract infections 1 or 2 g 12 hrl
Septicemia, infections in neutropenic & immunocompromised patients, severe infections in ICU pat
12 hrly.
Cream Apply twice daily. Forte cream Apply once or twice daily.
1 softcap daily.
Adult 2-4 g daily IM/IV in 2 divided doses. In severe infections, doses may be increased to 8 g/day t
given in 2 divided doses. Uncomplicated gonococcal urethritis 500 mg IM as a single dose. Prophyla
peri-op infections 1-2 g IV 30-90 min before surgery.
Depends on severity. Infusion 1st dose of 2% v/v at rate of 40-80 drop/min then repeat dose after 6
needed, doses may be given 24 hrly to max of 80-100 mL. Childn Same dose as adult.
Adult 150 mg 2 times daily or 300 mg once daily, childn 5-8 mg/kg/day in 2 divided doses.
Adult, childn & infant >2 wk 50 mg/kg body wt/day in 3-4 divided doses, =2 wk & premature infant
mg/kg body wt/day in 4 divided doses.
Adult & childn >12 yr 1-2 g once daily. Dosage may be increased to 4 g daily in severe infections. I
childn <12 yr 50-70 mg/kg body wt.
Oral gel Apply liberally to gums & tongue as needed or squeeze approx 1.5 cm onto the tongue.
Mouthspray Spray liberally to gums, tongue & lips as often as required. Toothpaste Brush at least tw
daily after meals. Mouthwash Rinse mouth w/ approx 10 mL of the soln.
Adult 1-6 g daily. UTI & some serious infections 500 mg or 1 g 12 hrly. Severe infections esp in
immunocompromised patients, neutropenia 2 g 8 or 12 hrly. Fibrocystic patients w/ pulmonary infe
due to Pseudomonas 100-150 mg/kg/day in 3 divided doses. Childn & infant >2 mth 30-100 mg/kg
wt/day in 2-3 divided doses. Immunocompromised or fibrocystic childn or w/ meningitis 150 mg/kg
divided doses. Max: 6 g/day. Infants <2 mth 25-60 mg/kg/day in 2 divided doses.
1 tab daily. Mild case: 1 tab daily, severe case: 2 tab daily.
1 tab daily.
CHF Gradually titrate as 1.25 mg for 1 wk, 2.5 mg for a further wk, 3.75 for a further wk, 5 mg for 4
following wk, 7.5 mg for 4 following wk. Maintenance: 10 mg. HTN & angina pectoris 1 tab, may be
increased to 2-4 tab daily. All doses to be taken once daily. Final stages of renal dysfunction & seve
hepatic dysfunction Max: 2 tab daily.
Uterine involution 1 tab 3 times daily for 3-4 days. Control of uterine bleeding in emergency state 0
IV. Subinvolution, puerperium & lochiometral bleeding 1-2 tab 3 times daily or 0.5-1 mL IM. Caesare
section 1 mL IM or 0.5-1 mL IV following baby delivery.
Total dose: 300-400 mg. Twice a wk in average cases, should be adjusted according to patient's con
the range from once a day to once a wk. Pleural effusion 30-60 mg dissolved in 50-100 mL saline s
instilled via needle or catheter used for aspiration.
Anovulatory infertility 1 tab daily for 5 days starting on the 5th day of the menstrual cycle. If no ov
occurs, a 2nd course of 1 tab twice daily for 5 days may be given. Oligospermia 1 tab daily for 40-9
Emergency treatment of acute HTN during surgery 0.01-0.02% IV drip infusion (equiv 0.1-0.2 mg/m
starting rate of 2-10 mcg /kg/min until the desired BP value is reached. Rapid BP reduction 10-30
mcg/kg/min IV inj. Hypertensive emergency 0.01-0.02% IV drip infusion (equiv 0.1-0.2 mg/mL) at a
0.5 mcg/kg/min until the desired BP value is reached.
1 tab daily.
1 tab once daily. Adult Recommended dose: Initially 12.5 mg once daily for the 1st 2 days. Thereaft
mg once daily. May be subsequently increased at intervals of at least 2 wk up to the recommended
daily dose of 50 mg once daily or in divided doses (twice daily).
1 cap daily at night for a mth, followed by 2 x 1 cap daily for the next mth.
Metastatic bone disease 6 mg IV every 3-4 wk infused over 1-2 hr or 50 mg FCT once daily. Tumour
hypercalcaemia Moderate: 2 mg; severe: 4 mg as single dose. CrCl <30 mL/min 50 mg once wkly.
Prevention of skeletal events in breast cancer & bone metastases Reduce to 2 mg every 3-4 wk inf
over 1 hr.
Tab 150 mg once a mth. Inj 3 mg/3 mL IV bolus inj over 15-30 sec every 3 mth.
Strabismus For vertical muscles & horizontal strabismus of <20 prism diopters: 1.25-2.5 units in an
muscle. For horizontal strabismus of 20-50 prism diopters: 2.5-5 units in any 1 muscle. For persiste
nerve palsy of =1 mth: 1.25-2.5 units in the medial rectus muscle. Max: 25 units as single inj for an
muscle. Blepharospasm Initially 1.25-2.5 units into the medial & lateral pre-tarsal orbicularis oculi o
upper lid & into the lateral pre-tarsal orbicularis oculi of the lower lid. Glabellar lines 0.1 mL of
reconstituted soln into each of 5 sites, 2 in each corrugator muscle & 1 in the procerus muscle. Tota
20 units.
Tab/caplet/powd 1,000-2,000 mg daily in divided doses. O-dis tab 500 mg 2 times daily.
Unconsciousness due to head injury or brain surgery 100-500 mg IV drip or IM 1-2 times daily.
Unconsciousness in acute cerebral infarct 1000 mg IV once daily continuously for 2 wk. Post-apople
hemiplegia 1000 mg once daily by oral or IV inj.
Childn =4 yr 1 tsp 3 times daily, <4 yr 1 tsp daily.
Mild to moderate disease 1-2 drops 4 hrly. Severe infections 2 drops hrly until improvement, reduce
discontinuation.
1-2 drops 4-6 hrly. During initial 24-48 hr, dosage may be increased to 1-2 drops 2 hrly.
Recommended initial dose: Anovulation 75-150 IU daily for at least 7 days. Controlled ovarian
hyperstimulation 150-225 IU daily for the 1st 5 days of treatment.
Adult 3-4 tab daily. Elderly & debilitated Initially 1-2 tab daily, increase gradually to the effective do
Cerebral circulatory disorders & equilibrium disturbances 1 tab 3 times daily. Peripheral circulatory
disorders 2 tab 3 times daily.
Childn & infant >1 mth Nasal spray 1 spray/day in each nostril. Nasal drops 1-2 drops into each nos
Cap Psychoorganic symptoms associated w/ aging Initially 800 mg 3 times daily for 6 wk. Maintena
mg 3 times daily. Post-trauma syndrome Initially 800 mg 3 times daily. Doses can be gradually redu
400 mg 3 times daily after desired effect has been achieved. Usual dose: 1.2-4.8 g/day in 2-3 divid
doses. Syr Childn 30-50 mg/kg body wt/day. Childn >12 yr Adult dose, 6-12 yr -1 tsp 3 times daily
- tsp 3 times daily.
Breast cancer Recommended dose: 100 mg/m2 IV over 1 hr 3 wkly. 1st-line treatment: 75 mg/m2 i
combination w/ doxorubicin 50 mg/m2. Nonsmall cell lung cancer Failure of prior platinum-based
chemotherapy Recommended dose: 75 mg/m2 IV over 1 hr 3 wkly. Chemotherapy-naive patients
Recommended dose: 75 mg/m2 IV over 1 hr immediately followed by cisplatin 75 mg/m2 over 30-6
wkly. Ovarian cancer Recommended dose: 100 mg/m2 as 1 hr infusion 3 wkly.
Tab Adult 1-2 tab 2-3 times daily. Max: 15 mg/day. Childn 7-15 yr 1 tab 2-3 times daily. Inj Adult IV:
mg, may be repeated in few hr. Max: 2 mg/day. SC: 1-2 mg/day in 4 divided doses. Infusion: 1-2 mg
a continuous infusion. Childn 25 mcg/kg body wt/day as continuous infusion or in 4 divided SC dose
Turbuhaler Adult & childn >12 yr -1 inhalation as required or, when used as regular maintenance
6 hrly. Severe cases: Single dose may be increased to 3 inhalations. Max: 4 inhalations in 24 hr. Ch
yr -1 inhalation as required or, when used as regular maintenance therapy, 6 hrly. Severe cases:
dose may be increased to 2 inhalations. Max: 2 mg (4 inhalations). Respules Childn >25 kg 5 mg to
inhaled up to 2-4 times in a 24-hr period.
Initially 180 mg as single loading dose, followed by 90 mg twice daily w/ maintenance dose of ASA
mg daily.
Adult & childn >12 yr 1-2 g once daily depending on type & severity of infection. Max: 4 g daily.
Uncomplicated gonococcal infection 250 mg IM as a single dose. Childn <12 yr & infant For serious
infection other than meningitis 50-75 mg/kg daily in equally divided doses 12 hrly. Max: 2 g/day. M
100 mg/kg daily in divided doses 12 hrly w/ or w/o a loading dose of 75 mg/kg. Max: 4 g/day. Preop
(surgical prophylaxis) 1 g as a single dose -2 hr before surgery. To be administered by IV, IM or sh
infusion.
Caplet & Plus tab Adult & childn >10 yr 1 tab 3 times daily; childn 5-10 yr tab 3 times daily; 2-5
twice daily (for Bromifar caplet) or 3 times daily (for Bromifar Plus tab). Syr Adult & childn >12 yr 2
mL) 3 times daily; childn 6-12 yr 1 tsp (5 mL) 3 times daily.
Adult & childn >10 yr 2 measuring spoonful or as prescribed by physician, 5-10 yr 1 measuring spo
5 yr measuring spoonful. To be taken 3 times daily.
Adult 1 tab 3 times daily. In long-term therapy, the dose may be reduced to twice daily. Childn 1.2mg/kg body wt/day.
Adult & childn >12 yr 2-4 mg; childn 6-12 yr 2 mg; 2-6 yr 1-2 mg. All doses to be taken 3-4 times d
may be gradually increased. Elderly Initiate treatment w/ lower dose.
Brufen syr Relief of pain Adult 2 tsp. Reduction of fever & relief of pain Childn 6-12 yr 2 tsp; 3-7 yr 1
2 yr tsp. All doses should be taken 3-4 times daily. Brufen Forte tab Initially 1,200-1,800 mg daily
divided doses. RA & OA Max dose of 2,400 mg/day in acute exacerbation & may be reduced to max
1,800 mg/day in stable condition.
Adult 1 cap or 1 tbsp. Childn 6-12 yr 1-2 tsp. All doses to be taken 3 times daily.
Adult & childn =20 kg 250-500 mg. Childn <20 kg 20-40 mg/kg body wt. All doses to be taken 8 hr
Severe infection Dosage may be doubled. Acute gonorrhea 2-3 g as a single dose.
Bufect tab Adult & childn 8-12 yr 1 tab, 3-7 yr tab, 1-2 yr tab. All doses to be taken 3-4 times
Bufect oral susp Adult 2 tsp 3-4 times daily. Bufect Forte oral susp Adult 1 tsp 3-4 times daily. Child
of pain & reduction of fever 20 mg/kg in divided doses.
Individualized dosage.
After cleansing & debriding of the wound, the cream is applied w/ a sterile glove to the burned surf
times daily to a 2 mm thickness. Therapy is continue until satisfactory healing has occurred or unti
burned site is ready for grafting.
Tab Adult & childn >6 yr 1-2 tab 4 times daily. Inj Adult & childn >12 yr 1-2 amp (20-40 mg) slow IV
times daily. Max 100 mg/day.
Tab Adult 1-2 tab 3 times daily. Childn 1-2 tab 2 times daily. Syr Adult 10 mL 3 times daily. Childn 5
times daily.
1 cap daily.
Osteoporosis in postmenopausal period 0.25 mcg twice daily. Renal osteodystrophy 0.25 mcg daily.
Hypoparathyroid & rachitis Initially 0.25 mcg daily to be given in the morning. Infant & childn 1-5 y
hypoparathyroidism 0.25-0.75 mcg daily.
Adult & childn >12 yr 1 caplet 2-3 times daily. Childn <12 yr -1 caplet 3 times daily.
1 tab daily.
Adult 1 tsp twice daily. Childn 6-12 yr 1 tsp 1-2 times daily; 1-6 yr 1 tsp once daily; 6 mth-1 yr ts
daily.
Caplet Adult 1 caplet 1-2 times daily. Adolescent & childn >8 yr caplet 1-2 times daily. Susp Child
tsp once daily.
Caplet Adult 1 caplet. Adolescent & childn >8 yr caplet. Susp Childn >2 yr 1 tsp, 6 mth-2 yr 1
doses are to be taken once daily.
Pregnancy & lactation 2 cap daily. Menopausal period & elderly 2-3 cap daily.
Childn >4 yr 1 tsp 1-2 times daily; <4 yr 1 tsp once daily.
HTN 5 mg once daily. Max: 10 mg. Patients w/ liver dysfunction, elderly & infants Initially 2.5 mg on
Chronic stable or vasospastic (Prinzmetal's) angina 5-10 mg.
CalSource syr Childn 4-12 yr 30-45 mL, =3 yr 10-15 mL. To be taken daily. CalSource Forte Adult 1tab/day. CalSource Plus Vitamin C Adult 1 tab. Childn 3-7 yr -1 tab. To be taken 1-2 times daily.
CalSourceJunior Strength Childn 2 tab/day. CalSource Junior Growth Childn >3 yr 2 tab/day, 1-3 yr 1
tab/day.
1 tab daily.
Adult 1-6 g daily by IV or IM inj. Uncomplicated UTI 500 mg or 1 g twice daily. Severe infection,
immunocompromised patient & neutropenia 2 g 2-3 times daily. Cystic fibrosis & pseudomonas infe
90-150 mg/kg body wt/day in 3 divided doses. Childn & infant >2 mth 30-100 mg/kg body wt/day i
divided doses. Childn Immunocompromised infections, cystic fibrosis, meningitis Up to 150 mg/kg b
wt/day. Max: 6 g daily in 3 divided doses. Newborn & infant <2 mth 25-60 mg/kg body wt/day in 2
doses. Elderly Max: 3 g daily in 2-3 divided doses.
Adult & childn >14 yr Initially 100 mg, may be increased by 50-60 mg at 30-60 min interval if nece
Max: 400 mg/day.
Wash & dry affected area. Apply sparingly to the affected parts & surrounding areas & rub twice da
morning & evening. Max period of treatment is 7 days. Regular application is essential for treatmen
should be continued for 2 wk after all clinical signs have disappeared. Attention to hygiene is impo
the management of candidiasis, particularly on the folds & feet.
Wash & dry affected area. Apply adequately to the affected area twice or 3 times daily. Allow to be
further treatment to prohibit contagious of fungal disease of the folds or on the skin. All clinical sig
should improve w/in the 1st wk of treatment.
HTN Initially 4 mg once daily; max: 16 mg/day. Patients w/ moderate & severe renal impairment &
moderate hepatic impairment Initially 2 mg once daily. Heart failure Usual recommended initial dos
once daily, may be up-titrated to target dose 32 mg or to the highest tolerated dose by doubling th
w/ at least 2-wk interval.
Adult 250-500 mg 3-4 times daily. Childn 50 mg/kg/day in 3-4 divided doses. Premature & newborn
<2 wk 25 mg/kg/day in 4 divided doses.
Adult & elderly Recommended dose: 30 mg once daily. Duration of therapy: Duodenal ulcer & reflu
esophagitis 4 wk; benign gastric ulcer 8 wk. Hepatic & renal impairment Max dose: 30 mg daily.
Adult Pneumonia, UTI, gynecological infections eg endometritis, skin & skin structure infections 500
8 hrly. Nosocomial pneumonia, peritonitis, septicemia, presumed infections in neutropenic patients
hrly. Meningitis 2 g IV 8 hrly. Renal impairment: CrCl 26-50 mL/min 1 unit dose 12 hrly, 10-25 mL/m
unit dose 12 hrly, <10 mL/min -1 unit dose 24 hrly. Childn >3 mth up to 12 yr 10-20 mg/kg body
depending on type & severity of infection, susceptibility of the pathogen & condition of the patient
body wt Same as adult dose. Meningitis 40 mg/kg body wt 8 hrly.
Adult Mild to moderate UTI 500 mg-1 g IM/IV. Mild to moderate infections except UTI 1 g IM/IV. Seve
infections including skin & skin structure infections 2 g IV. Doses are given 12 hrly. Very severe or li
threatening infections 2 g IV 8 hrly. IV doses should be given approx over 30 min. Childn 2 mth-<16
=40 kg body wt Pneumonia, UTI, skin & skin structure infections; empiric therapy for febrile neutro
mg/kg body wt/dose 12 hrly for 7-10 days. Febrile neutropenic patient 50 mg/kg body wt/dose 8 hr
10 days.
Adult & childn =12 yr 10 mg daily during the evening meal. Childn 6-12 yrs 10 mg daily either as s
dose or as divided doses 5 mg ( caplet) in the morning & in the evening. Patient w/ renal insuffici
Reduce to of the usual recommended dose.
Complicated upper & lower UTI, skin & soft tissue infections 1 g, may be increased to 2 g in very se
cases. Lower resp tract infections 1-2 g. Infections in neutropenic patient, bacteremia/septicemia 2
doses should be given 12 hrly.
Caplet Adult & childn >12 yr Mild to moderate infections: 250 mg 3 times daily. Severe infections: 5
3 times daily. Childn Usual recommended dose: 25 mg/kg/day 8 hrly in divided doses. Dental infect
Adult & childn >12 yr 250 mg 3 times daily for 5 days. Renal impairment: Moderate (CrCl 10-30 mL
250-500 mg 12 hrly. Severe (CrCl <10 mL/min) Max: 250 mg tab 12 hrly. Dry syr 1-6 yr 5 mL. Child
2.5 mL. Forte dry syr Childn >6 yr 5 mL. Doses of syr should be taken 3 times daily.
Infections Adult & childn >12 yr 1.2 g inj 8 hrly. Childn 3 mth-12 yr 30 mg/kg of body wt 8 hrly. In m
serious infections, increase frequency to 6 hrly. Childn 0-3 mth 30 mg/kg body wt 8 hrly. In more se
infections, increase frequency to 8 hrly. Surgical prophylaxis 1.2 g inj given after the induction of an
Operations where there is a high risk of infections eg colorectal surgery, may require 3-4 times dail
HTN Initially 2.5 mg once daily. Maintenance: 2.5-5 mg daily. Max: 10 mg daily. Patients treated w/
Diuretics should be discontinued 2-3 days before starting treatment. Initially 1.25 mg daily. CHF Ini
1.25 mg once daily. Max: 10 mg daily. Post-MI treatment Initially 2.5 mg twice daily; patients unabl
tolerate should take 1.25 mg twice daily for 2 days. Dose may be doubled at 1-3 day intervals to m
mg daily.
HTN Initially 5 mg daily may be increased up to 7.5 mg/day w/ max 10 mg/day. Chronic stable or
vasospastic angina 5-10 mg. Elderly & hepatically impaired 2.5 mg daily.
Initially 100-200 mcg/min & increase gradually to >1,000-2,000 mcg depending on clinical & hemo
response. Infusion rate: Increase cardiac output 2.5-10 mcg/kg/min. Adequate hemodynamic impro
20 mcg/kg/min. Infusion rates for up to 40 mcg/kg/min have been required to obtain the desired eff
1 softcap daily.
Rate of infusion: 2.5-10 mcg/kg/min which may be increased up to 40 mcg/kg/min. Dose adjustmen
depends on heart rate & rhythm, BP & diuresis.
5 mg once daily. Max: 10 mg/day. Patients w/ hepatic insufficiency, elderly Initially 2.5 mg.
Adult 1 tab twice daily, if necessary 1 tab up to 3 times daily. Max: 120 mg/day.
Initially 5 mg once daily. Max: 10 mg once daily. Elderly or patients w/ liver dysfunction Initially 2.5
daily. Chronic stable angina, vasospastic angina 5-10 mg once daily.
HTN 1-16 mg daily. Usual dose: 2-4 mg once daily. BPH Initially 1 mg once daily. Usual dose: 2-4 mg
daily. Max: 8 mg daily.
Adult 1-2 tab or 25-50 drops 3 times daily. Childn 7-15 yr 75-100 drops daily in 3 divided doses, 3-7
drops/kg body wt/day, max 60 drops. Infant & childn <3 yr 2-3 drops/kg body wt/day. Duration of
treatment: 1-3 wk.
Adult Pneumonia, UTI, endometritis, gynecological infections, skin & soft tissue infections 500 mg I
Nosocomial pneumonia, peritonitis, infections in patient w/ neutropenia, septicemia 1 g IV 8 hrly. M
2 g IV 8 hrly. Childn 3 mth-12 yr 10-20 mg/kg body wt 8 hrly. Childn w/ >50 kg body wt Adult dose.
Meningitis 40 mg/kg body wt 3 times daily.
Essential HTN Adult Initially 25 mg/day, then increased to 100 mg/day as a single dose or in 2 divid
doses. Childn 1-2 mg/kg body wt/day in 2 divided doses. Severe HTN 100 mg/day. May be increase
wkly intervals up to 400 mg/day. Cardiac edema Adult 50-100 mg/day as a single or divided doses.
mg/kg body wt 3 times daily. Edema due to hepatic cirrhosis w/ or w/out ascites Adult 300-600 mg/
Edema due to nephrotic syndrome Adult 100-200 mg/day. Idiopathic edema 100 mg/day. Edema in
3.3 mg/kg body wt in either divided dose or as a single dose. Diagnosis & treatment of primary
aldosteronism 400 mg/day for 3-4 wk for long test. For short test, 400 mg/day for 4 days.
Emergency treatment of acute HTN crisis during surgery 2-10 mcg/kg/min IV drip infusion until des
value is reached & adjusted thereafter w/ monitoring to maintain BP. For rapid BP reduction 10-30 m
IV inj. Hypertensive emergencies 0.5-6 mcg/kg/min IV drip infusion at rate of 0.5 mcg/kg/min until
BP value is reached & adjusted thereafter w/ monitoring to maintain BP.
50 mg Adult males including the elderly 1 tab once a day. Start treatment at least 3 days before
commencing treatment w/ an LHRH analogue or at the same time as surgical castration. 150 mg A
males including the elderly 150 mg once daily.
Adult 100-150 mg in 2-3 divided doses daily. Max dose: 150 mg/day (pain & osteoarthritis); 225 mg
(RA); 125 mg/day (ankylosing spondylitis).
Adult Initially 100-150 mg daily, milder cases 50-100 mg daily in 2-3 divided doses. Max: 150 mg/d
management & osteoarthritis); 225 mg/day (RA); 125 mg/day (ankylosing spondylitis). Migraine Ini
mg, further 50 mg may be taken if insufficient relief w/in 2 hr. Max: 200 mg/day. Childn & adolesce
yr 50-100 mg daily in 1-2 divided doses. Max: 150 mg.
Adult 100-150 mg in 2-3 divided doses. Milder cases & for childn >14 yr 75-100 mg daily.
1 tab daily.
1 tab daily.
During pregnancy & lactation: 2-3 tsp. Childn >4 yr 2 tsp, <4 yr 1 tsp. To be taken 1-2 times daily.
Adult 1-2 mL 4 times daily. Infant & childn 1 mL 3-4 times daily. Prophylaxis 1 mL once daily.
Apply twice daily, may be used by itself or in combination w/ other dermatological treatments.
Apply twice daily, may be used by itself or in combination w/ other dermatological treatments.
Apply twice daily, may be used by itself or in combination w/ other dermatological treatments.
Cedantron: Tab Prevention of post-op nausea & vomiting Initially One 8-mg tab 1 hr before anaesth
followed by 2 doses of 8-mg tab 8 hrly. Radiotherapy-induced nausea & vomiting 8 mg orally 1-2 hr
radiotherapy followed by 8 mg orally 8 hrly for up to 5 days. Inj Treatment of post-op nausea & vom
mg IM as single dose or slow IV inj. Highly emetogenic chemotherapy Initially 8 mg by slow IV inj o
infusion immediately before chemotherapy, then continuous IV infusion of 1 mg/hr for up to 24 hr o
further 2 doses of 8 mg by slow IV inj or 15-min infusion 4 hr apart. Either regimen is then followed
orally 12 hrly up to 5 days. Less emetogenic chemotherapy 8 mg by slow IV inj or 15-min infusion
immediately before chemotherapy or 8 mg orally 1-2 hr before chemotherapy followed by 8 mg ora
hrly for up to 5 days. Cedantron Syr Adult 2 tsp 3 times daily. Childn >11 yr 2 tsp twice daily, 4-11
twice daily, 1-4 yr 0.15 mg/kg body wt.
Adult Cedocard 5 tab Angina acute attack 1 tab. Prophylaxis: 1-2 tab 3-4 times daily. Prevention of
nocturnal attacks 1-2 tab before sleep. Cedocard 10 tab 1-3 tab 4 times daily. Cedocard 20 tab Prev
of expected attack or of nocturnal angina 1 tab. General dose: 30-160 mg/day, taken 3-4 times dai
Initially tab. Effective dose: 40-160 mg daily, in severe cases up to 240 mg daily. Cedocard IV inf
10 mg/hr. Cedocard Retard tab 1 tab 2 times daily.
Adult Usual dose: 50-100 mg twice daily. Renal impairment CrCl >60 mL/min Standard dose, 21-60
75% of the standard dose, <20 mL/min 50% of the standard dose. Uncomplicated gonorrhea 400 m
single dose. Childn >30 kg Recommended daily dose: 50-100 mg twice daily. Childn =30 kg 1.5-3 m
body wt twice daily. More severe or intractable infections Up to 6 mg/kg body wt daily in divided do
twice daily.
Adult & childn >12 yr Usual dose: 1 g 2 times daily (12 hrly), may be increased to max 12 g in seve
cases. Gonorrhoea 1 g IM as a single dose. Uncomplicated infection 1 g IM/IV 12 hrly. Moderate to s
infection 1-2 g IM/IV 8 hrly. High-level infection 2 g IV 6-8 hrly.
Cap Adult & childn =30 kg 100 mg 1-2 times daily, may be increased to 200 mg 2 times daily in se
infections. Dry syr Childn 1.5-3 mg/kg body wt 2 times daily, may be increased to 6 mg/kg body wt
daily in severe infection.
Adult 1-2 g daily in 2 divided doses. Cystitis 1-2 g daily as a single dose or in 2 divided doses. Othe
daily in 2 divided doses. Skin & soft tissue infections 1 g daily as a single dose or in 2 divided dose
& lower resp tract infections 1 g daily. The dose may be increased up to 2 g daily in severe infectio
divided doses. Pharyngitis & tonsillitis caused by group A -haemolytic streptococci 1 g daily in div
doses for 10 days. Childn 25-50 mg/kg/day in 2 divided doses.
Adult 1 g in 2 equally divided doses, may be increased to 1.5-3 g in 3 divided doses. Childn 20-40 m
2 equally divided doses, may be increased to 100 mg/kg in =3 equally divided doses.
Adult Dosage range: 1-6 g daily IV/IM 8 or 12 hrly. Uncomplicated UTI 500 mg or 1 g 12 hrly. Severe
infection or infections in immunocompromised patient 2 g 8 or 12 hrly. Cystic fibrosis & Pseudomon
infections 90-150 mg/kg body wt/day in 3 divided doses. Childn & infant >2 mth 30-100 mg/kg bod
wt/day in 2-3 divided doses. Childn up to 2 mth & neonate 25-60 mg/kg/day in 2 divided doses.
Adult & childn =30 kg 50-100 mg twice daily, may be increased up to 200 mg twice daily. Childn 1.
mg/kg body wt twice daily.
Adult 0.5 g IM/IV in 2-4 divided doses, may be increased to 4 g/day. Childn =6 mth 40-80 mg/kg bo
wt/day IV in 2-4 divided doses, may be increased to 120 mg/kg body wt/day.
Adult Mild to moderate UTI 500 mg-1 g IV/IM 12 hrly. Mild to moderate infections except UTI 1 g IV/
hrly. Severe infections 2 g IV 12 hrly. Very severe to life-threatening infections 2 g IV 8 hrly. Paed pa
mth-16 yr up to 40 kg Pneumonia & empiric therapy for febrile neutropic patient 50 mg/kg/dose 12
8 hrly in neutropenic patient) for 7-10 days.
Adult 0.5-2 g IM/IV in 2-4 divided doses, may be increased to 4 g/day. Childn =6 mth 40-80 mg/kg/d
2-4 divided doses, may be increased to 120 mg/kg/day.
Upper & lower UTI, skin & soft tissue infections 1 g IM/IV 12 hrly. Septicemia, infections in neutrope
immunocompromised patient, severe infections in ICU patient 2 g IM/IV 12 hrly.
Individualized dose.
Adult 2-4 g in 2 divided doses12 hrly, may be increased up to 8 g daily in severe or refractory infec
Childn 40-80 mg/kg/day in divided doses 6-12 hrly, may be increased up to 160 mg in severe or re
infections.
Adult 2-4 g/day in 2 divided doses. Severe infections 8 g/day in 3 divided doses. Max of 16 g/day.
Uncomplicated gonococcal urethritis 500 mg IM as single dose.
Adult 2-4 g daily in 2 divided doses 12 hrly. May be increased up to 8 g daily in severe or refractory
infections. Childn 40-80 mg/kg/day in divided doses 6-12 hrly. Dose may be increased up to 160 m
in severe or refractory infections.
Adult Inj Usual dose: 2-4 g/day in divided doses 12 hrly. May increase dose to 6-12 g in 2-4 divided
severe infections. Infusion 1 g diluted into 20-100 mL of sterile IV soln to be given w/in 15 min to 1
Dose: 16 g daily.
Adult 2-4 g daily in 2 divided doses, to be given 12 hrly. Severe infection or infections to less sensit
organisms 1.5-4 g 2-4 times daily.
Adult 2-4 g/day in divided doses every 12 hr. Dosage may be increased to 8-12 g/day in severe infe
Max: 16 g daily. Uncomplicated gonococcal urethritis 500 mg IM as a single dose.
Mild to moderate UTI 500 mg-1 g IV/IM 12 hrly. Mild to moderate infections other than UTI 1 g IM/IV
Severe infections 2 g IV 12 hrly. Very severe or life-threatening infections 2 g IV 8 hrly. Childn =40 k
mg/kg 12 hrly Febrile neutropenia 50 mg/kg 8 hrly.
Complicated upper & lower UTI, skin & soft tissue infections 1 g 12 hrly. Lower resp tract infections
hrly. Bacteremia/septicemia & severe infections, infections in neutropenic patients 2 g 12 hrly.
Adult 0.5-2 g IM/IV 2-4 times daily. Septicaemia dosage may be increased to 4 g daily. Childn 40-80
body wt IV 3-4 times daily. Severe infection (eg septicaemia & meningitis) dosage may be increase
mg/kg body wt.
Adult 2-4 g daily in 2 divided doses. Max: 4 g/day. Childn 40-80 mg/kg body wt/day in 2-4 divided d
Max: 160 mg/kg/day.
Adult & childn >12 yr 1-2 g once daily depending on the type & severity of infection. Max: 4 g daily
Uncomplicated gonococcal infections 250 mg IM as a single dose. Surgical prophylaxis 1 g IV as a s
dose -2 hr before surgery. Meningitis 100 mg/kg body wt/day in equally divided doses 12 hrly w/
loading dose of 75 mg/kg. Max: 4 g/day. Childn <12 yr & infant Serious infections other than menin
75 mg/kg/day in equally divided dose 12 hrly. Max: 2 g/day.
Complicated UTI, skin & soft tissue infections 1 g. Lower resp tract infections 1 or 2 g.
Bacteremia/septicemia, severe infections, infections in patients w/ neutropenia 2 g. Doses are give
hrly.
Overdosage
Administration
Should be taken with food: Take after meals.; Take after meals.
May be taken with or without food: May be taken w/ meals for better
absorption or if GI discomfort occurs.
Should be taken with food: Dissolve tab in a glass of water (=200 mL)
May be taken with or without food: May be taken w/ meals for better
absorption or if GI discomfort occurs.
May be taken with or without food: May be taken w/ meals for better
absorption or if GI discomfort occurs.
Should be taken with food.
May be taken with or without food: Swish & hold in mouth for as long
as possible before swallowing.
May be taken with or without food: May be given w/o regard to meals.
Best taken at the start of meals for better absorption & to reduce GI
discomfort.
May be taken with or without food: May be taken w/ meals for better
absorption or if GI discomfort occurs.
May be taken with or without food.
Should be taken with food: Take after meals. Swallow whole, do not
chew/crush.
Should be taken with food: Take before meals. Drops are to be taken
w/ sugar & water, or in bottle feeds.
May be taken with or without food: May be taken w/ meals for better
absorption or if GI discomfort occurs.
Contraindications
Hypersensitivity.
Hypersensitivity.
Hypersensitivity to dihydropyridine.
Hypersensitivity to cephalosporins.
Hypersensitivity.
Pregnancy.
Hypersensitivity.
Hypersensitivity.
Hypersensitivity.
Hypersensitivity to penicillins.
Hypersensitivity.
Hypoglycemia.
Hypersensitivity.
Hypersensitivity.
Systemic fungal infections. Active gastric ulcer, ocular herpes simplex. Patients
receiving MAOIs. Neoneates, premature infants.
Hypersensitivity. Rare hereditary problems of fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase insufficiency.
Haemorrhage; CHF.
Hypersensitivity to penicillins.
Hypercalcemia.
Hepatic coma or risk of hepatic coma; severe renal disorder or azotemia; CHF;
severe acidosis; abnormal electrolyte metabolism, hyperpotassemia,
hyperphosphatemia, hypermagnesemia, hypercalcemia; reduced urine output;
abnormal amino acid metabolism.
Endogenous hepatic coma, acute liver atrophy, hyperkalaemia, shock,
decompensated cardiac insufficiency, fructose or sorbitol intolerance, fructose1,6-diphosphate deficiency, methanol poisoning, amino acid metabolism
anomalies.
Severe renal disorder; abnormal amino acid metabolism other than hepatic
disorders.
Sensitivity to dihydropyridines.
Hypersensitivity to dihydropyridines.
Hypersensitivity.
Hypersensitivity to penicillins.
BP <100 mmHg, acute psychosis. Pregnancy & lactation. Infant 1st mth birth.
Hypersensitivity to cephalosporins.
Hypersensitivity to penicillins.
Pernicious anemia.
Hypersensitivity. Stenosis of the renal artery (bilateral/unilateral) in the singlekidney patients; low BP or labile circulatory conditions. Pregnancy.
Hypersensitivity to cephalosporins.
Hypersensitivity.
Herpes simplex, varicella, skin TB, dermatitis caused by syphilis & skin ulcer.
Treatment of the eye.
Herpes simplex, varicella, skin TB, dermatitis caused by syphilis & skin ulcer.
Treatment of the eye. Hypersensitivity to neomycin.
Hypersensitivity to aripiprazole.
Patients who exhibit asthma, rhinitis & dyspnea, nasal polyp, angioedema,
bronchospastic reactions due to aspirin, severe & active peptic ulcer (gastric &
duodenal ulcer), last trimester of pregnancy.
Liver dysfunction; asthma, rhinitis & urticaria due to acetosal or other NSAIDs.
Severe & active peptic ulcer (gastric & duodenal ulcers). End trimester of
pregnancy.
Hypersensitivity to anthraquinone derivatives. Pregnancy & lactation.
Myasthenia gravis.
Hypersensitivity.
Hypotension.
Hypersensitivity to penicillins.
Hypersensitivity.
Hypersensitivity to penicillins.
Hypersensitivity to cephalosporins.
Hypersensitivity. Rare hereditary problems of galactose intolerance, Lapplactase deficiency or glucose-galactose malabsorption. Lactation.
Childn & juvenile before end of growth phase. Pregnancy & lactation.
Hypersensitivity to entecavir.
Autoimmune diseases.
Neonates. Lactation.
Bacterial, viral or fungal infections of the eye, ocular TB, acute purulent eye
infections, glaucoma. Do not use w/ contact lenses.
Cardiogenic shock, overt cardiac failure, 2nd- or 3rd-degree AV block, marked
sinus bradycardia.
Lactation.
Vaccinia, varicella, skin TB. Fungal & viral infection. Rosacea & acne vulgaris.
Perioral dermatitis, perianal & genital pruritus.
Pregnancy & lactation. Childn.
Viral diseases of the skin, skin TB, acute purulent infection of bacterial, fungal
origin.
Hypersensitivity to cephalosporins.
Hypersensitivity.
Hypersensitivity to cephalosporins.
Risk of intracranial bleeding. Concomitant use of drugs that can inhibit blood
coagulation. Childn <12 yr.
Hypersensitivity to Zn.
Hypersensitivity to cephalosporins.
Hypersensitivity to cephalosporins.
Hypersensitivity to cephalosporins.
Hypersensitivity to cephalosporins.
Hypersensitivity. Hypocalcaemia.
Hypersensitivity.
Hypersensitivity.
Viral diseases including skin TB, acne vulgaris, scabies, perioral dermatitis,
ringworm infection, bacterial & fungal infections unless appropriate
chemotherapy is given. Extensive & prolonged use in pregnancy.
Hypersensitivity to cephalosporins.
Peptic ulcer.
Hypersensitivity.
Hypersensitivity.
Local infections of the intestine, infants & young childn, severe disorders of
liver function.
Peptic ulcer.
Obstetric paracervical block & IV regional anesth. Hypersensitivity to amidetype local anesth.
Pregnancy, lactation.
Hypersensitivity to cephalosporins.
Severe hepatic impairment &/or cholestasis. 2nd & 3rd trimester of pregnancy,
lactation.
Hypersensitivity. Severe hepatic & renal impairment. Not for bacterial infection
prevention; trivial & laryngeal infections & flu treatment.
Hypersensitivity to lansoprazole.
Hypersensitivity.
Bleeding disorder.
Hypopigmentation.
Hypersensitivity to cephalosporins.
Hypersensitivity to cephalosporins.
Hypersensitivity to cephalosporins.
History of shock.
Hypersensitivity.
Hypersensitivity.
Hypersensitivity to cephalosporins.
Hypersensitivity.
Hypersensitivity.
Hypersenstivity.
Hypersensitivity.
Hypersensitivity to cephalosporins.
Special Precautions
Monotherapy treatment, preventive treatment for risk of HIV transmission, moderate to severe ren
pancreatitis, lactic acidosis, hepatomegaly & steatosis, severe immune deficiency. Lactation.
Administer only via IV route. When large or frequently repeated doses are required, patients of bloo
should be monitored for signs of progressive anemia. Pregnancy.
Avoid contact w/ eyes or mucous membrane. Pregnancy & lactation. Childn 2-23 mth & infants <2
Anaphylactic reaction.
Reduce dose or discontinue if signs or symptoms of tardive dyskinesia & neuroleptic malignant syn
Patient w/ history of seizure. May impair ability to drive or operate machinery. Pregnancy & lactatio
Reduce or discontinue dose if signs or symptoms of tardive dyskinesia & neuroleptic malignant syn
History of seizure. May impair ability to drive or operate machinery. Pregnancy & lactation.
Reduce dose or discontinue if signs or symptoms of tardive dyskinesia & neuroleptic malignant syn
impair ability to drive or operate machinery. Pregnancy & lactation.
Reduce or discontinue dose if sign or symptoms of tardive dyskinesia, neuroleptic malignant syndr
of seizure. May impair ability to drive or operate machinery. Pregnancy & lactation.
Monitor renal function during concomitant treatment w/ aminoglycocides. Pregnancy & lactation.
History of hypersensitivity to other cephem antibiotics & penicillins; allergy eg bronchial asthma, ra
serious renal dysfunction; poor oral nutrition, receiving parenteral nutrition, debility. Periodic monit
function is recommended. Pregnancy & lactation. Childn <6 mth, elderly.
Not for use in the reversal of bronchospasm in acute asthma attacks. Brittle or unstable asthma. Eo
conditions including Churg-Strauss syndrome & eosinophilic pneumonia. Hepatotoxicity. Elderly. Pre
impairment.
Impaired kidney function, renovascular diseases, vascular disorders, collagen diseases. Lactation. C
Administer after food intake in patients with gastritis. Not recommended for DM patients until blood
controlled at normal level. Pregnancy & lactation.
Do not apply to mucous membrane. Not for prevention of recurrent herpes simplex infection. Pregn
childn.
Ensure appropriate hydration prior to administration esp in elderly & in patients on diuretics. Adequ
intake prior to Aclasta therapy in patients w/ preexisting hypocalcemia & for 10 days following Acla
Paget's disease of bone. Should not be used in severe renal impairment (CrCl <35 mL/min); monito
Dental examination prior to treatment in patients w/ cancer, under chemotherapy or corticosteroid
hygiene; avoid invasive dental procedures for those who develop osteonecrosis of the jaw. 5-mg do
administered over at least 15 min.
Pseudomembranous colitis. Long-term usage. Childn <2 mth. Pregnancy & lactation.
Perform liver function test prior to initiation 12 wk after treatment initiation, during dose evaluation
thereafter. Alcohol consumption or history of liver disease. Promptly report unexplained muscle pai
weakness, especially if accompanied w/ malaise or fever. Discontinue use in case of markedly elev
diagnosed or suspected myopathy or w/ risk factor to development of renal failure secondary to rha
Regular hepatic & hematological monitoring; undernutrition, irregular meal times, missed meals, d
imbalance between physical exertion & carbohydrate intake, alcohol consumption; impaired renal f
liver dysfunction, endocrine system disorders affecting carbohydrate metabolism; galactose intoler
deficiency or glucose-galactose malabsorption. Childn.
Chronic renal & hepatic disorders, resp disorder, muscle weakness, history of drug or alcohol abuse
personality disorders, chronic pulmonary insufficiency. May cause dependence. Avoid single dose tr
depression or combined anxiety-depression. Avoid long-term therapy. May affect the ability to drive
machinery. Pregnancy & lactation.
Impaired liver & kidney function, glaucoma, prostate hypertrophy, hyperthyroid, DM, heart disease
Concomitant use w/ other CNS suppressants. May impair ability to drive or operate machinery. Preg
Elderly. Childn <2 yr.
Impaired liver & kidney function, glaucoma, prostate hypertrophy, hyperthyroid, DM, heart disease
debility, hypoxia; impaired resp function (eg asthma, emphysema), resp & CNS depression in large
use w/ other CNS suppressants. Discontinue treatment if insomnia, palpitation & dizziness occur. M
drive or operate machinery. Pregnancy & lactation. Elderly. Childn <2 yr.
Impaired liver & kidney function, glaucoma, prostate hypertrophy, hyperthyroid, DM, heart disease
Concomitant use w/ other CNS suppressants. Discontinue treatment if insomnia, palpitation & dizzi
impair ability to drive or operate machinery. Pregnancy & lactation. Elderly. Childn <2 yr.
Bleeding, recent IM inj or small recent traumas eg biopsies, puncture of major vessels, cardiac mas
resuscitation. Conditions w/ increased haemorrhagic risk, systolic BP >160 mmHg. Advanced age. I
acute MI: Coronary thrombolysis may result in arrhythmia associated w/ reperfusion, thromboembo
increased in patients w/ left heart thrombus eg mitral stenosis or atrial fibrillation. In treatment of A
Stroke: Pre-treatment with aspirin. Treatment should not be initiated later than 4.5 hr after onset of
Monitor BP up to 24 hr during treatment.
Treat hypocalcaemia & other disturbances of bone & mineral metabolism before starting therapy. M
Ca & vit D intake. Severe renal impairment, preexisting GI disease. Pregnancy & lactation.
Concomitant of food, certain medication & beverages (except plain water); history of esophageal d
hypocalcemia; bone & mineral metabolism dysfunction (eg vit D deficiency & parathyroid abnorma
effectively treated before starting therapy. Severe renal impairment (CrCl <30 mL/min); history of u
those using NSAIDs or aspirin concomitantly; osteonecrosis of the jaw. Dental examination w/ appro
dentistry should be considered prior to treatment w/ bisphosphonates in patients w/ concomitant ri
cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene).
Lactic acidosis may occur. Monitor renal & hepatic function. Discontinue 48 hr pre-op under genera
Elderly.
Infections & other feverish conditions or other diseases that increase insulin requirement. May imp
or operate machinery. Pregnancy.
Avoid contact w/ eyes & long-term use. Pregnancy & lactation. Childn.
Liver impairment, elderly, pregnancy, lactation, childn. Patients who are allergic to avian proteins,
products. Not for ophth treatment.
Chronic nasal congestion upon w/drawal (prolonged use). Concurrent administration w/ MAOI. Card
Patients who may be at risk of increased bleeding from trauma, surgery or other pathological cond
hepatic disease who may have bleeding diatheses; renal impairment. Acute ischaemic stroke (<7 d
rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose ma
Pregnancy.
Known or suspected CV disorders, renal insufficiency, hepatic dysfunction. Monitor blood counts, liv
functions. Lactation. Childn <16 yr.
Possibility of lesions or erosions of cartilage in wt bearing joints & other signs of arthropathy.
Patients requiring Na restriction. Patients w/ cardiac failure, renal insufficiency or chronic anemia at
developing circulatory overload, dehydration. Monitor BP, MI, serum K, platelet count & prothrombi
History of GI disease, particularly colitis; renal &/or hepatic disease; superinfections & overgrowth o
pregnancy.
IV route only. Monitor central venous pressure, blood coagulation parameters & hematocrit during t
of heart failure. Elderly. Pregnancy & lactation.
Impaired hepatic or renal function, prostatic hypertrophy, hyperthyroidism, glaucoma, cardiac diso
debilitated, childn <2 yr. Pregnancy & lactation. May impair ability to drive or operate machinery.
Monitor serum K & uric acid in conditions predisposed to hypokalemia or gout. History of hypersens
sulfonamide derivatives. Pregnancy & lactation.
Sinus syndrome or other supraventricular cardiac conditions; history of ulcer disease, asthma or ob
pulmonary disease. Concurrent treatment w/ NSAIDs. Pregnancy & lactation. May impair ability to d
machinery.
Monitored blood glucose. Antidiabetic drug dose may be adjusted if necessary to avoid hypoglycem
intake. Pregnancy & lactation.
Prolonged use may cause posterior subcapsular cataract, glaucoma & increase secondary fungal &
infections; suppress body resistance to infections. Avoid abrupt w/drawal. Patients w/ history of psy
HTN, gastric ulcer, diabetes, osteoporosis, fresh diverticulitis & intestinal anastomosis, myasthenia
angle glaucoma, pyloroduodenal obstruction, prostate hypertrophy, renal insufficiency. Pregnancy &
impair ability to drive or operate machinery.
Cardiac disease; diabetes; glaucoma; pregnancy. May impair ability to drive or operate machinery.
Sick-sinus syndrome, supraventricular cardiac conductions, history of ulcer disease, asthma or obs
disease.
HTN or at risk for stroke (eg overwt). Elderly. Liver & kidney dysfunction, glaucoma, prostate hyper
hyperthyroidism, urinary retention. Debility, hypoxia, asthma & emphysema. May impair ability to
machinery. Childn <6 yr. Pregnancy & lactation.
Discontinue gradually over a min of 1 wk. May affect ability to drive or operate machinery. Pregnan
Childn <12 yr.
Avoid single dose treatment in depression or combined anxiety-depression. Pregnancy & lactation,
liver disorders, resp disorder, atrophy & patients who are prone to abuse drugs. Childn <10 yr, geri
patients. Avoid long-term treatment. May impair ability to drive or operate machinery.
Childn especially when ambient temp is high, tachycardia, debilitated patients w/ COPD. May impa
operate machinery (chlorpheniramine maleate).
Renal insufficiency.
Abuse-prone individuals. Renal or hepatic dysfunction. Patients whose primary diagnosis is schizop
or suicidal patients. Pregnancy, lactation. Childn <18 yr. Avoid abrupt discontinuation. May affect a
operate machinery.
Diabetes.
Sick sinus syndrome, conduction defects, asthma, COPD, pregnancy, lactation. Patients receiving N
Regular monitoring of glucose levels in blood & urine. Milder or absent symptoms of hypoglycaemi
autonomic neuropathy or taking -blockers, clonidine, reserpine, guanethidine or other sympatholy
changeover to insulin in exceptional stress situations (trauma, surgery, febrile infections).
Regular monitoring of glucose levels in blood & urine. Milder or absent symptoms of hypoglycaemi
autonomic neuropathy or taking -blockers, clonidine, reserpine, guanethidine or other sympatholy
changeover to insulin in exceptional stress situations (trauma, surgery, febrile infections).
Regularly monitor glucose & glycosylated Hb. Milder or absent symptoms of hypoglycaemia eg in t
w/ autonomic neuropathy or taking -blockers, clonidine, reserpine, guanethidine or other sympath
Temporary changeover to insulin in exceptional stress situations (eg trauma, surgery, infections w/
renal impairment.
Hepatic & renal impairment, CHF. Pregnancy & lactation. Childn & elderly.
Hepatic failure, renal insufficiency dependent on dialysis; hypotension (systolic BP <90 mmHg) & C
lactation. May impair ability to drive or operate machinery.
Ensure adequate calorie intake (35-40 kCal/kg body wt/day). Monitor serum Ca level periodically. C
lactation.
Hepatic & renal disorders, CV dysfunction, acidosis, DM. Pregnancy & lactation. Elderly, childn.
Hypoglycemia, hyperammonemia.
Patients w/ impaired kidney function. Adjust or discontinue use if renal impairment, vestibular or he
occur. Prolonged use. Pregnancy & lactation.
Kidney failure, impaired liver function. Childn, elderly, pregnancy & lactation.
Check for urine vol not <60-70 mL/hr & re-examine dosage schedule when vol falls below the level
Periodically assess renal, hepatic & haematopoietic functions during prolonged therapy. Maintain a
& urinary output during high-dose treatment. Check indwelling catheters regularly for patency. Pre
HTN, ocular herpes simplex, cirrhosis, hypothyroidism, nonspecific ulcerative colitis, DM.
Lactation.
Moderate or severe renal/resp insufficiency, moderate or severe hepatic impairment, patients susc
opioid dependence, cranial trauma, convulsive disorder, biliary tract disorder, under altered state o
resp center problem. May affect ability to drive or operate machinery. Childn <16 yr.
Hypersensitivity to penicillins, renal impairment & colitis, prolonged use, superinfections. Pregnanc
Moderate or severe renal impairment, severe hepatic dysfunction, prolonged use. Pregnancy (esp 1
lactation.
Latent or overt cardiac failure, renal or hepatic impairment, HTN, epilepsy, migraine; benign prosta
mammary carcinoma, hypernephroma, bronchial carcinoma, skeletal metastases; monitor skeletal
regularly, prepuberty.
Should not be used as monotherapy for megaloblastic anemia associated w/ vit B12 deficiency.
History of GI disease esp colitis. Severe hepatic or renal disease. Atopic individuals. Pregnancy, lac
infants & the elderly. Monitor hepatic & renal function during prolonged therapy.
Elderly or debilitated patients w/ chronic renal failure, CHF. Impaired hepatic function, myasthenia g
ability to drive or operate machinery at least 12 hr after IV administration. Pregnancy & lactation. I
Childn <18 yr.
Monitor cardiac function continuously in patient w/ HTN or cardiac decompensation. Patient w/ elev
Avoid mechanical stimulation of the pharynx unless a muscle relaxant is co-administered. Chronic a
alcohol intoxication.
Angioedema unrelated to ACE inhibitor therapy; CHF w/ or w/o associated renal insufficiency.
Unstable epilepsy, hepatic impairment. May impair ability to drive or operate machinery.
Regular monitoring of glucose levels in blood & urine. Milder or absent symptoms of hypoglycaemi
autonomic neuropathy or taking -blockers, clonidine, reserpine, guanethidine & other sympatholy
change over to insulin in exceptional stress situations eg trauma, surgery, febrile inj.
Menstruation, tendency for bleeding or hemorrhagic diathesis, hepatic or severe renal impairment.
anticoagulants, antithrombotics or antiplatelet agents, prostaglandin E1 or its derivatives.
Controlled epilepsy, renal & hepatic impairment, acute cardiac failure, may impair ability to drive o
machinery.
Cardiac disease, diabetes; glaucoma; impaired kidney or liver function; pregnancy; may impair abi
operate machinery. Childn <6 yr.
CV thrombotic events, HTN, CHF, prior history of ulcer disease or GI bleeding & toxicity, impaired re
failure, liver dysfunction, taking diuretics & ACE inhibitors. Monitor renal function & blood count. Co
systemic NSAIDs including COX-2 selective inhibitors; rare hereditary problems of fructose intolera
galactose malabsorption or sucrose-isomaltase insufficiency; ulcerative colitis or Crohn's disease; i
function; hepatic porphyria. May impair female fertility. May affect ability to drive or operate machi
May impair ability to drive or operate machinery.
Treatment regimen changes. Uncorrected hypo- or hyperglycaemia. Renal & hepatic impairment. M
drive or operate machinery. Pregnancy & lactation.
Intravascular vol depletion, renovascular HTN, renal impairment, kidney transplantation, hypertens
2 DM, hyperkalemia, aortic/mitral valve stenosis, obstructive hypertrophic cardiomyopathy, primar
underlying renal disease including renal artery stenosis. Rare hereditary problems of galactose into
lactase deficiency or glucose-galactose malabsorption.
GI disorders, severe hepatic impairment; impaired cardiac or renal function; patients treated w/ diu
vol depletion. Pregnancy. Elderly.
Renal impairment & kidney transplantation, hyperkalemia, renovascular HTN, intravascular vol dep
valve stenosis, obstructive hyperthrophic cardiomyopathy.
Advanced renal disease. Preexisting significantly impaired renal function, uncompensated heart fai
Dehydrated patients. Preexisting edema, HTN or heart failure. History of CV or other thrombotic eff
ulcers & bleeding (PUB) & patients >65 yr. Patients being treated for infection. Patient who previou
acute asthmatic attacks, urticaria or rhinitis.
Lactation.
Lactation.
May cause a variety type of allergic reactions, including anaphylaxis or asthma in patients w/ sensi
Avoid use w/ occlusive dressing & intensive prolonged treatment, superinfection may occur. Pregna
Childn <2 yr.
Discontinue if hypersensitivity reactions occur. Pregnancy.
Sick sinus syndrome, supraventricular cardiac conduction conditions; history of ulcer disease, asthm
pulmonary disease.
Underlying cardiac condition abnormalities, history of ulcer disease or those receiving concurrent N
asthma or obstructive pulmonary disease. May impair ability to drive or operate machinery. Pregna
History of upper GI diseases, liver or kidney dysfunction, CHF, hypovolemia, dehydration, receiving
diuretic therapy.
Menopausal status should be defined biochemically if there are doubts. Assess bone mineral densit
at risk of osteoporosis. May impair ability to drive or operate machinery. Childn.
Orthostatic hypotension, CV disease (history of MI or ischemic heart disease, heart failure or condu
abnormalities), cerebrovascular disease, dehydration & hypovolemia. Seizure, alzheimer's disease.
judgement, thinking. Reduction of core body temp. Dysphagia. Heat exposure & dehydration. Neur
syndrome (NMS). Tardive dyskinesia. May impair ability to drive or operate machinery. Pregnancy &
Elderly.
Bleeding disorders, active ulcerative GI disease, recent intracranial hemorrhage; shortly after brain
surgery; current use of spinal/epidural anesth or spinal puncture; patients w/ <50 kg body wt; not t
patients w/ renal impairment (CrCl <30 mL/min). Pregnancy & lactation. Elderly.
Tachycardia, thyrotoxicosis, MI, hyperpyrexia, renal & hepatic disease. Childn. Elderly.
In combination w/ other ophth soln, instil as last w/ an interval of at least 10 min following instillati
soln.
Patients at risk of increased bleeding from trauma, surgery or other pathological conditions. Moder
bleeding diatheses; renal impairment.
Hepatic or renal impairment. Patients w/ SLE. Asthma. History of upper GI diseases. Peptic ulcer. Hi
failure. CV diseases. Bleeding disorders. Elderly. Pregnancy & lactation. Childn <1 yr.
History of upper GI disease (peptic ulcer), kidney dysfunction, blood coagulation disorders, heart fa
diseases which lead to fluid retention, SLE. Lactation. Childn <12 yr.
Renal impairment. Monitor CBC, LFT & urinalysis every 6 mth.
Pregnancy & lactation. May affect ability to drive or operate machinery. Habituation & dependence
Childn, elderly, hypertensive patients & pregnancy toxemia. Do not administer together w/ blood tr
term use.
Patients in whom aspirin & other NSAIDs precipitate symptoms of bronchospasm, allergic rhinitis or
Pregnancy. Childn <14 yr.
Patients w/ hypoxemia, renal & hepatic disorder. Pregnancy, lactation. Childn & elderly.
Thyrotoxicosis, HTN, CV dysfunction, hyperthyroidism & DM. Pregnancy & lactation. Childn <2 yr.
Avoid single dose treatment in depression or combined anxiety-depression. Pregnancy & lactation,
liver disorders, resp disorder, atrophy & patients who are prone to abuse drugs. Childn <10 yr, geri
patients. Avoid long-term treatment. May impair ability to drive or operate machinery.
Hyperthyroidism, HTN, heart disease, DM. Pregnancy & lactation. Elderly, childn.
Intensive use for >2 wk & prolonged use. Patients w/ low phosphorus diet. Childn <6 yr.
Perform liver function test prior initiation, 12 wk after, during evaluation of dose & periodically ther
diffuse myalgias, muscle tenderness or weakness &/or marked elevation of CPK. Promptly report un
pain, tenderness or weakness, esp if accompanied w/ malaise or fever. Discontinue use in case of m
CPK levels, diagnosed or suspected myopathy or w/ risk factor to development of renal failure seco
rhabdomyolysis.
Monitor for creatine phosphokinase & transaminase elevations. Avoid alcohol consumption.
Perform liver function test prior to initiation 12 wk after treatment initiation, during dose evaluation
thereafter. Alcohol consumption, active or history of liver disease, unexplained persistent transami
diffuse myalgia, muscle tenderness or weakness &/or marked CPK elevation. Discontinue use in ca
elevated CPK levels, diagnosed or suspected myopathy or w/ risk factor predisposing to developme
secondary to rhabdomyolysis.
Liver function test should be performed before the initiation of treatment & periodically thereafter.
unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever
markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Myopathy or having a
predisposing to the development of renal failure secondary to rhabdomyolysis.
Previous hypersensitivity reactions. Avoid prolonged use. Periodically monitor renal, hepatic & hem
Hepatic dysfunction, renal impairment, reduced urine output, phenylketonuria, suspected glandula
adequate fluid intake. Pregnancy & lactation.
Babies born of mother hypersensitive to penicillins. Renal impairment, severe hepatic dysfunction.
lactation.
Severe liver disease, impaired adrenal function; history of increased IOP, glaucoma &/or cataracts.
use w/ high doses. Regularly monitor height of childn under prolonged treatment. Pregnancy & lact
Moderate or severe renal or liver impairment. Pregnancy & lactation. Childn <16 yr. Mild to modera
Impaired liver or kidney function, patients taking other hepatotoxic agents. Reduced visual acuity.
disorders, DM, chronic alcoholism.
Overgrowth of nonsusceptible organisms. Check periodically for organ system dysfunction eg renal
haematopoietic system. Neonates.
Monitor renal function during concomitant treatment w/ aminoglycosides. Pregnancy & lactation.
Avoid contact w/ eyes, moderate to severe renal impairment. Pregnancy, lactation. Prolonged use.
Hepatic dysfunction & concomitant renal impairment; ingestion of alcoholic beverages; overgrowth
organisms. Serious & occasionally fatal hypersensitivity (anaphylactic) reactions.
Hematological disorders; elderly; lactation; G6PD & folate deficiency; impaired renal function.
Cream: Not for intranasal use. Avoid contact w/ eyes. Oint: Not for ophth or intranasal use. Avoid co
w/ caution if there is evidence of moderate or severe renal impairment.
Severe CV disease, hepatic or renal disorders, elderly patients, history of haematological disorders
Poor oral ingestion, unclear parenteral alimentation, poor general conditions (carefully observed fo
symptoms), severe renal impairment, genetically predisposed to allergic reactions (eg bronchial as
urticaria). History of GI disease (eg colitis). +ve Coombs' test. Childn & elderly.
Heart & thyroid disease, HTN, diabetes, difficulty in urination due to enlargement of prostate gland
to asthma, smoking, emphysema or accompanied by excessive phlegm, fever, drowsiness, debile &
<2 yr.
Prolonged use may result in overgrowth of nonsusceptible organisms. Discontinue use at first appe
or other signs of hypersensitivity reactions.
Lactic acidosis & severe hepatomegaly w/ steatosis. Monitor hepatic function closely.
Pregnancy, lactation. Monitor serum Na levels & blood counts. Renal, hepatic or cardiac dysfunction
discontinuation of treatment. Cross-allergy to carbamazepine. Alcohol consumption. Elderly. May aff
or operate machinery.
Pregnancy. Childn <6 yr.
Liver & renal impairment. Heart disease. Patients w/ bronchostatic, hypoglycaemia or diabetes rece
hypoglycemics.
Renal impairment, severe hepatic dysfunction. High-dose or long-term use may cause superinfectio
pregnancy, lactation.
Liver disease, asthma; glaucoma; MAOI therapy. May affect ability to drive or operate machinery. P
lactation.
Discontinue use if irritation, sensitivity, excessive dryness or other reactions develop. May cause ad
manifestation of Cushing's syndrome, hyperglycaemia & glucosuria especially in infants & childn. P
treatment, when treating extensive body surface areas, when using the occlusive technique & whe
stasis dermatitis & other skin diseases w/ impaired circulation. Pregnancy & lactation. Not for ophth
Discontinue use if irritation, sensitivity or other reaction develop & institute appropriate treatment.
systemic effects eg hypothalamic-pituitary-adrenal axis suppression, manifestation of Cushing's sy
hyperglycemia & glucosuria. Prolonged treatment when treating extensive BSA, when using the oc
when treating childn. Pregnancy & lactation. Not for ophth use. Avoid contact w/ mucous membran
Bronchial asthma, mild COPD; insufficiently controlled DM; recent MI, severe organic heart or vascu
underlying severe heart disease eg ischaemic heart disease, arrhythmia or severe heart failure; na
glaucoma, pre-existing urinary outflow tract obstruction. Pregnancy & lactation. Childn.
Insufficiently controlled DM, recent MI &/or severe organic heart or vascular disorders, hyperthyroid
pheochromocytoma, acute rapidly worsening dyspnoea. Patients on prolonged regular use must be
additional or increase of anti-inflammatory therapy. Severe asthma. Monitor serum K levels. Myoca
Underlying severe heart disease eg ischaemic heart disease, arrhythmia or severe heart failure. Ma
drive or operate machinery. 1st trimester of pregnancy & lactation.
Use of contact lenses, prolonged use. Childn <6 yr. Pregnancy. Discontinue use if eye irritation, sen
superinfection occurs. May lead to overgrowth of nonsusceptible organisms.
Hepatic disorders. Elderly. Pregnancy & lactation.
Renal or hepatic impairment. CAD, spontaneous hypoglycemia or diabetic patients receiving insulin
hypoglycemic agents. Childn. Pregnancy & lactation.
Discontinue therapy if sensitisation or irritation is present. Application to large body areas or for pro
Avoid contact w/ eyes. Pregnancy, lactation. Childn <2 yr.
Allergy to seafood.
Childn, pregnancy.
Renal impairment.
GI disorder (colitis), vit K deficiency. Pregnancy & lactation.
Nursing mother should continue or increase frequency of breastfeeding during & after diarrhea.
History of allergy to cephalosporins, penicillins & other -lactams. GI disease especially colitis. Kidn
Pregnancy & lactation.
Not for upper resp tract infections. History of GI diseases esp colitis. Severe liver & kidney dysfunct
function should be monitored in long-term use. Pregnancy & lactation. Newborn. Elderly.
Therapy should not be exceeded >2 days or in the presence of fever. Childn <6 yr. Severe renal ins
For external use only. Avoid contact w/ eyes & mucosal membrane.
Black stool.
For external use only. Avoid contact w/ eye & mucous membrane.
Vol-depleted patients. Unstable angina pectoris (major or not), hypotension, mitral valve & aortic s
hypertrophic cardiomyopathy; renovascular HTN, renal impairment; jaundice or marked hepatic en
collagen vascular disease, concomitant immunosuppressant, allupurinol or procainamide therapy;
hyperkalemia, diabetics. Galactose intolerance, glucose-galactose malabsorption, Lapp-lactase defi
complete blood counts, serum K levels. 1st trimester of pregnancy. Childn & adolescent <18 yr.
Renal & hepatic impairment, allergic patient under desensitation treatment, under venom immuno
vascular disease, concomitant immunosuppressant therapy; anaphylactoid reactions, photosensitiv
electrolyte imbalance. Renal artery stenosis, CHF or cirrhosis w/ oedema & ascites. Regular monito
Ca levels & renal function. Galactose intolerance, Lapp-lactase deficiency or glucose-galactose mal
Atherosclerosis, renovascular HTN, severe cardiac insufficiency (grade IV), diabetic patients, surger
mitral valve stenosis/hypertrophic cardiomyopathy, gout. 1st trimester of pregnancy. Elderly.
May cause cross-sensitivity reactions especially in patients who have hypersensitivity to penicillins
kidney function in concomitant use w/ loop diuretics or aminoglycosides. Avoid prolonged use. May
Coombs' +ve reaction in Coombs' test. Kidney failure. Childn.
Avoid use around eyes or on open wounds. Avoid exposure to sunlight. Childn <12 yr. For Bioquin F
lactation.
Sensitivity to penicillin, liver disease, biliary obstruction, kidney failure. Patients receiving anticoag
Prolonged use. History of GI disease especially colitis. May cause false +ve result in urine-glucose t
Benedict's or Fehling's soln. May cause vit K deficiency. Pregnancy & lactation. Childn.
Perform sensitivity test prior treatment. Not effective to snake bites caused by snakes from Eastern
given in patients w/ history of severe asthma who shown symptoms of systemic toxicity.
Cross-sensitivity to penicillins. Long-term therapy. Use of lignocaine HCl solvent in patients w/ liver
blood circulation in liver.
Bronchospasm, bronchial asthma, other chronic obstructive lung disease; concomitant treatment w
anesth, DM w/ large fluctuations in blood glucose values, strict fasting, ongoing desensitization the
block, Prinzmetal's angina, psoriasis; may mask symptoms of thyrotoxicosis & increase sensitivity t
severity of anaphylactic reactions. May impair ability to drive or operate machinery. Pregnancy.
Undiagnosed red eye. Avoid prolonged use >7 days. Not to be applied on open wounds or damage
small childn. Hypersensitivity to streptomycins (neomycin, paramomycin, kanamycin).
HTN, sepsis, vascular stricture; heart or kidney impairment. If inverse, methylergometrine is not all
over. If twins, then wait until the last baby birth is over.
Unilateral or bilateral renal artery stenosis, severe renal disease, patients w/ intravascular vol or Na
impaired hepatic function or progressive liver disease, SLE. Periodic determinations of serum electr
recommended.
Laboratory tests should be performed at the 1st symptom of liver dysfunction. Discontinue if liver i
evident. Peripheral vascular disease; spontaneous hypoglycemia or diabetic patients receiving insu
hypoglycemic agents; heart failure; suspected of having Prinzmetal's (variant) angina; w/ labile or
Abrupt w/drawal may exacerbate symptoms of hypothyroidism or may precipitate thyroid storm. EC
monitored when administered orally w/ Ca-channel blockers of the verapamil or diltiazem type. Pre
Childn.
Treat hypocalcaemia & other bone & mineral metabolism disturbances prior to therapy. Maintain Ca
Avoid invasive dental procedures. Avoid overhydration in patients at risk of cardiac failure. Monitor
serum Ca, phosphate & Mg.
Treat hypocalcemia & other bone & mineral metabolism disturbances prior to therapy. Avoid invasiv
procedures. History of prolonged esophageal transit time, CrCl <30 mL/min or creatinine serum >2
Peripheral motor neuropathic disease eg amyotrophic lateral sclerosis, motor neuropathy; neuromu
disorders eg myasthenia gravis or Lambert-Eaton syndrome; preexisting CV disease; VII nerve diso
skin problem at inj site, marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal
sebaceous skin. Administration must not be more frequent than every 3 mthly. Pregnancy & lactati
Elderly.
Patients w/ phenylketonuria & pregnant women w/ high phenylalanine. Childn. Pregnancy & lactatio
Acute, severe & progressive consciousness disturbance; concomitant therapy w/ hemostatic or intr
relieving drugs or use of measures to keep body temp low. Avoid high doses in intracranial bleeding
Long-term & prophylactic use; abrupt w/drawal. Avoid contact w/ eyes. Excessive skin damage.
Pregnancy.
Kidney insufficiency. Avoid abrupt w/drawal in myoclonic patients. Pregnancy & lactation.
All patients should be premedicated w/ oral corticosteroids for 3 days starting 1 day prior to doceta
Hepatic impairment. Contraceptive measures must be taken during & for at least 3 mth after thera
plasticized PVC equipment. Childn <16 yr. Elderly.
Pregnancy, lactation.
Thyrotoxicosis, HTN, CV disease, hyperthyroidism, DM. 1st trimester of pregnancy. Lactation. Childn
History of upper GI disease (peptic ulcer), impaired kidney or liver function, heart failure, HTN, othe
result in body fluid retention, blood coagulation disorders, asthma, SLE. Childn <1 yr.
TB, HTN, DM, osteoporosis, peptic ulcer, glaucoma, cataract, family history of diabetes or glaucoma
impairment. Pregnancy & lactation.
Hypoxemia, hepatic failure, chronic resp disease. Pregnancy & lactation. Elderly, infants & childn.
History of upper GI diseases (peptic ulceration); heart failure, renal & liver impairment, lupus eryth
other conditions predisposing to fluid retention; coagulation defect, asthma. 1st & 2nd trimester pr
lactation. Childn <1 yr.
History of glaucoma; tachycardia, heart failure, thyrotoxicosis, patients w/ difficulty in urinary proce
Renal, hepatic & CV function impairment. Pregnancy & lactation. Childn <12 yr.
Severe obstructive CAD. Increased frequency, duration &/or severity of angina or acute MI on starti
blocker therapy or at the time of dosage increase. Adolescents. Caution in patients who have a hist
heart failure, impaired hepatic function, myalgia, myopathy, hemorrhagic stroke, -blocker withdra
function & CNS toxicity.
Prolonged or extensive use. Avoid contact w/ eyes. Pregnancy. Occlusive dressing of large areas of
lesions.
Severe hypotension; close monitoring of dialysis patients w/ malignant HTN; heart failure, severe a
diabetes.
In large doses, monitor serum Ca conc & kidney function; impaired renal function, history of renal s
dependent tumour; hyperoxaluria.
Monitor serum Ca conc & kidney function in large doses, impaired renal function, history of renal st
Long-term use in childn. Monitor serum Ca, phosphorus, Mg & alkaline phosphatase; urine Ca & ph
periodically. Pregnancy & lactation.
Renal impairment.
Patients w/ mild hypercalciuria, impaired renal function, history of urinary calculi (monitor). Avoid h
Monitor diabetics & patients on low sodium diets.
Vit are taken as supplement when nutritional intake from diet is inadequate.
Vit are taken as supplement when nutritional intake from diet is inadequate.
Excessive dose may cause diarrhoea & kidney dysfunction. Patients w/ impaired kidney function &
therapy.
Patient with GI disorder esp colitis; prolonged use may enhance excessive growth of Candida & Ent
hypersensitivity reaction in patients w/ allergy to penicillins; false +ve result in urinary glucose tes
renal failure. Pregnancy, lactation.
History of peptic ulcer, upper GI/heart disease, HTN w/ any predisposition of fluid retention, impaire
function. Pregnancy & lactation. Childn.
Discontinue if irritation or sensitivity occurs. Avoid contact w/ eyes & mucous membranes. If no imp
(athlete's foot) or 2 wk (for jock itch), consult physician. Childn <2 yr. Pregnancy & lactation.
If irritation or sensitivity occurs, treatment should be discontinued. Do not use on childn <2 yr exce
advice and supervision of the physician. Avoid contact w/ eyes & mucous membranes. Advise to co
no improvement is seen in 4 wk (for athletes foot) or 2 wk (for jock itch). Not recommended in the
pregnancy & lactation.
Patients whose vascular tone & renal function depend predominantly on the activity of the renin-an
aldosterone system, severe CHF; renal impairment; haemodialysis; unilateral or bilateral renal arte
patients w/ vol- & salt-depletion secondary to salt restriction, prolonged diuretic therapy, heart failu
surgery/anaesth; aortic & mitral valve stenosis (obstructive hypertrophic cardiomyopathy); primary
hyperaldosteronism; CHF; history of angioedema associated w/ or unrelated to ACE or angiotensin
galactose intolerance, Lapp-lactase deficiency or glucose-galactose malabsorption. Avoid concomit
inhibitor in heart failure patients & K-sparing diuretics. Monitor BP, serum creatinine K levels period
ability to drive or operate machinery. Childn & adolescents <18 yr. Elderly >75 yr.
Perform periodic hematological test on long-term treatment. Renal impairment. Avoid prolonged us
lactation.
Hepatic disorders, exclude possibility of malignancy in suspected gastric ulcer. Elderly & childn. Pre
Hypersensitivity to -lactams. Do not use for infections due to MRSA. Monitor serum hepatic levels
hepatic disease. Consider diagnosis of pseudomembranous colitis in patients who develop diarrhea
to drive & operate machinery. Pregnancy & lactation. Infant <3 mth.
Impaired renal function (CrCl =50 mL/min); superinfection. Discontinue in case of allergic reactions
pseudomembranous colitis. Elderly. Pregnancy & lactation.
May affect ability to drive or operate machinery. Pregnancy. Childn <6 mth.
Severe hepatic impairment, moderate or severe renal impairment. Avoid prolonged use. Pregnancy
Liver impairment; maintain liver function monitoring; renal impairment. Prolonged use may result i
nonsusceptible organisms. Hypersensitivity to penicillin. In high doses administration, fluid intake &
should be ensure in excessive amount, to reduce the possibility of crystalluria. Patients using cathe
closed monitoring. Pregnancy & lactation.
Patients w/ hyperstimulated renin-angiotensin system, severe malignant HTN, heart failure, pretrea
fluid & salt deficiency; haemodynamically relevant stenoses of the coronary arteries or blood vesse
impairment, kidney transplant. Monitor renal function; serum K & WBC.
Monitor heart rate & rhythm, arterial BP & infusion rate, ECG, serum K. Correct hypovolemia prior t
w/ acute MI, treated w/ -blockers. Pregnancy & lactation. Childn.
Severe aortic stenosis, CHF, impaired liver function, heart failure. Pregnancy & lactation.
Not suitable for treating attacks of acute angina pectoris. severe hepatic or renal impairment; hypo
malnutrition, or hypothermia; recent history of MI. Pregnancy & lactation.
Postural hypotension/syncope, impaired hepatic function. Caution use w/ PDE-5 inhibitors. Intraope
syndrome (IFIS). Pregnancy & lactation.
Monotherapy in patients w/ critical illness & known or suspected Pseudomonas aeruginosa infectio
penicillins & cephalosporins. Monitor transaminase & bilirubin level in patients w/ liver disease. His
especially colitis; concomitant use w/ other nephrotoxic drugs. May affect the ability to drive vehicl
machinery. Pregnancy & lactation. Childn <3 mth.
Abrupt w/drawal. Hepatic or renal dysfunction, aortic stenosis. Elderly. Childn. Pregnancy & lactatio
Patients using warfarin. Discontinue use if hypersensitivity reactions occur. Pregnancy & lactation.
Moderate to severe hepatic impairment. Monitor liver function tests. Discontinue treatment in seve
progression of disease w/ elevated PSA.
Known or risk for CV disease, HTN, fluid retention or heart failure; history of ulcer or GI bleeding. St
diagnosis & close medical surveillance in patients w/ symptoms/history of GI disorder, Crohn's dise
hepatic, renal & cardiac functions; asthma, seasonal allergic rhinitis, swelling of nasal mucosa, COP
infections. Monitor liver function tests, BP & blood counts (prolonged use). Patients w/ hepatic porp
childn. May impair ability to drive or operate machinery.
Known or risk for CV disease, HTN, fluid retention or heart failure; history of ulcer or GI bleeding. St
diagnosis & close medical surveillance in patients w/ symptoms/history of GI disorder, Crohn's dise
hepatic, renal & cardiac functions; asthma, seasonal allergic rhinitis, swelling of nasal mucosa, COP
infections. Monitor liver function tests, BP & blood counts (prolonged use). Patients w/ hepatic porp
childn. May impair ability to drive or operate machinery.
History of GI disease, impaired cardiac & renal function. Long-term treatment: Perform periodic mo
function & blood count. Pregnancy, lactation, childn.
Cedantron Pregnancy & lactation. Elderly. Cedantron Syrup Total daily dose should not exceed than
moderate or severe liver function impairment.
Glaucoma. May develop tolerance & cross-tolerance to other nitrates & nitrites.
Sensitivity to penicillin; history of allergy eg bronchial asthma, rash, urticaria; impaired renal functi
oral nutrition or under therapy w/ parenteral nutrition; history of GI disease eg colitis. Childn w/ otit
treated w/ syr only. Discontinue if superinfection occurs. Pregnancy, lactation, childn <6 mth, elder
patients.
Cross-allergic reaction may occur in patients hypersensitive to penicillin or other -lactam antibioti
function in patients receiving aminoglycosides. Monitor haematologic effects in long-term use (>10
use may cause resistance. Pregnancy, lactation.
History of hypersensitivity to penicillin & other cephalosporins, personal or familial history of allerg
asthma, rash, urticaria, severe kidney function impairment, low oral nutrition; concomitant therapy
nutrition. Pregnancy, lactation. Elderly, debilitated patients. Childn <6 mth (including newborn & p
Hypersensitivity to penicillins. Impaired renal function. Patients receiving potent diuretics & nephro
Impaired renal function (CrCl =50 mL/min); developed pseudomembranous colitis or diarrhea durin
term usage. Pregnancy & lactation. Elderly.
Hypersensitivity to penicillins.
Penicillin-sensitive patients; hepatic or renal impairment; severe biliary colitis. Pregnancy & lactatio
Hepatic dysfunction & concomitant renal impairment; ingestion of alcoholic beverages; overgrowth
organisms.
Discontinue if allergy or serious anaphylaxis occurs. May cause false positive result in the urine glu
Benedict's or Fehling's soln. Liver failure, kidney disease. Monitor prothrombin time. GI disease esp
severe biliary obstruction. Long-term use. Infants and childn. Pregnancy & lactation.
Hypersensitivity to penicillins, severe biliary obstruction, severe hepatic disease or renal dysfunctio
Allergic symptoms; renal impairment. Monitor renal function if administered concurrently w/ nephro
Elderly. Pregnancy & lactation.
Sensitivity to penicillins. Pseudomembranous colitis. Monitor kidney function during treatment; kidn
Regularly monitor blood count in prolonged treatment (>10 days). Pregnancy & lactation.
Patients w/ poor diet, malabsorption or receiving parenteral nutrition for long-term period; liver & k
Pregnancy & lactation.
Renal insufficiency, pseudomembranous colitis, cross-sensitivity. Monitor blood count during long-te
days).
Hyperlactatemia, headache, nausea, vomiting, upper abdominal pain, diarrhea, rash, alopecia,
arthralgia, muscle disorders, fatigue, malaise, fever.
Symptoms associated w/ upper resp tract infection, headache, nausea, malaise, abdominal pain,
diarrhea.
Allergic reactions, tingling in the arm, ear & face, blurred vision, headache, nausea, stomachache,
jittery feeling.
Burning, itching, numbness, rash, redness, stinging, erythema, swelling or tingling of the scalp.
Mild reaction eg urticaria (treated w/ antihistamies & corticosteroids). Discontinue in case of more
severe reactions (eg anaphylactic shock), treat w/ high dose corticosteroids & then w/ adrenaline,
slowly administered.
Headache, edema, fatigue, somnolence, nausea, abdominal pain, flushing, palpitations, dizziness.
Diarrhea, nausea, abdominal pain & discomfort, abnormal taste, dyspepsia; headache.
Hypersensitivity reactions, GI disorders, renal & liver function disorders, changes in blood
constituent, local reactions, neurogical effects, superinfection.
Rash, urticaria, erythema, pruritus or fever; granulocytopenia or eosinophilia; increased SGOT,
SGPT or alkaline phosphatase; vomiting, diarrhea, abdominal pain, stomach discomfort, heartburn
or anorexia.
Nausea, vomiting, abdominal pain, rash, headache; malaise, insomnia. Rarely, hypersensitivity
reactions including urticaria & angioedema. Symptomatic hepatitis w/ & w/o hyperbilirubinaemia,
hyperbilirubinaemia w/o elevated liver function tests, hepatic failure, fulminant hepatitis. Lower
limb oedema, arthralgia, myalgia, bruising, bleeding disorders including menorrhagia,
thrombocytopenia & agranulocytosis.
Asthenia, fatigue, edema, abdominal pain, chest pain, headache, pharyngitis, angina pectoris, 2nd
degree AV block, CVA, hypotension, MI, liver function abnormalities.
Hypersensitivity reactions eg, bronchospasm, angioedema, rashes & pruritus. Nausea & vomiting,
fever, syncope, sweating, arthralgia, blurred vision, liver function disturbances.
Skin rash, reversible neurological reactions, GI disturbances, increased bilirubin & liver enzymes,
increased BUN & creatinine, lowering of haematological index, headache & fatigue.
Diarrhea, nausea, vomiting, abdominal discomfort, headache; skin rashes, urticaria; vaginitis,
flatulence, candidiasis; transient hepatitis, cholestatic jaundice.
Zn supplementation may cause GI upset, nausea, vomiting & diarrhea if taken on an empty
stomach (particularly w/ Zn sulfate).
Dizziness, nausea, pharyngitis, chest pain, fatigue, lower back pain, depression, dehydration,
myalgia; abdominal cramps, borborygmi, diarrhoea; rash, pruritus, urticaria, angioedema,
bronchospasm.
Hypersensitivity reactions, GI disorders, chest pain, tachycardia, cough, throat pain, dyspnea,
headache, dizziness, anxiety, confusion, local reactions.
Dizziness, headache, facial redness, flushing, somnolence, muscle fatigue, peripheral oedema
(ankles), palpitations, abdominal pain, nausea, drowsiness.
Local reactions eg erythema, swelling, tenderness or pain at inj site; fever, headache, malaise,
irritability, inconsolable& high-pitched crying.
Bleeding (either superficially or internally into GIT, urogenital tract, retroperitoneum or CNS or
bleeding of parenchymatous organs); cholesterol crystal embolisation or thrombotic embolisation,
reperfusion arrhythmias, nausea, vomiting, ecchymosis, epistaxis, drop in BP, increased temp,
anaphylactoid reactions.
GI disturbances, infection, musculoskeletal pain, HTN, depression, dizziness, rash, cataract, UTI.
GI disorders, infections & infestations, muscoskeletal & connective tissue disorders, general
disorders & administration site conditions (eg asthenia, chest pain, pyrexia), nervous system
disorders (eg headache, dizziness); injury, poisoning & procedural complications (fall), vascular
disorders (HTN), resp, thoracic & mediastinal disorders (cough), psychiatric disorders (depression),
metabolism & nutrition disorders (hypercholesterolemia).
Upper resp tract infection, diarrhea, combined edema/peripheral edema & headache; myalgia,
tooth disorder, aggravated DM & pharyngitis.
Hypoglycemia.
Pruritus, irritation, redness/flushing, feeling of facial warmth, papules, contact dermatitis, dry skin &
hot flushes.
Transient pain, swelling. Rarely, oedema, rash, flushing, sensation of heat, hypersensitivity
reactions, shock.
GI disorders.
Red coloration of urine; tachycardia, arrhythmia, abdominal pain, ECG changes, shock, anemia,
bleeding, leucopenia, thrombopenia; fever, cool sensation, urticaria, anaphylaxis, liver function
impairment, proteinuria, acute nausea & vomiting, mucositis, anorexia, diarrhea, alopecia,
hyperpigmentation, tiredness, headache, cystic stimulation symptoms, pulmonal metastasis,
blennophthalmia, epiphora, amenorrhea, aspermia.
Occasionally, burning sensation in nose/throat, local irritation, nausea, headache, dryness of nasal
mucosa. Rebound nasal congestion (prolonged use). Apnoea & instant collapse in infants.
Headache, sweating, myalgia & arthralgia, fever, malaise, shivering, fatigue. Redness, swelling,
pain, ecchymosis, induration.
CHF, MI, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, CVA, pericarditis,
pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, pancreatitis, gastric/duodenal
ulcer, seizure. Asthenia, fever, headache, malaise, abdominal pain, palpitations, tachycardia, GI
disturbances, edema, dizziness, paraesthesia, cough, dyspnea, pharyngitis, pruritus, rash.
Fever, urticaria, flushing, nausea, headache, dyspnea, rigors, hypotension, chills, malaise, vomiting
HTN, tachycardia, bradycardia.
Muscle weakness, loss of muscle mass, steroid myopathy, osteoporosis, vertebral compression
fracture, pathological fracture of long bone, osteonecrosis. GI effects. Impaired wound healing, thin
fragile skin, facial erythema, sweating. CNS disturbances, electrolyte imbalance, endocrine
disorders. Posterior subcapsular cataract, increased intraocular pressure, glaucoma, exophthalmus
Rarely, anaphylaxis.
Diarrhea, dry mouth, abdominal pain, nausea, vomiting, dyspepsia. Dizziness, fatigue, insomnia,
psychomotor hyperactivity, seizures. Tachycardia, palpitations. Fever, hepatitis, elevation of liver
enzymes, increased bilirubin, anaphylaxis, angioedema, pruritus, rash & urticaria.
Hypersensitivity reactions, rise in IOP, posterior subcapsular cataracts formation.
Rash & eruption, itching; palpitation, tachycardia, hot flushes; headache, vertigo, lightheadedness,
insomnia & sleepiness; GI disturbances, increase serum levels.
Abdominal pain & distention, diarrhoea or constipation, flatulence, musculoskeletal pain &
headache.
Diarrhea, muscle cramps, fatigue, nausea, vomiting, insomnia, dizziness, psychiatric disturbances.
Somnolence, dizziness, ataxia, fatigue, nystagmus, headache, tremor, nausea, vomiting, diplopia,
amblyopia, rhinitis.
GI disorders eg gastralgia, nausea or vomiting, diarrhoea. Rarely, anaphylactic shock have been
reported w/ IM administration. Constipation, dyspepsia, abdominal pain, headache, dizziness,
vertigo, insomnia, hemorrhage, perforation, rash, liver & renal impairment, thrombocytopenia.
Increased intravascular pressure, dry mouth, cycloplegia, mydriasis, constipation; drowsiness &
dizziness.
Enlarged abdomen, abdominal pain, abnormal stools, diarrhea, dyspepsia, dysphagia, flatulence,
nausea, vomiting; asthenia, pain; headache, insomnia, paresthesia; decreased libido, depression;
vascular disorder; lipodystrophy, rash; myalgia; bronchitis; hypogonadism (male); anorexia, wt loss
amenorrhea.
Diarrhea, muscle cramps, weakness, nausea, vomiting, insomnia, dizziness. Mild increased blood
creatinine-kinase level.
GI disturbances, infection, musculoskeletal pain, HTN, depression, dizziness, rash, cataract, UTI.
Rarely, thrombocytopenia, leucopenia & haemolytic anaemia.
Headache, edema, fatigue, somnolence, nausea, abdominal pain, flushing, palpitations & dizziness
Hypercalcemia.
Rash, chest discomfort, palpitation, cerebral, pulmonary & peripheral edema, hyperpotassemia,
acidosis, water intoxication, vascular pain, phlebitis, chills, fever, feeling of warmth, headache.
Nausea, vomiting.
Hypercalcemia.
Local reactions consisting of erythema, phlebitis & thrombosis at the infusion site can occur w/
peripheral infusion. Generalized flushing, vomiting & fever furing infusion of amino acid soln.
May lead to an increased production of gastric acid & stress ulcer.
Neurotoxicity, ototoxicity, nephrotoxicity; skin rash, drug fever, headache, paresthesia, tremor,
nausea & vomiting, eosinophilia, arthralgia, anemia, hypotension; acute muscular paralysis, apnea
Chest discomfort, palpitation, nausea, vomiting, chills, fever, hot flush, headache, vascular pain.
Headache, edema, fatigue, somnolence, nausea, abdominal pain, flushing, palpitation, dizziness.
Rarely joint pain, dyspepsia, gingival hyperplasia, gynecomastia, impotence, frequent urination,
mood changes, muscle cramps & pain, pruritus, skin rash, visual disturbances.
Headache, edema, fatigue, somnolence, nausea, abdominal pain, flushing, palpitations, dizziness.
Occasionally nausea & vomiting; acidosis & CHF (large doses & rapid administration).
Fluid & electrolyte disturbance, steroid myopathy, muscle weakness, peptic ulcer, osteoporosis,
purpura, striae, hyperpigmentation.
Minor GI disturbance.
Nausea, dizziness, somnolence. Asthenia, fatigue, hot flushes; headache, tremor; abdominal pain,
constipation, diarrhea, dyspepsia, flatulence, dry mouth, vomiting; anorexia, anxiety, confusion,
euphoria, insomnia, nervousness; pruritus, rash, increased sweating.
Nausea, vomiting, abdominal pain, diarrhea; skin allerg; possible transient rise of ASAT/ALAT
transaminase &/or alkalline phosphatase.
Rash, urticaria, angioedema, pseudomembranous colitis.
Skin sensitization.
Water & Na retention. In male, priapism, signs of excessive sexual stimulation, oligospermia,
decreased ejaculatory vol. In prepubertal boys, precocious sexual development, increased
frequency of erections, phallic enlargement, premature epiphyseal closure.
Arterial BP, pulse rate & breathing changes; nausea, vomiting, headache, hiccups, laryngospasm,
dyspnea, hallucination, ataxia, skin rash, paradoxical reactions, amnesic episodes, resp depression
apnea.
Anorexia, nausea, diarrhea, dyspepsia, tremor, headache, insomnia, male sexual dysfunction.
Rash, palpitation, tachycardia, hot flushes, headache, dizziness, nausea, vomiting, diarrhea.
Anxiety, nervousness, insomnia, drowsiness, fatigue, asthenia, tremor, sweating, anorexia, nausea
diarrhea, dizziness or lightheadedness.
Drowsiness, dizziness, dry mouth; epileptiform seizures (large doses); skin rashes.
Headache, dizziness; vertigo; nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence,
anorexia; increased transaminases; rash.
Drowsiness.
Hypoglycaemia. Inj site & local hypersensitivity reactions eg redness, swelling & itching at the inj
site. Uncommonly, systemic hypersensitivity reactions.
Blood & lyphatic system disorders, metabolism & nutrition disorders, nervous system, eye, ear &
labyrinth, cardiac, vascular, resp, throracic & mediastinal, GI, skin & SC tissue, musculoskeletal &
connective tissue, renal & urinary disorders, & reproductive system & breast disorders; fatigue,
peripheral edema, edema, gait abnormalities, asthenia, thirsty, chest tightness, pain, exacerbated
anasarca, pyrexia, rigors;increased alanine aminotransferase, blood creatinine, phosphokinase,
aspartate aminotransferase; decreased platelet count; increased blood glucose.
Epigastric pain, nausea, vomiting, diarrhea, abdominal cramps, dyspepsia, flatulence, anorexia,
headache, dizziness or vertigo, drowsiness, sensation disturbances (paresthesia, rashes, skin
eruptions); asthma, anaphylactic/anaphylactoid systemic reactions (hypotension).
Asthenia/fatigue, dizziness, lower extremity edema, HTN, dyspepsia, heartburn, nausea, headache
ALT & AST increased.
Nausea, vomiting, diarrhea, constipation, abdominal pain or transient burning of the upper
stomach, skin rashes, bronchospasms or thrombocytopenia.
Diarrhoea, muscle cramps, fatigue, nausea, vomiting, insomnia, dizziness, psychiatric disturbances
Diarrhea, muscle cramps, fatigue, nausea, vomiting, insomnia, headache, anorexia, hallucination,
agitation, aggressive behavior, depression, abnormalities, somnolence, syncope, dizziness,
abdominal disturbance, rash, pruritus, urinary incontinence, pain, decreased wt, ecchymosis,
infection.
Dyspepsia, nausea, vomiting, abdominal pain, diarrhea; anemia, leucopenia, thrombocytopenia;
pruritus, skin rash; headache, vertigo, tinnitus, drowsiness; edema, increased BP.
Hot flushes, asthenia, arthralgia/joint stiffness, arthritis, vag dryness & bleeding, hair thinning,
allergic reaction, rash, nausea, diarrhea, vomiting, headache; increased ALP, ALT & AST, anorexia,
hypercholesterolemia, somnolence, bone pain, myalgia, carpal tunnel syndrome, sensory
disturbances (eg paraesthesia, taste loss & taste perversion).
GI reactions. Peptic ulceration. GI bleeding. Rarely, insomnia, irritability, agitation, minor hearing
disorders, edema, skin rashes, palpitations. Bronchospasm, thrombocytopenia, lymphopenia, visua
disturbances.
Nausea, epigastric pain, heartburn, dizziness, sleeplessness, headache, rash, itching, tinnitus,
edema.
Diarrhea, epigastric pain, nausea, vomiting, urine discoloration.
Paradoxical reactions, dry mouth, constipation, nausea, tremor of fingers, urinary retention, blurred
vision, changes in libido.
GI disturbances.
Fever, infection of the inj site, venous thrombosis or phlebitis on the inj site, hypervolemia.
Nausea, digestive disorders, vomiting, vasomotor rhinitis, urticaria, angioneurotic oedema, allergic
reactions, hypoprothrombinemia during prolonged use.
Insomia, headache, nausea, diarrhea, abdominal pain, dyspepsia, constipation, flatulence, myalgia
asthenia, hyppoglycemia, hyperglycemia, anorexia, peripheral neuropathy, paresthesia,
pancreatitis, vomiting, hepatitis, cholestatic jaundice, alopecia, pruritus, rash, myopathy, myositis,
muscle cramps, impotence.
GI effects, kidney or liver functions abnormality, hematological changes, CV effects, resp & CNS
disorders.
Diarrhea, nausea, vomiting, dyspepsia, pseudomembranous colitis; skin rash, urticaria; candidiasis
Headache, abdominal pain, diarrhea, nausea, vomiting, muscle & joint pain; loss of appetite,
insomnia, irritability, fever, asthenia.
Impotence, decreased libido, ejaculation disorders, breast disorders including breast enlargement
&/or tenderness; allergic reactions including rash, pruritus, urticaria, localized edema &
angioedema.
Acne, oily skin, deepening of voice, hot flushes, mild hirsutism, decrease in breast size, wt gain,
clitoral hypertrophy (rarely); hepatic dysfunction, alteration in value of lab test, allergic,
dermatologic, GI, genitourinary, musculoskeletal, CNS, hematological.
Nausea, vomiting, diarrhea or abdominal pain; vertigo, dizzines, headache; skin rash,
photosensitivity, angioedema; palpitation, chest pain; monilia, vaginitis, nephritis; fatigue.
Diarrhoea, vomiting, abdominal discomfort, flatulence, nausea, gastric distension, gastric pain,
dyspepsia, cholestatic jaundice. Skin rash, GUT disturbances, headache, vertigo, somnolence,
fatigue.
Retrobulbar neuritis w/ a reduction of visual acuity, central scotoma & green-red color blindness.
Allergic rashes. GI disturbances. CNS effects. Hyperuricemia. Peripheral neuritis. Liver damage.
Blood disorders.
Retrobulbar neuritis w/ reduced visual acuity, central scotoma, green-red colour blindness. Allergic
rashes. GI disturbances. Rarely, jaundice & peripheral neuritis. CNS effects. Hyperuricaemia.
Hypersensitivity reactions, GI disorders, renal & liver functions disorders, changes in blood
constituent, local reactions, neurological effects, superinfection.
Rash, burning, pruritus.
Nausea (w/ or w/o vomiting), stomatitis, diarrhea, skin rash, leucopenia, erythema multiforme,
Stevens-Johnson syndrome, Lyell's syndrome; neutropenia, thrombocytopenia. Rarely,
agranulocytosis, megaloblastic anemia, pancytopenia or purpura, eosinophilic, allergic alveolitis.
Cream: Cutaneous hypersensitivity reactions. Oint: Burning localised on the area of application,
itching, erythema, stinging & dryness on the application area.
Local irritation.
Loss of appetite, dry mouth, nausea, diarrhoea or constipation, headache, dizziness, somnolence,
ataxia, confusion, agitation, visual accommodation disorders. Rarely, allergic skin reactions, fever,
haematological effects.
High dose may cause nervousness, fatigue, drowsiness, nausea, headache, resp & CNS
depressions.
Diarrhea, indigestion, pseudomembranous colitis, nausea, vomiting & candidiasis; urticarial rash,
morbilliform rash; transient hepatitis, cholestatic jaundice, erythema multiforme, Stevens-Johnson
syndrome, exfoliative dermatitis.
Renal losses due to rapid infusion; nausea & flushing in susceptible patients; febrile response, inj
site infection, venous thrombosis or phlebitis extending from inj site, extravasation & hypervolemia
Cough, dry mouth, headache, tremor, pharyngitis, nausea, dizziness, dysphonia, tachycardia,
palpitations, vomiting, increased systolic BP & nervousness; anaphylactic reactions, hypokalemia,
agitation, mental disorder, glaucoma, increased IOP, accommodation disorder, mydriasis, blurred
vision, eye pain, corneal oedema, conjunctival hyperaemia, halo vision, arrhythmia, atrial
fibrillation, supraventricular tachycardia, myocardial ischemia, bronchospasm, throat irritation,
pharyngeal edema, laryngospasm, paradoxical bronchospasm, dry throat, stomatitis, glossitis, GI
motility disorder, diarrhea, constipation, mouth edema, urticaria, rash, pruritus, angioedema,
hyperhydrosis, muscular weakness, muscle spasm, myalgia, urinary retention, decreased diastolic
BP.
Sedation.
Irritation, hypersensitivity, rise in IOP, blurred vision, subcapsular cataract, corneal thinning &
perforation.
Constipation, diarrhea, dry mouth, abdominal distention, headache, nausea, vomiting, urticaria,
rash. Rarely, hepatic enzyme & hematologic changes.
Rise in IOP, hypersensitivity reactions, blurred vision, posterior subcapsular cataracts formation.
Rarely, abdominal cramps, diarrhea, dizziness, headache, nausea, erectile dysfunction, slow heart
rate, low BP, numbness, tingling, cold extremities, sore throat & shortness of breath or wheezing.
Nausea, anorexia, epigastric pain, metallic taste, vomiting, GI disturbances, urticaria, skin redness,
pruritus, angioedema, anaphylaxis.
Abdominal discomfort.
Skin reactions, fever, hematological changes, increased hepatic enzyme function, diarrhea, nausea
vomiting, pseudomembranous colitis, pain at the inj site, phlebitis.
Headache, light GIT disorder, skin rash, thrombocytopenia, epistaxis, purpura or hemorrhages w/in
the skin.
Reduced plasma lipoprotein conc & copper absorption which may lead to anemia, neutropenia &
other hematologic effects; nausea, bitter taste & oral irritation.
Anaphylactic shock; serum sickness; fever w/ trembling; pain at inj site after high dose of antisera
inj.
Rash, urticaria, pruritus, erythema, fever, acute & severe allergic reactions, nausea, vomiting,
abdominal pain, diarrhea, dyspepsia, constipation, colitis, chest pain, tachycardia, cough, dyspnea,
sore throat, dizziness, headache, anxiety, confusion, paresthesia, inflammation & pain at inj site,
anaphylactic reactions, laboratory test abnormalities, vaginitis, oral moniliasis, unspecific
moniliasis, vasodilatation, genital pruritus, taste perversion, convulsion.
Resp disorders, chest pain & discomfort, rash, skin itching & swelling.
GI disturbances eg nausea; gastritis, gastric ulcer. Skin allergic reactions eg itching & swelling
(discontinue).
Nausea, gastritis or gastric ulcer.
Paresthesia, headache, dizziness, vertigo; visual disturbance; tinnitus; hypotension; dry cough,
dyspnea; GI disorders; rash, pruritus, maculopapular eruptions; muscle cramps; asthenia.
Hypersensitivity reactions & hypoprothrombinemia. Transient increase of SGOT, SGPT & alkaline
phosphatase. Diarrhea, loose stools, nausea, vomiting, pseudomembranous colitis. Transient
increase of BUN & serum creatinine. Pain at inj site (IM), phlebitis (IV).
Anaphylactic shock; serum sickness; fever w/ trembling; pain at inj site after high dose of antisera
inj.
Anaphylactic shock; serum sickness; fever w/ trembling, pain at inj site after high dose of antisera
inj.
GI disturbances, allergic reaction.
HTN, nausea, vomiting, headache, hypotension, hallucination, diarrhea, chest pain/transient chest
pain; tinnitus, diaphoresis, palpitation, dyspnea, thrombophlebitis, hematuria, leg cramp, nasal
congestion, taste disturbance, allergic reaction, severe arrhythmia, cerebrovascular attack &
disturbance, skin eruption, CV reactions.
Reversible ovarian enlargement, abdominal discomfort or pain, nausea, vomiting, transient visual
disturbances, headache, abnormal uterine bleeding, dizziness, fatigue, insomnia, vertigo.
Upper resp tract infections, back pain, flu-like symptoms, dizziness, headache.
Occassional dizziness, headaches, fatigue, bradycardia, postural HTN, GI upset, flare-like syndrome
reduced lacrimations.
Diarrhea.
Headache, pain in face, flu syndrome, inj site pain & edema, back pain, accidental injury, infections
bronchitis, sinusitis, pharyngitis, dyspnea, sinus infection, laryngitis, rhinitis, erythema, skin
tightness, skin irritation, nausea, dyspepsia, tooth disorder, abnormal liver function, blepharoptosis
dizziness, paresthesia, anxiety, twitch, muscle weakness, UTI, ecchymosis, HTN.
Localised ocular toxicity & hypersensitivity including itching, swelling & conjunctival erythema.
Localized ocular toxicity & hypersensitivity including lid itching, swelling & conjunctival erythema.
Secondary infection.
Headache, abdominal pain, nausea, vag hemorrhage, OHSS, abdominal distention, inj site reaction
Dry skin, pruritus, irritation, mild to moderate transient burning/stinging, local atrophic skin
changes (prolonged & extensive treatment), hypercorticism (systemic absorption on prolonged
use), folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic
contact dermatitis, skin maceration, secondary infections, striae, miliaria; ototoxicity,
nephrotoxicity.
Mental & visual disturbance, drowsiness, amnesia, dependence; urinary retention, hypotension.
Rash, itching or swelling (especially of the face, tongue or throat), severe dizziness, trouble in
breathing.
Myelosuppression, hypersensitivity, cutaneous & infusion site reactions, fluid retention, neuropathy
GI symptoms (including stomatitis, nausea & vomiting), hypotension, elevation of liver enzymes.
Dyspnea, bleeding, headache, cough, dizziness, nausea, atrial fibrillation, HTN, non-cardiac chest
pain, diarrhea, back pain, hypotension, fatigue, chest pain, bradycardia, gynecomastia,
hypersensitivity eg angioedema.
Nausea, vomiting & diarrhea, stomatitis, glottis; headache & dizziness; skin reactions; eosinophilia,
thrombocytosis, leukopenia, granulocytopenia & hemolytic anemia; transient elevations of SGOT o
SGPT, BUN. Rarely, inflammatory reactions at inj site.
Nausea, diarrhea, indigestion, bloating, headache, vertigo, increased sweating, skin, rash,
increased serum transaminase.
Nausea, diarrhea, GI disturbances; headache, vertigo, sweating, skin rash, transient rise in
transaminase levels.
Mild GI disturbances.
Nausea, abdominal pain, vomiting; rash, urticaria, & coughing; dyspnea, asthma; fever, fatigue,
allergic reactions.
Fine tremor of skeletal muscle especially hand, palpitation, muscle cramp, tachycardia, headache.
GI disturbances including nausea, vomiting, diarrhea, gastric pain; skin rash, bronchospasm,
thrombocytopenia. Very rarely, blurred vision & color vision changes.
Allergic exanthema, red striae, petechiae, ecchymosis, steroid acne, delayed wound healing,
contact dermatitis, muscle weakness, osteoporosis, aseptic necrosis of the bone, glaucoma,
cataract, depression, irritability, euphoria, GI discomfort, duodenal ulcer, pancreatitis, Cushing's
syndrome, HTN, increased risk of thrombosis & vasculitis, delayed immune response.
Nausea, vomiting, epigastric pain, headache, irritation, insomnia, palpitation, tachyarrhythmia,
tachypnea, rash, hyperglycemia.
Nausea, vomiting, diarrhea, constipation, abdominal pain or transient burning on the upper
stomach, skin rashes, bronchospasm, thrombocytopenia, lymphopenia, blurred or diminished
vision.
Hypotension, bradycardia, post-spinal anesth headache, high or total spinal blockade resulting in
CV & resp depression, neurological complications.
Amlodipine: Arrhythmia (including ventricular tachycardia & atrial fibrillation), bradycardia, chest
pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural
hypotension, vasculitis, arthralgia, angioedema, dyspepsia, anorexia, hypoesthesia, peripheral
neuropathy, paresthesia, tremor, vertigo, anorexia, constipation, dyspepsia, dysphagia, diarrhea,
flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reaction, asthenia, back pain, hot
flashes, malaise, pain, rigors, wt gain/decrease, arthralgia, arthrosis, muscle cramps, myalgia,
sexual dysfunction, insomnia, nervousness, depression, abnormal dreams, anxiety,
depersonalization, dyspnea, epistaxis, angioedema, erythema multiforme, pruritus, rash, abnorma
vision, conjunctivitis, diplopia, eye pain, tinnitus, micturition frequency, micturition disorder,
nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura,
thrombocytopenia. Atorvastatin: Chest pain, face edema, fever, neck rigidity, malaise,
photosensitivity reaction, generalized edema, nausea, gastroenteritis, abnormal liver function tests
colitis, vomiting, gastritis, dry mouth, rectal hemorrhage, esophagitis, eructation, glossitis, mouth
ulceration, anorexia, increased appetite, stomatitis, biliary pain, chellitis, duodenal ulcer,
dysphagia, enteritis, melena, gum hemorrhage, stomach ulcer, tenesmus, ulcerative stomatitis,
hepatitis, pancreatitis, cholestatic jaundice, bronchitis, rhinitis, pneumonia, dyspnea, asthma,
epistaxis, insomnia, dizziness, paresthesia, somnolence, amnesia, abnormal dreams, decreased
libido, emotional lability, incoordination, peripheral neuropathy, torticollis, facial paralysis,
hyperkinesias, depression, hypesthesia, hypertonia, arthritis, leg cramps, bursitis, tenosynovitis,
myasthenia, tendinous contracture, pruritus, contact dermatitis, alopecia, dry skin, sweating, acne
urticaria, eczema, seborrhoea, skin ulcer, UTI, urinary frequency, cystitis, hematuria, impotence,
dysuria, kidney calculus, nocturia, epididymitis, fibrocystic breast, vag hemorrhage, albuminuria,
breast enlargement, metorrhagia, nephritis, urinary incontinence, urinary retention, urinary
urgency, abnormal ejaculation, uterine hemorrhage, amblyopia, tinnitus, dry eyes, refraction
disorder, eye hemorrhage, deafness, glaucoma, parosmia, taste loss, taste perversion, palpitation,
vasodilatation, syncope, migraine, postural hypotension, phlebitis, arrhythmia, angina pectoris,
HTN, peripheral edema, hyperglycemia, increased creatine phosphokinase, gout, wt gain,
hypoglycaemia, ecchymosis, anemia, lymphadenopathy, thrombocytopenia, petechia.
Irritation.
Mild & transient vasodilation, HTN, feeling of warmth, nausea, dizziness, SC oedema & palpitation.
Hypercalciuria.
Mild GI disturbances.
Mild GI disturbances.
Mild GI disturbances.
Peptic ulcer, dizziness, headache, hematologic changes, skin rash, kidney failure, reduced Hb &
hematocrit.
Back pain, dizziness, upper resp tract infections, pharyngitis & rhinitis.
GI disturbances.
Blood dyscrasias, GI & hypersensitivity reactions; headache, mental depression, optic neuritis &
Gray syndrome.
Diarrhea, headache, nausea, skin allergy, abdominal pain, constipation, flatulence & vomiting.
Inflammation, thrombophlebitis, inj site pain; pruritic rash, urticaria; abdominal pain, nausea,
vomiting, diarrhea, pseudomembranous colitis; reversible thrombocythemia, eosinophilia,
thrombocytopenia, leucopenia, neutropenia; increased serum conc eg bilirubin, transaminases,
alkaline phosphatase & lactic dehydrogenase alone or combination; headache, paresthesia,
convulsion; oral & vag candidosis.
Rash, pruritus, urticaria, nausea, vomiting, oral moniliasis, diarrhea, colitis, headache, fever,
vaginitis, erythema; abdominal pain, constipation, vasodilation, dyspnea, dizziness, paresthesia,
genital pruritus, taste perversion, chills & unspecified moniliasis; phlebitis & inflammation at inj
site; transient BUN &/or serum creatinine elevations, thrombocytopenia, leucopenia, neutropenia;
Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, toxic nephropathy,
aplastic anemia, hemolytic anemia, hemorrhage.
Drowsiness, dizziness, headache, agitation, dry mouth & GI discomfort; hypersensitivity reactions,
including skin reactions & angioedema.
Headache, diarrhea, nausea, upper abdominal pain, flatulence, skin rash, pruritus, dizziness,
edema, fever, thrombophlebitis, depression, blurred vision.
Diarrhea, nausea, vomiting, indigestion, pseudomembranous colitis & candidiasis; hepatitis &
cholestatic jaundice; phlebitis at inj site; urticaria & erythematous rashes; erythema multiforme,
Stevens-Johnson syndrome, toxic epidermal necrolysis & exfoliative dermatitis; angioedema &
anaphylaxis; transient leucopenia, thrombocytopenia & hemolytic anemia.
Initial hypotension, nausea, dizziness, headache, drowsiness, cough. Rarely, angioneurotic oedema
Headache, edema, fatigue, somnolence, nausea, abdominal pain, flushing, palpitations, dizziness.
Increased heart rate, BP & ventricular ectopic activity, hypotension, phlebitis, local inflammatory
changes, nausea, headache, anginal pain, nonspecific chest pain, palpitation, shortness of breath.
Increased heart rate, BP, hypotension, phlebitis, headache, unspecified chest pain, palpitation,
dyspnea.
Edema, headache.
Asthenia, fatigue, malaise, edema, postural dizziness, syncope, dizziness, headache, vertigo,
nausea, somnolence, rhinitis, hot flushes, hypotension, gynecomastia, retrograde ejaculation.
Intraoperative floppy iris syndrome (IFIS).
Mild GI symptoms eg transient nausea & vomiting, abdominal cramps & diarrhea.
Inflammation, thrombophlebitis & inj site pain. Skin rash, pruritus, urticaria. Abdominal pain,
nausea, vomiting, diarrhea, pseudomembranous colitis. Reversible thrombocytopenia, eosinophilia
neutropenia, leucopenia, +ve result in direct or indirect Coombs' test, headache, paresthesia, oral
& vag candidiasis.
Hot flushes, pruritus, breast tenderness & gynaecomastia, diarrhoea, nausea, vomiting, asthenia,
dry skin, hepatic changes, GI effects, dizziness, insomnia, somnolence, decreased libido, dyspnoea
impotence, nocturia, anaemia, thrombocytopenia, alopecia, rash, sweating, hirsutism, DM,
hyperglycaemia, oedema, wt gain, wt loss, abdominal & chest pains, headache, pain, pelvic pain,
chills.
Headache, dizziness, vertigo; nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence,
anorexia, epigastric pain; increased transaminases; rash.
Headache, dizziness, vertigo; nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence,
anorexia, epigastric pain; increased transaminases; rash.
Constipation.
GI upset, CNS effect, local inj site reactions & phlebitis or thrombophlebitis. Very rarely,
hypersensitivity reactions, transient hematological changes.
Hypersensitivity reactions, interstitial nephritis, GI effects, increased liver enzyme, mild increase in
serum creatinine level, thrombocytopenia, irritation & inflammation on inj site, overgrowth of
nonsusceptible microorganism.
Allergic reaction of the skin. Prolonged use may cause reversible neutropenia. Diarrhea, nausea,
vomiting. May cause false positive results in Coombs' test. Reduced Hb & hematocrit. Temporary
increased SGOT/SGPT/alkaline phosphatase, BUN & serum creatinine level.
Hypersensitivity reactions, nausea, vomiting, diarrhea; increased creatinine & urea serum,
interstitial nephritis, kidney failure; increased serum liver enzyme; thrombocytopenia, eosinophilia,
hemolytic anemia; thrombophlebitis & pain at inj site; convulsion, reversible encephalopathy;
superinfections.
Diarrhea, nausea, vomiting, maculopapular rash, urticaria, eosinophilia, drug fever, reversible
neutropenia, decreased Hb or hematocrit; headache, fever, pain at inj site, tremor; increased
SGOT/SGPT, alkaline phosphatase, bilirubin.
Nausea, vomiting & diarrhea, stomatitis, glossitis, headache, dizziness, skin reactions, anaemia,
granulocytopenia, haemolytic anaemia, transient elevations of SGOT or SGPT, leukopenia,
thrombocytosis.
Hypersensitivity reactions; GI, kidney & liver function effects; haematological changes, local
reactions, neurological effects, superinfection; temporary sensation disorder, headache, fever.
Drug Interactions
Theophylline, carbamazepine.
Increased clearance & lower blood levels w/ CYP3A4 inducers eg carbamazepine. Inhibit
elimination & increased blood levels w/ CYP3A4 inhibitors eg ketoconazole & CYP2D6
inhibitors eg quinidine, fluoxetine or paroxetine.
Increased clearance & lower blood levels w/ CYP3A4 inducers eg carbamazepine. Inhibit
elimination & increased blood levels w/ CYP3A4 inhibitors eg ketoconazole & CYP2D6
inhibitors eg quinidine, fluoxetine or paroxetine.
Increased clearance & lower blood levels w/ CYP3A4 inducers eg carbamazepine. Inhibit
elimination & increased blood levels w/ CYP3A4 inhibitors eg ketoconazole & CYP2D6
inhibitors eg quinidine, fluoxetine or paroxetine.
Increased clearance & lower blood levels w/ CYP3A4 inducers eg carbamazepine. Inhibit
elimination & increased blood levels w/ CYP3A4 inhibitors eg ketoconazole & CYP2D6
inhibitors eg quinidine, fluoxetine or paroxetine.
Increased t w/ probenecid.
Concomitant intake of medications containing polyvalent cations (eg Ca, Mg, Fe, Al,
antacids) will interfere w/ the absorption; & should be taken at a different time of the day.
Significantly increased AUC w/ CYP2C8 enzyme inhibitor eg gemfibrozil & decreased AUC
w/ CYP2C8 enzyme inducer eg rifampin. Competing for common renal tubular transport
systems w/ cationic drugs. Loss of glycemic control when in concomitant w/ thiazides &
other diuretics, corticosteroids, phenothiazines, thyroid prep, estrogen, OC, phenytoin,
nicotinic acid, sympathomimetics, Ca-channel blockers & INH.
Immunosuppressants.
Sucralfate.
Antidiabetic drugs.
ACE inhibitors.
Ascorbate may increase the absorption of chromium. Concomitant w/ foods rich in phytic
acid may decrease the absorption of chromium. Antibiotic may decrease the biotin
distribution to the body. Anticonvulsants (carbamazepine, phenytoin, phenobarb,
primidone) can accelerate biotin metabolism & reduce biotin status.
Additive effects w/ phenobarb, CNS depressants.
Increased plasma conc of drugs metabolized by CYP3A. Increased conc w/ drugs that
inhibit CYP3A. Decreased conc w/ co-administration w/ drugs that induce CYP3A &
rifampin. May significantly increase fluticasone propionate plasma conc & reduce serum
cortisol conc. Increase hypotensive effect & prolonged erection w/ sildenafil, tadalafil or
vardenafil. Reduce plasma conc of protease inhibitors w/ concomitant use w/ St. John's
wort-containing products. May increase potential for serious reactions eg myopathy,
including rhabdomyolysis, of HMG-CoA reductase inhibitors. Decrease levels of OCs &
patch contraceptives.
Anticholinergics, succinylcholine.
Effects potentiated when used w/ insulin & other antidiabetics, ACE inhibitors, allopurinol,
anabolic steroids & male sex hormones, chloramphenicol, coumarin derivatives,
cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine,
guanethidine, ifosfamide, MAOIs, miconazole, para-aminosalicylic acid, pentoxifylline
(high dose parenteral), phenylbutazone, azapropazone, oxyphenbutazone, probenecid,
quinolones, salicylates, sulfinpyrazone, sulfonamides, tetracyclines, tritoqualine,
trofosfamide. Effects weakened when used w/ acetazolamide, barbiturates,
corticosteroids, diazoxide, diuretics, epinephrine & other sympathomimetics, glucagon,
laxatives (after protracted use), nicotinic acid (high dose), oestrogens & progestogens,
phenothiazines, phenytoin, rifampicin, thyroid hormones. -blockers decrease glucose
tolerance.
Effects potentiated when used w/ insulin & other antidiabetics, ACE inhibitors, allopurinol,
anabolic steroids & male sex hormones, chloramphenicol, coumarin derivatives,
cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine,
guanethidine, ifosfamide, MAOIs, miconazole, p-aminosalicylic acid, pentoxifylline (high
dose parenteral), phenylbutazone, azapropazone, oxyphenbutazone, probenecid,
quinolones, salicylates, sulfinpyrazone, sulfonamides, tetracyclines, tritoqualine,
trofosfamide. Effects weakened when used w/ acetazolamide, barbiturates,
corticosteroids, diazoxide, diuretics, epinephrine & other sympathomimetics, glucagon,
laxatives (after protracted use), nicotinic acid (high dose), oestrogens & progestogens,
phenothiazines, phenytoin, rifampicin, thyroid hormones. -blockers decrease glucose
tolerance.
Potentiation of the blood glucose-lowering effect by insulin & other oral antidiabetics,
ACE inhibitors, allopurinol, anabolic steroids, male sex hormones, chloramphenicol,
coumarin anticoagulants, cyclophosphamide, disopyramide, fenfluramine, fenyramidol,
fibrates, fluoxetine, guanethidine, ifosfamide, MAOIs, miconazole, fluconazole, salicylates,
pentoxyfylline, phenylbutazone, probenecid, quinolones, sulfinpyrazone, sulfonamides,
tetracyclines, tritoqualine, trofosfamide, azapropazone, oxyphenbutazone. Weakening of
the blood glucose-lowering effect by acetazolamide, barbiturates, corticosteroids,
diazoxide, diuretics, epinephrine & other sympathomimetics, glucagon, laxatives (longterm use), nicotinic acid (high dose), estrogens, progestogens, phenothiazines,
phenytoin, rifampicin, thyroid hormones.
Enhanced effect by other antihypertensive drugs & TCAs. Nitrates, -blockers, Ca-channel
blockers.
Nonselective MAOIs may cause HTN. Drugs which will form insoluble comp w/ Ca eg
tetracycline. Antacids, other Ca-containing drugs.
Ca prep.
Oral anticoagulants.
Increased & prolonged amoxicillin blood levels w/ probenecid. Increased skin allergic
reaction w/ allopurinol.
Potentiation of effects when used w/ insulin & other antidiabetics, ACE inhibitors,
allopurinol, anabolic steroids & male sex hormones, chloramphenicol, coumarin
derivatives, cyclophosphamide, disopyramide, fenfluramine, fenylramidol, fibrates,
fluoxetine, guanethidine, ifosfamide, MAOIs, miconazole, para-amino salicylic acid,
pentoxifylline, high dose quinolones, salicylates, sulfinpyrazones, sulfonamides,
tetracyclines, tritoqualine, trofosfamide. Weakening of the blood glucose lowering effects
when used w/ acetazoliamide, barbiturates, corticosteroids, diazoxide, diuretics,
epinephrine & other sympathomimetics, glucagon, laxatives (other protracted use),
nicotinic acid (high dose), oestrogens & progesterons, phenothiazines, phenytoin,
rifampicin, thyroid hormones, -blockers decrease glucose tolerance.
Diazepam, MAOIs, drugs highly bound to plasma protein, CNS active drugs.
Increase plasma conc of lithium & digoxin. Diuretics or antihypertensive agents (eg blocker, ACE inhibitors). Increased frequency of GI undesirable effects w/ other systemic
NSAIDs or corticosteroids. Increase the risk of bleeding w/ anticoagulants & antiplatelet
agents. Increase risk of GI bleeding w/ SSRIs. Increased toxicity of methotrexate. May
increase nephrotoxicity of ciclosporin. Antidiabetics, quinolone antibacterials, warfarin.
Anticoagulants, alcohol.
Warfarin, rifampin, methotrexate, ACE inhibitors, lithium, aspirin, OC, diuretics, inhibitors
& angiotensin II antagonists.
Increased bleeding risk w/ concomitant administration of agents that may enhance the
risk of hemorrhage (desirudin, fibrinolytic agents, GP IIb/IIIa receptor antagonists,
heparin, heparinoids, low molecular wt heparins); antiplatelet drugs & NSAIDs.
Concomitant use w/ coumarin anticoagulant may increase risk of bleeding. Acetosal may
reduce ibuprofen conc in blood & reduce anti-inflammatory effect.
Decreased absorption w/ Al &/or Mg hydroxide antacids. Increased risk of diarrhea w/
laxatives, antibiotics. Avoid co-administration w/ fibres & phytates.
Coumarin.
Oral anticoagulants.
Aminoglycosides, diuretics.
Ketoconazole, ritonavir.
Verapamil, diltiazem.
Ethambutol reduces the efficacy of uricosuric agents, esp in the presence of INH &
pyridoxine. INH enhances the effects of phenytoin & inhibits metabolism of primidone.
May reduce efficacy of uricosurics, esp in the presence of INH & pyridoxine. Al-containing
antacids.
Al- or Mg-containing antacids may reduce absorption. May increase plasma theophylline
levels. Probenecid, clindamycin, metronidazole.
Alcohol.
Antihypertensives or antidepressants.
Drugs that reduce renal function or compete for active tubular secretion may increase
serum conc of either entecavir or co-administered drug.
Immunosuppressants.
Theophylline, antacids.
Alcohol.
Warfarin.
Warfarin.
Aminoglycosides.
Anticoagulants.
Alcohol. Concomitant use w/ aminoglycosides or other cephalosporins may increase risk
of nephrotoxicity.
Ergot derivatives.
Nephrotoxic drugs.
Ca antagonist, clonidine, MAOIs (except MAO-B inhibitors), class I & III antiarrhythmics,
parasympathomimetics, other -blockers (including eye drops); insulin & oral
antidiabetics, anesth agents, digitalis glycosides, prostaglandin synthetase inhibitors,
ergotamine derivatives, sympathomimetics, TCA, barbiturates, phenothiazines, other
antihypertensives, rifampicin.
Ca antagonist, clonidine, MAOIs (except MAO-B inhibitors), class I & III antiarrythmic
drugs, parasympathomimetic drugs, other -blockers (including eye drops), insulin & oral
antidiabetic drugs, anesth agents, digitalis glycosides, prostaglandin synthetaseinhibiting drugs, ergotamine derivatives, sympathomimetic agents, tricyclic
antidepressants, barbiturates, phenothiazines, other antihypertensive agents, rifampicin.
Ca-antagonists, clonidine, MAOIs except MAO- inhibitors are not recommended. Class I
& III antiarrhythmics, parasympathomimetic drugs, other -blockers, insulin & oral
antidiabetic drugs, anaesth agents, digitalis glucosides, ergotamine derivatives,
sympathomimetic agents, TCAs, barbiturates, phenothiazines & other antihypertensive
agents; rifampicin.
K-sparing diuretics.
Rifampicin may reduce AUC or Cmax. Cimetidine & grapefruit juice may increase AUC.
Quinidine, fluoxetine, paroxetine & propafenone may increase blood levels of R(+)
enantiomer. Digoxin plasma conc increased when administered concomitantly. Clonidine
may potentiate BP & heart rate-lowering effects.
Drugs affecting intestinal transit time, Al- &/or Mg-containing antacids; concomitant use
w/ antibiotic or chemotherapy may increase enterocolic incidence.
Oral tetracyclines or fluoride; vit D, spinach, rhubarb, bran, cereal, milk, milk products,
Ca-channel blockers, digitalis.
Aminoglycosides.
Ketoconazole.
OCs, anticoagulants.
K-supplements & K-sparing agents. Diuretics & other antihypertensives, nitrates, TCA,
anaesth. Glucocorticoids or laxatives. Vasopressor sympathomimetics & NSAIDs.
Allopurinol, immunosupressants, corticosteroids, procainamide, cystostatics. Lithium
salts. Heparin. Alcohol.
Nitroprusside, -blockers.
Nitroprusside, -blocker.
Warfarin.
Warfarin.
Coumarin anticoagulants.
Warfarin.
Drugs which may inhibit drug oxidation eg cimetidine & ketoconazole. Warfarin.
Terfenadine, astemizole or cisapride. Cyclosporin, Ca-channel blockers, coumarin,
anticoagulant & prothrombin.
Lithium, digoxin, diuretics & other antihypertensives, other NSAIDs & corticosteroids,
anticoagulants & antiplatelets, SSRIs, methotrexate, cyclosporin, quinolones, warfarin.
Lithium, digoxin, diuretics & other antihypertensives, other NSAIDs & corticosteroids,
anticoagulants & antiplatelets, SSRIs, methotrexate, cyclosporin, quinolones, warfarin.
Increases plasma conc of lithium, methotrexate, digoxin. May reduce effects of diuretics,
-blockers. May reduce absorption of neomycin, cholestyramine & liquid paraffin.
Nephrotoxic drugs.
Alcohol.
Alcohol.
Alcohol.
Aminoglycosides, probenecid.
Aminoglycosides, diuretics.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
ManufacturerContentsIndicationsDosageOverdosageContraindicationsSpecial PrecautionsAdverse D
ReactionsSide EffectsDrug InteractionsPregnancy Category (US FDA)StorageDescriptionMechanism
ClassATC ClassificationDrug ClassificationPresentation/Packing
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant
acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious
which safer drugs cannot be used or are ineffective).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there i
foetal risk based on human experience or both, and the risk of the use of the drug in pregnant wom
outweighs any possible benefit. The drug is contraindicated in women who are or may become pre
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or e
other) and there are no controlled studies in women or studies in women and animals are not avail
should be given only if the potential benefit justifies the potential risk to the foetus.
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are n
studies in pregnant women or animal-reproduction studies have shown an adverse effect (other tha
in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is
a risk in later trimesters).
Storage
Description
View 3TC description for details of the chemical structure and excipients
(inactive components).
View Abilify Injection description for details of the chemical structure and
excipients (inactive components).
View Abilify Tablet description for details of the chemical structure and
excipients (inactive components).
View Aclasta description for details of the chemical structure and excipients
(inactive components).
View Actifed description for details of the chemical structure and excipients
(inactive components).
View Actilyse description for details of the chemical structure and excipients
(inactive components).
View Actonel description for details of the chemical structure and excipients
(inactive components).
View Actos description for details of the chemical structure and excipients
(inactive components).
View Adant Dispo description for details of the chemical structure and
excipients (inactive components).
View Aerius description for details of the chemical structure and excipients
(inactive components).
View Aerius D-12 description for details of the chemical structure and
excipients (inactive components).
View Amaryl description for details of the chemical structure and excipients
(inactive components).
View Amcor description for details of the chemical structure and excipients
(inactive components).
View Aminovel 600 description for details of the chemical structure and
excipients (inactive components).
View Andriol Testocaps description for details of the chemical structure and
excipients (inactive components).
View Anuva description for details of the chemical structure and excipients
(inactive components).
View Apidra description for details of the chemical structure and excipients
(inactive components).
View Aprovel description for details of the chemical structure and excipients
(inactive components).
View Arava description for details of the chemical structure and excipients
(inactive components).
View Arcalion 200 description for details of the chemical structure and
excipients (inactive components).
View Ardium CVD description for details of the chemical structure and
excipients (inactive components).
View Arixtra description for details of the chemical structure and excipients
(inactive components).
View Atorwin description for details of the chemical structure and excipients
(inactive components).
View Avamys description for details of the chemical structure and excipients
(inactive components).
View Avastin description for details of the chemical structure and excipients
(inactive components).
View Avodart description for details of the chemical structure and excipients
(inactive components).
View Berotec description for details of the chemical structure and excipients
(inactive components).
View Bioprexum Plus description for details of the chemical structure and
excipients (inactive components).
View Blopress Plus description for details of the chemical structure and
excipients (inactive components).
View Brilinta description for details of the chemical structure and excipients
(inactive components).
View Caduet description for details of the chemical structure and excipients
(inactive components).
View Cataflam Fast description for details of the chemical structure and
excipients (inactive components).
Mechanism of Action
MIMS Class
Topical Antifungals & Antiparasites
Antivirals
Antivirals
Cytotoxic Chemotherapy
Haemostatics
Haemostatics
Macrolides
Antipsychotics
Antipsychotics
Antipsychotics
Cephalosporins
Cephalosporins
Angiotensin II Antagonists
Analgesics (Opioid)
Macrolides
Antacids, Antireflux Agents & Antiulcerants
Topical Antivirals
Penicillins
Antidiabetic Agents
Cephalosporins
Dyslipidaemic Agents
Calcium Antagonists
Antidiabetic Agents
Anxiolytics
Cytotoxic Chemotherapy
Antidiabetic Agents
Antidiabetic Agents
Insulin Preparations
Topical Antibiotics
Antivirals
Calcium Antagonists
Haemostatics
Vasoconstrictors
Cytotoxic Chemotherapy
Haemostatics
Topical Corticosteroids
Antimalarials
Supplements & Adjuvant Therapy
Topical Antibiotics
Quinolones
Other Antibiotics
Diuretics
Diuretics
Antidiabetic Agents
Antacids, Antireflux Agents & Antiulcerants
Eye Corticosteroids
Cytotoxic Chemotherapy
Anxiolytics
Cytotoxic Chemotherapy
Skin Antiseptics & Disinfectants
Mouth/Throat Preparations
Aminoglycosides
Other Dermatologicals
Topical Corticosteroids
Mouth/Throat Preparations
Cough & Cold Preparations
Antidiarrheals
Analgesics (Non-Opioid) & Antipyretics
Anxiolytics
Anxiolytics
Antivirals
Anxiolytics
Cephalosporins
Antidiabetic Agents
Antidiabetic Agents
Penicillins
Anorectal Preparations
Penicillins
Calcium Antagonists
Antidiarrheals
Other Drugs Acting on the Genito-Urinary System
Aminoglycosides
Calcium Antagonists
Calcium Antagonists
Calcium Antagonists
Penicillins
Penicillins
Penicillins
Penicillins
Penicillins
Penicillins
Penicillins
Penicillins
Penicillins
Penicillins
Penicillins
Corticosteroid Hormones
Analgesics (Opioid)
Cephalosporins
Macrolides
Cephalosporins
Penicillins
Depot Contraceptives
Oral Contraceptives
Analgesics (Opioid)
Topical Antihistamines/Antipruritics
Antidepressants
Antidiarrheals
Other Antibiotics
Antidepressants
Cephalosporins
Antifungals
Topical Antifungals & Antiparasites
Oestrogens, Progesterones & Related Synthetic Drugs
Anti-Anginal Drugs
Angiotensin II Antagonists
Enteral/Nutritional Products
Enteral/Nutritional Products
Enteral/Nutritional Products
Enteral/Nutritional Products
Enteral/Nutritional Products
Enteral/Nutritional Products
Enteral/Nutritional Products
Antidepressants
Supplements & Adjuvant Therapy
Antidepressants
Antidepressants
Antiemetics
Anxiolytics
Cytotoxic Chemotherapy
Anxiolytics
Appetite Enhancers
Insulin Preparations
Anti-Obesity Agents
Topical Corticosteroids
Anticonvulsants
Angiotensin II Antagonists
Angiotensin II Antagonists
Antidiarrheals
Anorectal Preparations
Antipsychotics
Antiparkinsonian Drugs
Quinolones
Anti-TB Agents
Antiparkinsonian Drugs
Antimalarials
Antiglaucoma Preparations
Anthelmintics
Supplements & Adjuvant Therapy
Anthelmintics
Vitamin C
Antiasthmatic & COPD Preparations
Anxiolytics
Dyslipidaemic Agents
Dyslipidaemic Agents
Dyslipidaemic Agents
Dyslipidaemic Agents
Cardiac Drugs
Muscle Relaxants
Muscle Relaxants
Penicillins
Penicillins
Penicillins
Antidepressants
Penicillins
Antidiabetic Agents
Antidiabetic Agents
Antidiabetic Agents
Targeted Cancer Therapy
Quinolones
Macrolides
Antiglaucoma Preparations
Macrolides
Anti-TB Agents
Cephalosporins
Penicillins
Quinolones
Cephalosporins
Topical Antibiotics
Antibacterial Combinations
Cephalosporins
Antibacterial Combinations
Antibacterial Combinations
Antibacterial Combinations
Topical Antibiotics
Cephalosporins
Quinolones
Antivirals
Anticonvulsants
Enteral/Nutritional Products
Enteral/Nutritional Products
Enteral/Nutritional Products
Antimigraine Preparations
Supportive Care Therapy / Analgesics (Opioid)
Anti-TB Agents
Nootropics & Neurotonics/Neurotrophics
Antidiabetic Agents
Corticosteroid Hormones
Topical Anti-Infectives with Corticosteroids
Digestives
Parenteral Nutritional Products
Other Dermatologicals
Topical Corticosteroids
Haemostatics
Topical Corticosteroids
Cough & Cold Preparations
Topical Corticosteroids
Digestives
Beta-Blockers
Mouth/Throat Preparations
Antivertigo Drugs
Antivertigo Drugs
Emollients & Skin Protectives
Topical Anti-Infectives with Corticosteroids
Topical Corticosteroids
Topical Corticosteroids
Miotic Drugs
Vitamin B-Complex / with C
Cephalosporins
Other Antibiotics
Laxatives, Purgatives
Macrolides
Cephalosporins
Vitamin C
Cephalosporins
Antidiarrheals
Penicillins
Macrolides
Penicillins
Calcium/with Vitamins
Cephalosporins
Cephalosporins
Other Dermatologicals
Supplements & Adjuvant Therapy
Other Antibiotics
Antidiarrheals
Cephalosporins
Vitamins A, D & E
Mouth/Throat Preparations
Analgesics (Non-Opioid) & Antipyretics
Other Antibiotics
Other Dermatologicals
Topical Antihistamines/Antipruritics
Topical Antibiotics
Medicated Surgical Dressings
Topical Antibiotics
ACE Inhibitors/Direct Renin Inhibitors
Other Dermatologicals
Vitamins A, D & E
Macrolides
Cephalosporins
Vitamins &/or Minerals
Cephalosporins
Mouth/Throat Preparations
Cephalosporins
Beta-Blockers
Beta-Blockers
Cough & Cold Preparations
Cough & Cold Preparations
Beta-Blockers
Beta-Blockers
Beta-Blockers
Beta-Blockers
Cytotoxic Chemotherapy
Cytotoxic Chemotherapy
Calcium Antagonists
Angiotensin II Antagonists
Beta-Blockers
Anorectal Preparations
Anorectal Preparations
Antispasmodics
Cephalosporins
Cephalosporins
Cephalosporins
Cough & Cold Preparations
Penicillins
Topical Antibiotics
Antispasmodics
Antispasmodics
Antispasmodics
Anxiolytics
Calcium/with Vitamins
Cytotoxic Chemotherapy
Antimigraine Preparations
Calcium/with Vitamins
Topical Corticosteroids
Electrolytes
Calcium/with Vitamins
Calcium Antagonists
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Enteral/Nutritional Products
Enteral/Nutritional Products
Enteral/Nutritional Products
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Cephalosporins
Calcium/with Vitamins
Calcium/with Vitamins
Corticosteroid Hormones
Analgesics (Opioid)
Cytotoxic Chemotherapy
Angiotensin II Antagonists
Angiotensin II Antagonists
Antifungals
Antifungals
Vitamin C
Chloramphenicols
Other Beta-Lactams
Cephalosporins
Cephalosporins
Penicillins
Penicillins
Beta-Blockers
Cytotoxic Chemotherapy
Cytotoxic Chemotherapy
Cytotoxic Chemotherapy
Cytotoxic Chemotherapy
Calcium Antagonists
Cardiac Drugs
Cardiac Drugs
Calcium Antagonists
Calcium Antagonists
Anti-Anginal Drugs
Calcium Antagonists
Calcium Antagonists
Other Dermatologicals
Anti-Obesity Agents
Other Beta-Lactams
Diuretics
Calcium Antagonists
Other Antihypertensives
Calcium/with Vitamins
Ophthalmic Lubricants
Calcium/with Vitamins
Calcium/with Vitamins
Calcium/with Vitamins
Antifungals
Calcium/with Vitamins
Calcium/with Vitamins
Other Dermatologicals
Vitamin C
Anti-Anginal Drugs
Vitamin C
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
Cephalosporins
ATC Classification
D11AC08 - sulfur compounds ; Belongs to the class of medicated shampoos.
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse
transcriptase inhibitors. Used in the systemic treatment of viral infections.
M09AX01 - hyaluronic acid ; Belongs to the class of other drugs for disorders of
the musculo-skeletal system.
A11BA - Multivitamins, plain ; Used as dietary supplements.
A10BA02 - metformin ; Belongs to the class of biguanides. Used in the treatment
of diabetes.
A03AX13 - silicones ; Belongs to the class of other drugs used for functional
bowel disorders.
N01AB06 - isoflurane ; Belongs to the class of halogenated hydrocarbons. Used
as general anesthetics.
P01BC01 - quinine ; Belongs to the class of methanolquinoline antimalarials.
A13A - TONICS ; Used as tonics.
D06AX01 - fusidic acid ; Belongs to the class of other topical antibiotics used in
the treatment of dermatological diseases.
B01AC23 - cilostazol ; Belongs to the class of platelet aggregation inhibitors
excluding heparin. Used in the treatment of thrombosis.
C03EA14 - butizide and potassium-sparing agents ; Belongs to the class of lowceiling diuretics in combination with potassium-sparing agents. Used as
diuretics.
A10BB07 - glipizide ; Belongs to the class of sulfonamides, urea derivatives.
Used in the treatment of diabetes.
A02BA02 - ranitidine ; Belongs to the class of H2-receptor antagonists. Used in
the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
M01AE03 - ketoprofen ; Belongs to the class of propionic acid derivatives of nonsteroidal antiinflammatory and antirheumatic products.
R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, nonselective beta-adrenoreceptor agonists. Used in the treatment of obstructive
airway diseases.
J05AE - Protease inhibitors ; Used in the systemic treatment of viral infections.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
V06DB - Fat/carbohydrates/proteins/minerals/vitamins, combinations ; Used as
general nutrients.
R03DA05 - aminophylline ; Belongs to the class of xanthines. Used in the
systemic treatment of obstructive airway diseases.
V06DE - Amino acids/carbohydrates/minerals/vitamins, combinations ; Used as
general nutrients.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
V06DE - Amino acids/carbohydrates/minerals/vitamins, combinations ; Used as
general nutrients.
B05BA01 - amino acids ; Belongs to the class of solutions for parenteral nutrition
used in I.V. solutions.
N02AX02 - tramadol ; Belongs to the class of other opioids. Used to relieve pain.
M01AE03 - ketoprofen ; Belongs to the class of propionic acid derivatives of nonsteroidal antiinflammatory and antirheumatic products.
A11HA02 - pyridoxine (vit B6) ; Belongs to the class of other plain vitamin
preparations. Used as dietary supplements.
N05BA09 - clobazam ; Belongs to the class of benzodiazepine derivatives
anxiolytics. Used in the management of anxiety, agitation or tension.
L01CD01 - paclitaxel ; Belongs to the class of plant alkaloids and other natural
products, taxanes. Used in the treatment of cancer.
M01AE01 - ibuprofen ; Belongs to the class of propionic acid derivatives of nonsteroidal antiinflammatory and antirheumatic products.
S01ED05 - carteolol ; Belongs to the class of beta blocking agents. Used in the
treatment of glaucoma.
M01AE01 - ibuprofen ; Belongs to the class of propionic acid derivatives of nonsteroidal antiinflammatory and antirheumatic products.
A11GA01 - ascorbic acid (vit C) ; Belongs to the class of ascorbic acid (vitamin
C). Used as dietary supplements.
R03CC02 - salbutamol ; Belongs to the class of adrenergics for systemic use,
selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive
airway diseases.
M03AC04 - atracurium ; Belongs to the class of other quaternary ammoniumcontaining agents used as peripherally-acting muscle relaxants.
M03AC04 - atracurium ; Belongs to the class of other quaternary ammoniumcontaining agents used as peripherally-acting muscle relaxants.
J04AK02 - ethambutol ; Belongs to the class of other drugs used in the systemic
treatment of tuberculosis.
M02AX10 - various ; Belongs to the class of other topical products used in the
treatment of joint and muscular pains.
D06AX07 - gentamicin ; Belongs to the class of other topical antibiotics used in
the treatment of dermatological diseases.
N03AF01 - carbamazepine ; Belongs to the class of carboxamide derivatives
antiepileptic.
D01AE14 - ciclopirox ; Belongs to the class of other antifungals for topical use.
G04BX - Other urologicals ; Used in the treatment of urological problems.
J01DD01 - cefotaxime ; Belongs to the class of third-generation cephalosporins.
Used in the systemic treatment of infections.
D01AC20 - combinations ; Belongs to the class of imidazole and triazole
derivatives. Used in the topical treatment of fungal infection.
C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents.
Used in the treatment of cardiovascular diseases.
A02BX - Other drugs for peptic ulcer and gastro-oesophageal reflux disease
(GORD) ; Used in the treatment of peptic ulcer and gastro-oesophageal reflux
disease (GERD).
A11JA - Combinations of vitamins ; Used as dietary supplements.
A11JA - Combinations of vitamins ; Used as dietary supplements.
A11DA01 - thiamine (vit B1) ; Belongs to the class of vitamin B1. Used as dietary
supplements.
C07FB03 - atenolol and other antihypertensives ; Belongs to the class of
selective beta-blocking agents in combination with other antihypertensives.
Used in the treatment of cardiovascular diseases.
C07AB03 - atenolol ; Belongs to the class of selective beta-blocking agents.
Used in the treatment of cardiovascular diseases.
A11GA01 - ascorbic acid (vit C) ; Belongs to the class of ascorbic acid (vitamin
C). Used as dietary supplements.
J01DD12 - cefoperazone ; Belongs to the class of third-generation
cephalosporins. Used in the systemic treatment of infections.
A01AD11 - various ; Belongs to the class of other agents for local oral treatment.
N02BE01 - paracetamol ; Belongs to the class of anilide preparations. Used to
relieve pain and fever.
B03AE02 - iron, multivitamins and folic acid ; Belongs to the class of iron in other
combinations. Used in the treatment of anemia.
A11DB - Vitamin B1 in combination with vitamin B6 and/or vitamin B12 ; Used as
dietary supplements.
J06AA03 - snake venom antiserum ; Belongs to the class of immune sera. Used
in the treatment of acute infectious diseases caused by toxigenic strains.
J01FA06 - roxithromycin ; Belongs to the class of macrolides. Used in the
systemic treatment of infections.
A01AD11 - various ; Belongs to the class of other agents for local oral treatment.
C07AG02 - carvedilol ; Belongs to the class of alpha and beta blocking agents.
Used in the treatment of cardiovascular diseases.
M05BX - Other drugs affecting bone structure and mineralization ; Used in the
treatment of bone diseases.
M01AX05 - glucosamine ; Belongs to the class of other non-steroidal
antiinflammatory and antirheumatic products.
M01AX05 - glucosamine ; Belongs to the class of other non-steroidal
antiinflammatory and antirheumatic products.
M01AX05 - glucosamine ; Belongs to the class of other non-steroidal
antiinflammatory and antirheumatic products.
A11CC03 - alfacalcidol ; Belongs to the class of vitamin D and analogues. Used
as dietary supplements.
R01AX10 - various ; Belongs to the class of other nasal preparations for topical
use.
M01AE01 - ibuprofen ; Belongs to the class of propionic acid derivatives of nonsteroidal antiinflammatory and antirheumatic products.
M01AE01 - ibuprofen ; Belongs to the class of propionic acid derivatives of nonsteroidal antiinflammatory and antirheumatic products.
B03AE02 - iron, multivitamins and folic acid ; Belongs to the class of iron in other
combinations. Used in the treatment of anemia.
A11GB01 - ascorbic acid (vit C) and calcium ; Belongs to the class of ascorbic
acid (vitamin C), with other combinations. Used as dietary supplements.
N02AX02 - tramadol ; Belongs to the class of other opioids. Used to relieve pain.
A11GA01 - ascorbic acid (vit C) ; Belongs to the class of ascorbic acid (vitamin
C). Used as dietary supplements.
V06DB - Fat/carbohydrates/proteins/minerals/vitamins, combinations ; Used as
general nutrients.
G01AF02 - clotrimazole ; Belongs to the class of imidazole derivative
antiinfectives. Used in the treatment of gynecological infections.
A11GA01 - ascorbic acid (vit C) ; Belongs to the class of ascorbic acid (vitamin
C). Used as dietary supplements.
A11GA01 - ascorbic acid (vit C) ; Belongs to the class of ascorbic acid (vitamin
C). Used as dietary supplements.
Drug Classification
W
G
B
B
B
B
B
G
G
G
B
B
G
G
G
G
W
G
B
B
B
B
B
B
B
B
W
G
G
G
B
B
B
B
B
G
G
B
W
G
G
G
G
B
G
B
G
B
G
B
B
B
Drag: B; amp: G
B
B
B
G
G
W
W
W
G, W
Presentation/Packing
2-4 Zalf topical application
15 g x 1's (Rp2340.00/tube)
3TC tab 150 mg
60's (Rp436,364/pak)
Abilify tab 10 mg
10's (Rp385,880/pak)
Abilify tab 15 mg
10's (Rp446,500/pak)
Abilify tab 5 mg
10's (Rp202,130/pak)
Abirom powd for inj 1 g
1's (Rp200,000/vial)
Abixim cap 100 mg
3 10's (Rp360,000/boks)
Abixim cap 200 mg
1 10's (Rp180,000/boks)
Abixim dry syr 100 mg/5 mL
30 mL x 1's (Rp53,000/botol)
Accolate film-coated tab 20 mg
2 14's (Rp206,490/boks)
Accupril tab 20 mg
30's (Rp352,800/pak)
Acendril tab 12.5 mg oral
10 10's (Rp18,000/boks)
Acendril tab 25 mg oral
10 10's (Rp23,000/boks)
Acenor-M tab 10 mg
10 6's (Rp600,930/boks)
Acepress tab 12.5 mg
10 10's (Rp187,000/boks)
Acepress tab 25 mg
10 10's (Rp308,000/boks)
Acetated Ringer's infusion
1 L x 12 1's (Rp16,000/boks)
500 mL x 24 1's (Rp9,900/boks)
Acetensa tab 50 mg
3 10's (Rp255,000/boks)
Acetin 600 effervescent tab 600 mg
1 10's (Rp80,000/boks)
Acifar cream 5 %
5 g x 1's (Rp9,926/tube)
Acilaz cap 30 mg
2 10's (Rp220,000/boks)
Aclonac tab 25 mg
3 10's (Rp39,600/boks)
Aclonac tab 50 mg
3 10's (Rp69,300/boks)
Acna Care softcap
10's (Rp100,000/blister)
Acne Feldin lotion 6.6 %
110 mL x 1's (Rp33,250/kontainer)
Acne-Aid bar soap 63 mg/g
100 g x 1's (Rp29,000/kontainer)
Acnezol cream 20 mg
5 g x 1's (Rp22,000/tube)
Acpulsif 5 tab 5 mg
5 10's (Rp132,500/boks)
Actapin tab 10 mg
3 10's (Rp195,000/boks)
Actapin tab 5 mg
3 10's (Rp105,000/boks)
Actaryl tab 1 mg
3 10's (Rp45,000/boks)
Actaryl tab 2 mg
3 10's (Rp81,000/boks)
Actaryl tab 3 mg
3 10's (Rp111,000/boks)
Actaryl tab 4 mg
3 10's (Rp141,000/boks)
Actazolam tab 0.5 mg
30's (Rp45,000/pak)
Actazolam tab 1 mg
30's (Rp65,000/pak)
Acticoat dressing 10 cm x 10 cm
12's
Acticoat dressing 10 cm x 20 cm
12's
Actifed syr
60 mL x 1's (Rp35,000/botol)
120 mL x 1's (Rp54,000/botol)
Actifed Plus Cough Suppressant syr
60 mL x 1's (Rp35,000/botol)
120 mL x 1's (Rp54,000/botol)
Actilyse infusion 50 mg
(+ vial 50 mL water for Inj & IV kit) 1's (Rp6,547,530/vial)
Actos tab 15 mg
2 7's (Rp94,080/boks)
Actos tab 30 mg
2 7's (Rp141,225/boks)
Adrome tab 10 mg
10 10's (Rp40,000/boks)
Advantan cream 10 g
1's (Rp77,050/tube)
Aerius film-coated tab 5 mg
30's (Rp180,090/pak)
Aerius syr 0.5 mg/mL
60 mL x 1's (Rp64,170/botol)
Aerius D-12 tab
10's (Rp60,500/boks)
Aeroson tab 40 mg
5 10's (Rp16,000/boks)
Aerrane inhalation vapour liqd 100 %
6 1's (Rp8,910,000/boks)
250 mL x 1's (Rp1,400,000/botol)
Aethylcarbonas Chinin (Euchinin) tab 100 mg
1000's (Rp151,388/pak)
Afamed cap 320 ng
10's (Rp180,000/blister)
Afinitor tab 10 mg
10's
3 10's (Rp57,986,335/boks)
Afinitor tab 5 mg
10's
3 10's (Rp43,489,750/boks)
Afomix FC caplet
3 10's (Rp136,620/boks)
Afrin Adult nasal drops 0.05 %
10 mL x 1's (Rp53,400/kontainer)
Afrin Paed nasal drops 0.025 %
10 mL x 1's (Rp50,500/kontainer)
Afrin Adult nasal spray 0.05 %
15 mL x 1's (Rp63,700/kontainer)
Afucid cream 2 %
5 g x 1's
Aggravan tab 50 mg
30's (Rp180,000/pak)
Aggrenox cap
30's (Rp263,780/pak)
Agrelano FC tab 75 mg
30's (Rp249,000/pak)
Agrezol tab 50 mg
5 10's (Rp235,000/boks)
Agrippal S1 vaccine 0.5 mL
1's (Rp121,000/pre-filled syringe)
Agrylin cap 0.5 mg
100's (Rp5,000,000/pak)
Albothyl ovule 90 mg
6's (Rp101,640/pak)
Albothyl topical soln conc 360 mg/g
5 mL x 1's (Rp17,600/botol)
10 mL x 1's (Rp26,950/botol)
30 mL x 1's (Rp66,000/botol)
100 mL x 1's (Rp236,500/botol)
Albothyl vag gel 50 g
1's (Rp74,580/tube)
Albucid eye drops 10 %
10 mL x 1's (Rp12,500/kontainer)
Albuman infusion soln 20%
50 mL x 1's (Rp799,000/vial)
100 mL x 1's (Rp1,598,000/vial)
Albuminar-25 infusion 25 %
50 mL x 1's (Rp750,000/vial)
100 mL x 1's (Rp1,500,000/vial)
Albumin-Human 20% infusion 200 g/L
50 mL x 1's (Rp350,000/kontainer)
100 mL x 1's (Rp690,000/kontainer)
Alburaas infusion 20 %
100 mL x 1's (Rp1,700,000/vial)
Albutein inj 20 %
50 mL x 1's
100 mL x 1's
Albutein inj 25 %
50 mL x 1's
100 mL x 1's
Alco oral drops 7.5 mg
15 mL x 1's (Rp36,850/botol)
Alco Plus DMP syr
100 mL x 1's (Rp25,300/botol)
Alco Plus syr
100 mL x 1's (Rp23,100/botol)
Alcon Cilox eye drops 3 mg/mL
5 mL x 1's (Rp52,000/kontainer)
Aldactone tab 100 mg
100's (Rp311,500/pak)
Aldactone tab 25 mg
100's (Rp96,300/pak)
Aldapres cap 2.5 mg
6 10's (Rp198,000/boks)
Aldazide tab
100's (Rp126,000/pak)
Aldiab tab 5 mg
2 20's (Rp35,530/boks)
Aldin tab 150 mg
30's (Rp94,017/pak)
Aldisa SR cap
5 10's (Rp185,500/boks)
Aldovas cap
5 6's (Rp96,000/boks)
Alegi tab
10 10's (Rp70,000/boks)
Alegysal eye drops 0.1 %
5 mL x 1's (Rp49,000/kontainer)
Alenoxal tab 10 mg
3 10's (Rp159,000/boks)
Alerdex tab
10 10's (Rp85,000/boks)
Alerfed syr
60 mL x 1's (Rp16,000/botol)
Alerfed tab
5 10's (Rp42,500/boks)
Alodan tab 100 mg
10 10's
Alodan tab 300 mg
10 10's
Alernitis tab 10 mg
10 10's (Rp365,000/boks)
Alista tab 50 mg
10 10's (Rp360,000/boks)
Alovell tab 10 mg
3 10's (Rp245,000/boks)
cap 100 mg
(Rp170,000/boks)
cap 300 mg
(Rp315,000/boks)
Amadiab caplet 1 mg
50's (Rp67,500/pak)
Amadiab caplet 2 mg
50's (Rp125,000/pak)
Amadiab caplet 3 mg
50's (Rp170,000/pak)
Amadiab caplet 4 mg
50's (Rp217,500/pak)
Amboid oint
5 g x 1's (Rp4,950/tube)
Aminofluid infusion
500 mL x 1's
1000 mL x 1's
Aminoleban Infusion
500 mL x 12 1's (Rp145,147/boks)
Aminoleban Oral powd for oral susp
50 g x 21 1's (Rp39,690/boks)
Aminophyllin Indo Farma tab 200 mg
100's (Rp8,030/pak)
1000's (Rp43,440/pak)
Aminoral FC caplet
10 10's (Rp550,000/boks)
Aminosteril infusion 10 %
500 mL x 10 1's (Rp95,000/botol)
Aminosteril infusion 5 %
500 mL x 10 1's (Rp75,000/botol)
Aminosteril Infant infusion 6 %
100 mL x 10 1's (Rp50,000/botol)
Aminosteril N-Hepa infusion 8 %
500 mL x 10 1's (Rp135,000/karton)
Aminovel 600 infusion
500 mL x 1's
Amiosin inj
4 mL x 5
Amiosin inj
2 mL x 5
Amiosin inj
2 mL x 5
(vial) 1 g/4 mL
1's
(vial) 250 mg/2 mL
1's
(vial) 500 mg/2 mL
1's
Amiparen infusion
500 mL x 12 1's
Amiten infusion
200 mL x 1's (Rp80,000/kontainer)
Amlocor tab 10 mg
3 10's (Rp150,000/boks)
Amlocor tab 5 mg
3 10's (Rp90,000/boks)
Amlogrix tab 10 mg
30's
Amlogrix tab 5 mg
30's
Amnorel 600 infusion
(glass bottle) 500 mL x 1's (Rp50,000/botol)
Analtram FC caplet
3 10's (Rp180,000/boks)
Anaprin syr
60 mL x 1's (Rp4,125/botol)
Anatensol tab 2.5 mg
100's (Rp266,090/pak)
Anatensol tab 5 mg
100's (Rp371,140/pak)
Anavit oral drops
15 mL x 1's (Rp10,958/botol)
Anbacim FC caplet 500 mg
5 4's (Rp336,200/boks)
Anbacim powd for inj 1 g
(vial) 1's (Rp61,245/vial)
Androcur tab 50 mg
20's (Rp379,575/pak)
Androlon tab 25 mg
3 10's (Rp180,000/boks)
Anelat caplet 1000 mcg
10 10's
Anemolat tab 1 mg
10 10's (Rp14,545/boks)
Anerocid cap 300 mg
30's (Rp160,000/pak)
Anexia tab 10 mg
30's (Rp300,000/boks)
Anexia tab 2.5 mg
30's (Rp117,000/boks)
Anexia tab 5 mg
30's (Rp172,500/boks)
Anore tab
3 10's (Rp60,000/boks)
Anpiride
5 10's
Anpiride
5 10's
Anpiride
5 10's
Anpiride
5 10's
tab 1 mg
(Rp92,250/boks)
tab 2 mg
(Rp174,250/boks)
tab 3 mg
(Rp230,750/boks)
tab 4 mg
(Rp282,000/boks)
Ansi cap 20 mg
5 10's (Rp231,000/boks)
Anstrep syr
60 mL x 1's (Rp7,700/botol)
Antalgin Berlico caplet 500 mg
100's (Rp29,500/pak)
1000's (Rp81,690/pak)
Antalgin Corsa tab 500 mg
1000's
50 10's
Antalgin Indo Farma captab 500 mg
100's (Rp10,008/pak)
1000's (Rp63,514/pak)
Antasida Plus Famotidine chewable tab
5 6's (Rp30,000/boks)
Anthramed cream 0.02 %
20 g x 1's (Rp20,900/tube)
Anti Stries cream
150 mL x 1's (Rp385,000/kontainer)
Antidine tab 20 mg
30's (Rp71,500/pak)
Antidine tab 40 mg
30's (Rp93,500/pak)
Antikun cap 1200 mg
10 6's
Antikun amp 1 g/5 mL
5's
Antikun amp 3 g/15 mL
4's
Antikun syr 5 mg/5 mL
100 mL x 1's
Anti-Maag tab
10 10's (Rp30,800/boks)
Antion cap
10 10's (Rp123,000/boks)
Antiplat tab 50 mg
30's (Rp150,000/pak)
Antiza drag
10 10's (Rp90,000/boks)
Antiza syr
60 mL x 1's (Rp14,500/botol)
Antox cap
6 10's (Rp203,500/boks)
Antrain inj 1 g/2 mL
5 1's (Rp46,200/boks)
Antrain tab 500 mg
10 10's (Rp90,200/boks)
Antrexol cap
10 10's (Rp75,300/boks)
Antrotik caplet 250 mg
30's (Rp180,000/pak)
Anuva 50 mg dispersible tab
50's
Apisate tab
30's
Apolar cream 0.5 mg/g
10 g x 1's (Rp28,000/tube)
Apolar-N cream
10 g x 1's (Rp32,000/tube)
Aprion cap 150 mg
10's
Aprion cap 300 mg
10's
Aprion cap 75 mg
10's
Ardivit-PL caplet
3 10's (Rp48,000/boks)
Argensol cream
5 g x 1's (Rp32,000/tube)
Argomed FC tab 20 mg
5 6's
Aricept tab 5 mg Aricept tab 5 mg
2 14's (Rp481,423/blister)
30's (Rp982,500/botol)
Aricept Evess orodispersible tab 10 mg Aricept Evess orodispersible tab 10
mg
2 14's (Rp577,707/boks)
Arimed tab 15 mg
2 10's (Rp120,000/boks)
Arimidex FC tab 1 mg
2 14's (Rp1,922,126/film-coated tab)
Ariski tab 10 mg
10's (Rp289,000/strip)
Ariski tab 15 mg
10's (Rp335,000/strip)
Arkine caplet 2 mg
10 10's (Rp55,000/boks)
250's (Rp125,000/pak)
Armacort cream
5 g x 1's (Rp5,830/tube)
10 g x 1's
Armolev 500 film-coated tab 500 mg
10's (Rp173,000/pak)
Armovit cap
6 5's (Rp33,500/boks)
Ascorbec syr
100 mL x 1's (Rp14,300/botol)
Asedas syr
60 mL x 1's (Rp28,000/botol)
Asmadex tab
25 4's (Rp17,000/boks)
Asmano tab
20 10's (Rp52,800/boks)
Asmasolon tab
25 4's (Rp28,754/boks)
Astina cap 4 mg
3 6's (Rp103,950/boks)
Astria softcap 4 mg
2 10's (Rp90,000/boks)
Asvex tab 33.21 mg
100's (Rp76,500/pak)
Atarax film-coated tab 0.5 mg
10 10's (Rp130,000/boks)
Atopiclair cream
10 mL x 1's (Rp75,000/tube)
Atorsan film-coated tab 10 mg
3 10's (Rp330,000/boks)
Atorsan film-coated tab 20 mg
3 10's (Rp330,000/boks)
Atorsan film-coated tab 40 mg
3 10's (Rp330,000/boks)
Atorvastatin Yarindo film-coated tab 20 mg
3 10's (Rp120,000/boks)
Atorwin FC tab 10 mg
3 10's (Rp234,000/boks)
Atorwin FC tab 20 mg
3 10's (Rp270,000/boks)
Avogin FC caplet
5 6's (Rp66,000/boks)
Axamed liqd-filled cap 4 mg
(blister) 3 10's (Rp165,000/boks)
Axamed Plus cap
5 6's (Rp210,000/boks)
Axanthin cap 4 mg
3 6's (Rp100,000/boks)
Axtan cap 4 mg
3 10's (Rp257,400/boks)
Axtan Syr syr 2 mg/5 mL
60 mL x 1's (Rp55,000/botol)
Aza 20 cream 200 mg
10 g x 1's (Rp25,000/tube)
Azathioprine Combiphar/Pharmachemie tab 50 mg
20's (Rp135,000/pak)
Azmacon tab 2 mg
10 10's (Rp67,000/boks)
Azmacon tab 4 mg
10 10's (Rp92,000/boks)
Azol cap 200 mg
30's (Rp385,000/pak)
Bactigras dressing
(10 cm x 10 cm) 10's
(15 cm x 20 cm) 10 cm x 10's
Bactiprox film-coated tab 500 mg
2 10's (Rp193,600/boks)
Bd-GARD cap
30's (Rp230,000/pak)
Becombion Injection
2 mL x 6 1's (Rp24,310/boks)
Becombion Plus Syrup (Multivitamin + Omega 3/DHA)
100 mL x 1's (Rp24,703/botol)
Becombion Syrup Extra Lysine
(Tutti fruitty Flavor) 100 mL x 1's (Rp24,703/botol)
Becombion Forte sugar-coated tab
100's (Rp67,257/blister)
Becombion oral drops
15 mL x 1's (Rp22,628/botol)
Becombion syr
110 mL x 1's (Rp22,628/botol)
Becom-C FC caplet
10 10's (Rp105,000/boks)
Becom-Zet FC caplet
10 10's (Rp140,500/boks)
Beconase nasal spray 50 mcg/dose
200 spray x 1's (Rp84,700/kontainer)
Befozi cap
3 10's (Rp15,000/boks)
Bekamin C Forte tab 250 mg
250's (Rp20,020/pak)
Bekarbon tab 250 mg
750's (Rp14,300/pak)
Bellacid caplet 500 mg
100's (Rp98,000/pak)
Bellamox caplet
15's (Rp142,500/pak)
Bellamox Forte syr
60 mL x 1's (Rp70,000/botol)
Bellamox syr
60 mL x 1's (Rp48,000/botol)
Bellapheen drag
500's (Rp650,000/pak)
Bellatram cap 50 mg
2 10's (Rp19,500/boks)
Bellatram amp 100 mg/2mL
5 1's (Rp22,000/boks)
Bellatram amp 50 mg/mL
5 1's (Rp16,700/boks)
Benolicrol tab
100's (Rp27,500/pak)
Benomet 300 tab 300 mg
100's (Rp88,000/pak)
Benoson tab 500 mcg
100's (Rp115,500/pak)
Benoson G cream
10 g x 1's (Rp38,500/tube)
Benoson M cream
5 g x 1's (Rp33,000/tube)
Benostan tab 500 mg
10 10's (Rp110,000/boks)
Benoviplex drag
10 10's (Rp83,600/boks)
Benovit C drag
10 10's (Rp110,000/boks)
Benovit M drag
10 10's (Rp192,500/boks)
Bepanthen oint 5 %
20 g x 1's (Rp60,261/tube)
Beprosalic oint
15 g x 1's
Beprosone cream
15 g x 1's
Beprosone oint
15 g x 1's
Beprosone topical soln
5 g x 1's
Berea syr 15 mg/5 mL
60 mL x 1's
Berea tab 30 mg
10 10's
Beriplast P Combi-Set topical application
1 mL x 1's (Rp2,255,000/vial)
Berlicort cream 25 mg
5 g x 1's (Rp7,950/tube)
Berlifed syr
60 mL x 1's (Rp7,950/botol)
Berlison FC caplet 200 mg
100's (Rp39,950/pak)
1000's (Rp185,000/pak)
Berlosid caplet
10 10's (Rp27,100/boks)
Berlosid oral susp
60 mL x 1's (Rp7,800/botol)
Berloson-N cream
5 g x 1's (Rp8,050/tube)
Bernesten cream 1 %
5 g x 1's (Rp6,450/tube)
Berno Yeast drag
10 10's (Rp22,000/boks)
Bernoflox captab 500 mg
5 4's (Rp209,000/boks)
Bernoflox infusion 200 mg/100 mL
1's (Rp165,000/botol)
Berodual inhaler
10 mL x 1's (Rp152,130/canister)
Betalitik tab 30 mg
5 10's
Betam-Ophtal eye drops 0.1 %
5 mL x 1's (Rp47,255/kontainer)
Beta-One tab 2.5 mg
5 10's (Rp80,000/boks)
Beta-One tab 5 mg
3 10's (Rp96,000/boks)
Betarhin oral drops 10 mg/mL
30 mL x 1's (Rp36,000/botol)
Betarhin syr 5 mg/5 mL
60 mL x 1's (Rp33,000/botol)
Betarhin tab 10 mg
20's (Rp60,000/pak)
Betaserc tab 24 mg
20's (Rp107,000/pak)
Betaserc tab 8 mg
100's (Rp130,650/pak)
Betasin cream
1's (Rp18,000/tube)
Betaslim FC caplet
30's (Rp60,000/pak)
Betason tab 0.5 mg
10 10's (Rp5,500/boks)
Betason-N cream
5 g x 1's (Rp7,040/tube)
Betaver tab 6 mg
10 10's (Rp200,000/boks)
Betiga powd
12 1's (Rp32,500/boks)
Betnovate-N cream
10 g x 1's (Rp35,695/tube)
Betodermin cream 0.1 %
10 g x 1's (Rp11,500/tube)
Betopic cream 0.1 %
10 g x 1's (Rp20,000/tube)
Betoptima eye drops 0.5 %
5 mL x 1's (Rp50,000/kontainer)
Betrion sugar-coated tab
10 10's (Rp85,000/boks)
Betrix powd for inj 1 g
1's (Rp155,000/vial)
Bevalex cream
5 g x 1's (Rp7,000/tube)
Bevita syr
120 mL x 1's (Rp23,500/botol)
Bevitran syr
60 mL x 1's (Rp7,700/botol)
Bevizil FC caplet
25 4's (Rp119,000/boks)
Bexce caplet
10 10's (Rp80,000/boks)
Bexce Plus oral drops
15 mL x 1's (Rp15,600/botol)
Bexce syr
120 mL x 1's (Rp15,600/botol)
Bexicom FC caplet
10 10's (Rp122,715/boks)
Bexicom-Z FC caplet
10 10's (Rp247,500/boks)
Bexicom Fit FC caplet
10 10's (Rp168,300/boks)
Bicolax tab 5 mg
18's (Rp11,000/pak)
Bilotec caplet
5 6's (Rp120,000/boks)
Binapro softcap
6 10's (Rp420,000/boks)
Biocream cream
1's (Rp18,040/tube)
BioCurkem FC caplet 900 mg
3 10's (Rp300,000/boks)
BioCurlam FC caplet
2 10's (Rp110,000/boks)
BioCurliv caplet
5 6's (Rp180,000/boks)
Biodasin cap 300 mg
5 10's (Rp285,000/boks)
Biomoist cream
30 g x 1's (Rp62,000/tube)
500 g x 1's (Rp800,000/tube)
Bion 3 tab
30's (Rp87,120/pak)
Bionam cream
15 g x 1's (Rp25,000/tube)
bion-C topical serum
15 mL x 1's
Bionect cream 0.2%
15 mg x 1's
Bionect gauze pad
(10 cm x 10 cm) 10's
Bionemi cap
5 10's (Rp42,500/boks)
Bioneuron drag
100's (Rp89,334/pak)
Bioneuron inj
3 mL x 5 1's (Rp19,734/boks)
Bionutrion syr
60 mL x 1's (Rp12,000/botol)
Bion-W topical soln
15 mL x 1's
Bioplacenton jelly
15 g x 1's (Rp10,900/tube)
Bioplacenton Tulle gauze
10 1's (Rp141,750/boks)
Bioplan gel
15 g x 1's
Bioprexum FC tab 10 mg
30's (Rp385,000/pak)
Bioprexum FC tab 5 mg
30's (Rp280,000/pak)
Bio-Prolis cap 50 mg
30's (Rp277,200/blister)
Bioprom powd for inj 1 g
1's (Rp195,000/vial)
Bioquin cream 2%
48 1's (Rp15,500/boks)
Bioquin Forte cream 4%
48 1's (Rp29,000/boks)
Bioquinone softcap
5 10's (Rp675,000/boks)
Biorazon powd for inj 1 g
1's (Rp105,000/vial)
Bio-Retin cap
30's
6 5's
Biosan tab 275 mg
3 6's (Rp160,200/boks)
Biosanbe cap
10 10's (Rp78,500/boks)
Biosat 1.5 (Serum Anti Tetanus 1,500 IU) inj
1 mL x 10 1's (Rp158,125/ampul)
Bisovell FC tab 5 mg
3 10's (Rp135,000/boks)
Bital oint
40 g x 1's (Rp28,600/tube)
Blecidex ear drops
5 mL x 1's (Rp36,110/kontainer)
Blecidex eye drops
5 mL x 1's (Rp36,110/kontainer)
Bledstop inj 200 mcg/mL
(amp) 1 mL x 10 1's (Rp63,300/boks)
Bledstop sugar-coated tab 125 mcg
10 10's (Rp41,500/boks)
Blenamax powd for inj 15 u
1's (Rp320,000/vial)
Bleocin inj 15 mg
1's (Rp420,000/ampul)
Blephagel eye gel
40 g x 1's (Rp80,000/tube)
Blesifen tab 50 mg
2 10's (Rp216,300/boks)
BloodCare softcap
10's
30's
Blopress tab 16 mg
14's (Rp199,760/pak)
Blopress tab 8 mg
14's (Rp151,780/pak)
Blopress Plus tab
14's (Rp190,250/pak)
Bondronat infusion 6 mL
1's (Rp2,770,083/vial)
Bravoderm-N cream
5 g x 1's
Braxidin FC tab
10 10's (Rp77,000/boks)
Brazine caplet 25 mg
10 10's (Rp140,000/boks)
Brilinta FC tab 90 mg
4 14's
Bromifar caplet 8 mg
10 10's (Rp21,542/boks)
Bromifar Plus syr
60 mL x 1's
Bromifar Plus tab
100's
Bromika elixir 4 mg/5 mL
60 mL x 24 1's (Rp11,400/karton)
120 mL x 24 1's
Brommer 30 tab 30 mg
10 10's (Rp55,000/boks)
Bronchitin oral susp
50 mL x 1's (Rp8,138/botol)
Broncholit syr 250 mg/5 mL
60 mL x 1's (Rp15,000/botol)
Bronchophylin elixir 130 mg/15 mL
100 mL x 1's (Rp16,500/botol)
Bronchophylin softcap 130 mg
50's (Rp71,500/pak)
Bronchopront syr 15 mg/5 mL
100 mL x 1's (Rp31,000/botol)
Bronchosal caplet 4 mg
10 10's (Rp29,357/boks)
Broncho-Vaxom Adult cap 7 mg
10's
30's
Broncho-Vaxom Childn cap 3.5 mg
10's
30's
Broncozol syr 30 mg/5 mL
60 mL x 1's (Rp11,500/botol)
Broncozol tab 30 mg
50's (Rp32,500/pak)
Brondisal 2 tab 2 mg
10 10's (Rp18,000/boks)
Brondisal 4 tab 4 mg
10 10's (Rp22,000/boks)
Bronkris elixir 4 mg/5 mL
60 mL x 1's (Rp13,606/botol)
Bronkris tab 8 mg
10 10's (Rp7,102/boks)
Bronsolvan syr 150 mg/15 mL
100 mL x 1's (Rp11,000/botol)
Bronsolvan tab 150 mg
10 10's (Rp30,000/boks)
Brospec inj 1000 mg
1's (Rp125,000/vial)
Brospec 1000 inj 1 g
1's (Rp125,000/vial)
Broxal elixir 15 mg/5 mL
60 mL x 1's (Rp16,500/botol)
Broxal elixir 30 mg/5 mL
60 mL x 1's (Rp23,100/botol)
Broxal tab 30 mg
10 10's (Rp88,000/boks)
Brufen syr 100 mg/5 mL
60 mL x 1's (Rp25,000/botol)
Brufen Forte tab 600 mg
10 10's (Rp300,000/blister)
Brufen tab 200 mg
25 4's (Rp55,000/boks)
Bucain inj 5 mg/mL
4 mL x 5 1's (Rp275,000/boks)
Budenofalk cap 3 mg
50's (Rp1,045,000/pak)
Bycolen syr
60 mL x 1's (Rp16,800/botol)
100 mL x 1's (Rp12,000/botol)
Cado effervescent tab
10's (Rp20,000/pak)
Caduet 10 mg/10 mg film-coated tab
30's (Rp437,510/boks)
Caduet 10 mg/20 mg film-coated tab
30's (Rp437,510/boks)
Caduet 5 mg/10 mg film-coated tab
30's (Rp437,510/boks)
Caduet 5 mg/20 mg film-coated tab
30's (Rp437,510/boks)
Cafergot tab
10 10's (Rp666,314/boks)
Cal-95 FC caplet
30's (Rp75,000/pak)
Calcianta tab 10 mg
10 10's (Rp88,000/boks)
Calcianta tab 5 mg
10 10's (Rp54,000/boks)
CalciD tab
30's (Rp30,000/pak)
Calcidin film-coated tab
10 10's (Rp55,000/boks)
Calcidin syr
60 mL x 1's (Rp16,000/botol)
Calcidol syr
60 mL x 1's (Rp7,128/botol)
120 mL x 1's (Rp12,463/botol)
Calcifar Plus caplet
10 10's
Calciflavone tab
6's (Rp95,000/strip)
Calcimega cap
10 10's (Rp71,100/boks)
Calmin-AF drag
30's (Rp25,000/pak)
Calos caplet
60's (Rp48,000/pak)
Calosbon tab
30's (Rp54,000/pak)
Calplex caplet
30's (Rp87,000/pak)
Calporosis D 500 caplet
30's (Rp25,000/pak)
Calporosis D 800 caplet
30's (Rp45,000/pak)
Caltron caplet
50's (Rp115,000/pak)
Caltum inj 1 g
1's (Rp155,000/vial)
Campain cap 10 mg
5 10's (Rp18,000/boks)
Campain cap 20 mg
5 10's (Rp24,000/boks)
Campto infusion 100 mg/5 mL
1's (Rp2,779,635/vial)
Campto infusion 40 mg/2 mL
1's (Rp1,270,910/vial)
Candacort cream
5 g x 1's
Canderin tab 16 mg
3 10's
Canderin tab 8 mg
3 10's
Candesartan TI tab 16 mg
28's
Candesartan TI tab 8 mg
28's
Candipar cap 150 mg
10's (Rp330,000/pak)
Candipar cap 50 mg
10's (Rp115,000/pak)
Candistin oral drops 100000 u/mL
12 mL x 1's (Rp32,450/botol)
candyvit-C tab 50 mg
50's (Rp2,682/pak)
Canergy FC tab
15's
Canesten SD vag tab 500 mg
1's (Rp54,375/pak)
Canesten VT vag tab 100 mg
6's (Rp54,375/pak)
Canesten cream 1 %
3 g x 1's (Rp9,700/tube)
5 g x 1's (Rp12,105/tube)
10 g x 1's (Rp28,100/tube)
Canesten Powder topical powd (lyo) 1 %
20 g x 1's (Rp21,670/botol)
Canicol cap 500 mg
10 10's (Rp291,500/boks)
Caprazol cap 30 mg
2 10's (Rp198,800/boks)
Caprifim inj 1 g
1's (Rp237,440/vial)
Capritazin FC caplet 10 mg
3 10's (Rp69,000/boks)
Caprocef inj 1 g
1's (Rp215,375/vial)
Caproliv FC caplet
6 10's (Rp252,000/boks)
Cardiavit cap
4 10's (Rp30,000/boks)
Cardicap tab 10 mg
5 10's (Rp425,000/boks)
Cardicap tab 5 mg
5 10's (Rp243,000/boks)
Cardiject infusion 25 mg/mL
(vial) 10 mL x 1's (Rp90,000/vial)
Cardiomin softcap
5 4's (Rp42,000/boks)
Cardioplegia inj
20 mL x 5 1's (Rp117,000/boks)
Cardiotone soln for inj 250 mg/5 mL
(amp) 5 mL x 1's (Rp110,000/boks)
Cardiover tab 80 mg
10 10's (Rp35,182/boks)
Cardisan tab 10 mg
5 10's (Rp420,250/boks)
Cardisan tab 5 mg
5 10's (Rp236,500/boks)
Cardismo tab 20 mg
10 10's (Rp246,675/boks)
Cardivask tab 10 mg
3 10's (Rp235,000/boks)
Cardivask tab 5 mg
3 10's (Rp135,000/boks)
Cardura tab 1 mg
50's (Rp336,135/pak)
Cardura tab 2 mg
50's (Rp575,285/pak)
Cardyne caplet 30 mg
100's (Rp71,500/pak)
Carmed cream 10 %
40 g x 1's (Rp19,750/tube)
Carmed cream 20 %
40 g x 1's (Rp25,400/tube)
Carni Plus cap
60's (Rp137,500/pak)
Carniq FC caplet
3 10's (Rp112,800/boks)
Carniten softcap
30's (Rp135,000/boks)
Carnon FC caplet
3 10's (Rp180,000/boks)
Caronem powd for inj 1 g
(vial) 1's (Rp350,000/vial)
Car-Q FC caplet
3 10's (Rp154,000/boks)
Car-Q100 FC caplet
1's
Cartiflex caplet
20's (Rp99,750/pak)
Cartin cap
5 6's (Rp62,700/boks)
Cartin Plus cap
5 6's (Rp72,000/boks)
Cartogen cap
3 10's (Rp195,000/boks)
Caspol tab
100's
Cataflam D dispertab 50 mg
5 10's (Rp173,525/boks)
Cataflam sugar-coated tab 25 mg
5 10's (Rp93,265/boks)
Cataflam sugar-coated tab 50 mg
5 10's (Rp177,995/boks)
Cavida caplet
6 10's (Rp120,000/boks)
Cavit D3 tab
100's (Rp134,200/pak)
Cavital syr
60 mL x 1's (Rp13,000/botol)
100 mL x 1's (Rp20,240/botol)
Cazetin oral susp 100000 IU
15 mL x 1's (Rp33,264/botol)
Cebex FC caplet
10's (Rp110,000/pak)
Cebion oral drops 100 mg/mL
15 mL x 1's (Rp8,635/botol)
Cebion tab
100's (Rp18,150/pak)
Cedantron inj 4 mg/2 mL
5 1's (Rp105,000/boks)
Cedantron inj 8 mg/4 mL
5 1's (Rp160,000/boks)
Cedantron Syrup 4 mg/5 mL
50 mL x 1's (Rp60,000/botol)
Cedantron tab 8 mg
(amp) 10's (Rp165,000/pak)
Cefobet inj 1 g
2's
Cefobid inj 1 g
1's (Rp288,625/vial)
Cefoject powd for inj
1 g x 1's (Rp150,000/vial)
Cefradol inj 1 g
1's (Rp90,000/vial)
Cefratam inj
1 g x 1's
Cefriex inj 1 g
1's (Rp150,000/vial)
Cefrin inj 1 g
1's (Rp225,000/vial)
Off-Market
Captured Time
10/17/2014 8:40
5/10/2015 16:37
10/17/2014 9:30
10/17/2014 9:32
10/17/2014 9:35
10/17/2014 9:37
10/17/2014 9:45
10/17/2014 9:47
10/17/2014 9:49
10/17/2014 9:53
10/17/2014 9:55
10/17/2014 9:58
10/17/2014 10:00
10/17/2014 10:04
10/17/2014 10:08
10/17/2014 10:10
10/17/2014 10:14
10/17/2014 10:22
10/17/2014 10:33
10/17/2014 11:18
10/17/2014 11:20
10/17/2014 11:22
10/17/2014 11:24
10/17/2014 11:28
10/17/2014 11:37
10/17/2014 11:41
10/17/2014 11:44
10/17/2014 11:46
10/17/2014 11:51
10/17/2014 11:54
10/17/2014 11:58
10/17/2014 12:00
10/17/2014 12:02
10/17/2014 12:09
10/17/2014 17:36
10/17/2014 17:38
10/17/2014 19:12
10/17/2014 19:14
10/17/2014 19:17
10/17/2014 19:20
10/17/2014 19:45
10/17/2014 19:51
10/17/2014 19:59
10/17/2014 20:03
10/17/2014 20:09
10/17/2014 21:22
10/17/2014 21:25
10/17/2014 21:27
10/17/2014 21:30
10/17/2014 21:32
10/17/2014 21:35
10/17/2014 21:58
10/17/2014 22:00
10/17/2014 22:03
10/17/2014 22:05
10/17/2014 23:32
10/17/2014 23:34
10/17/2014 23:42
10/17/2014 23:51
10/17/2014 23:57
10/18/2014 0:33
10/18/2014 0:54
10/18/2014 1:02
10/18/2014 1:12
10/18/2014 1:16
10/18/2014 1:25
10/18/2014 1:29
10/18/2014 1:38
10/18/2014 1:46
10/18/2014 1:57
10/18/2014 2:07
10/18/2014 2:11
10/18/2014 2:19
10/18/2014 2:26
10/18/2014 2:31
10/18/2014 2:36
4/13/2015 6:24
10/18/2014 6:39
10/18/2014 6:41
10/18/2014 6:48
10/18/2014 8:03
10/18/2014 8:11
10/18/2014 8:24
10/18/2014 8:29
10/18/2014 8:32
10/18/2014 8:36
10/18/2014 9:08
10/18/2014 9:22
10/18/2014 9:37
10/18/2014 9:44
10/18/2014 9:55
10/18/2014 12:01
10/18/2014 13:48
10/18/2014 13:50
10/18/2014 13:53
10/18/2014 13:55
10/18/2014 13:58
10/18/2014 14:00
10/18/2014 14:02
10/18/2014 14:06
10/18/2014 14:08
10/18/2014 14:11
10/18/2014 14:14
10/18/2014 14:16
10/18/2014 14:18
10/18/2014 15:14
10/18/2014 15:18
10/18/2014 15:35
10/18/2014 15:47
10/18/2014 15:53
10/18/2014 16:16
10/18/2014 16:26
10/18/2014 16:32
10/18/2014 16:43
5/18/2015 6:54
10/18/2014 16:57
10/18/2014 17:05
10/18/2014 17:25
10/18/2014 17:35
10/18/2014 17:43
10/18/2014 18:05
10/18/2014 18:14
10/18/2014 18:30
10/18/2014 18:33
10/18/2014 18:51
10/18/2014 19:03
5/18/2015 6:43
5/18/2015 6:46
5/18/2015 6:57
10/18/2014 19:48
10/18/2014 20:01
10/18/2014 20:12
X
10/18/2014 20:29
10/18/2014 20:36
10/18/2014 20:45
5/22/2015 0:35
10/18/2014 21:45
10/18/2014 22:21
10/18/2014 22:24
10/18/2014 22:26
10/18/2014 22:28
10/18/2014 22:30
10/18/2014 22:32
10/18/2014 22:35
X
10/18/2014 22:37
10/18/2014 22:39
10/18/2014 22:40
10/18/2014 22:44
10/18/2014 22:47
10/18/2014 22:49
10/18/2014 22:51
10/18/2014 22:53
10/18/2014 22:56
10/18/2014 22:59
10/18/2014 23:02
10/18/2014 23:05
10/18/2014 23:07
10/18/2014 23:10
10/18/2014 23:13
10/19/2014 3:03
10/19/2014 3:07
10/19/2014 3:10
10/19/2014 3:13
10/19/2014 3:15
10/19/2014 3:17
10/19/2014 3:20
10/19/2014 3:24
10/19/2014 3:27
10/19/2014 3:31
10/19/2014 3:34
10/19/2014 3:37
10/19/2014 3:38
10/19/2014 3:39
10/19/2014 3:40
10/19/2014 3:42
10/19/2014 3:53
10/19/2014 3:58
10/19/2014 4:00
10/19/2014 4:03
10/19/2014 4:06
10/19/2014 4:08
10/19/2014 4:10
10/19/2014 4:14
10/19/2014 4:17
10/19/2014 4:19
10/19/2014 4:23
10/19/2014 4:25
10/19/2014 4:29
10/19/2014 4:33
10/19/2014 4:35
10/19/2014 4:38
10/19/2014 4:42
10/19/2014 4:46
10/19/2014 4:50
10/19/2014 4:52
10/19/2014 4:56
10/19/2014 5:00
10/19/2014 5:04
10/19/2014 5:07
10/19/2014 5:10
10/19/2014 5:13
10/19/2014 5:15
10/19/2014 5:20
10/19/2014 5:59
10/19/2014 6:01
10/19/2014 6:05
10/19/2014 6:07
10/19/2014 6:09
10/19/2014 6:11
10/19/2014 6:34
10/19/2014 6:37
10/19/2014 6:39
10/19/2014 6:42
10/19/2014 6:46
10/19/2014 6:48
10/19/2014 6:50
10/19/2014 6:52
10/19/2014 6:55
10/19/2014 6:59
10/19/2014 7:03
10/19/2014 7:05
10/19/2014 7:07
10/19/2014 7:09
10/19/2014 7:12
10/19/2014 7:13
10/19/2014 7:15
10/19/2014 7:18
10/19/2014 7:22
10/19/2014 7:24
10/19/2014 7:26
10/19/2014 7:28
10/19/2014 7:30
10/19/2014 7:32
10/19/2014 7:34
10/19/2014 7:38
10/19/2014 7:41
10/19/2014 7:44
10/19/2014 7:46
10/19/2014 7:51
10/19/2014 7:52
10/19/2014 8:07
10/19/2014 8:11
10/19/2014 8:13
10/19/2014 8:15
10/19/2014 8:18
10/19/2014 8:20
10/19/2014 8:23
10/19/2014 8:26
10/19/2014 8:29
10/19/2014 8:31
10/19/2014 8:33
10/19/2014 8:36
10/19/2014 8:40
10/19/2014 8:44
10/19/2014 8:47
10/19/2014 8:50
10/19/2014 8:53
10/19/2014 8:57
10/19/2014 9:00
10/19/2014 9:02
10/19/2014 9:06
10/19/2014 9:08
10/19/2014 9:49
10/19/2014 10:46
10/19/2014 9:51
10/19/2014 9:53
X
10/19/2014 9:56
10/19/2014 9:58
10/19/2014 10:03
10/19/2014 10:05
10/19/2014 10:08
10/19/2014 10:11
10/19/2014 10:15
10/19/2014 10:19
10/19/2014 10:23
10/19/2014 10:25
10/19/2014 10:27
10/19/2014 10:30
10/19/2014 10:32
10/19/2014 10:36
10/19/2014 10:49
10/19/2014 10:52
10/19/2014 10:55
10/19/2014 11:49
10/19/2014 11:52
10/19/2014 11:56
10/19/2014 11:58
10/19/2014 12:00
10/19/2014 14:04
10/19/2014 14:06
10/19/2014 14:12
10/19/2014 14:14
10/19/2014 14:17
10/19/2014 14:19
10/19/2014 14:22
10/19/2014 14:28
10/19/2014 14:30
10/19/2014 14:31
10/19/2014 14:35
10/19/2014 14:37
10/19/2014 14:41
10/19/2014 14:43
10/19/2014 14:46
10/19/2014 14:54
10/19/2014 14:56
10/19/2014 14:58
10/19/2014 15:02
10/19/2014 15:04
10/19/2014 15:07
10/19/2014 15:34
4/13/2015 6:24
10/19/2014 21:03
10/19/2014 21:06
10/19/2014 21:16
10/19/2014 21:20
10/19/2014 21:22
10/19/2014 21:25
10/19/2014 21:28
10/19/2014 21:29
10/19/2014 21:39
4/13/2015 6:24
10/19/2014 16:11
10/19/2014 16:14
10/19/2014 16:17
10/19/2014 16:18
10/19/2014 16:24
10/19/2014 16:26
10/19/2014 16:29
10/19/2014 16:31
10/19/2014 16:33
10/19/2014 16:37
10/19/2014 16:40
10/19/2014 16:43
10/19/2014 16:45
10/19/2014 16:48
10/19/2014 16:56
10/19/2014 17:01
10/19/2014 17:07
10/19/2014 17:18
10/19/2014 17:27
10/19/2014 17:32
10/19/2014 17:42
10/19/2014 18:02
10/19/2014 18:31
10/19/2014 18:57
10/19/2014 18:59
10/19/2014 19:07
10/19/2014 19:10
10/19/2014 19:15
10/19/2014 19:18
10/19/2014 19:20
10/19/2014 19:22
10/19/2014 19:24
10/19/2014 19:26
10/19/2014 19:37
10/19/2014 19:41
10/19/2014 20:00
10/19/2014 20:07
10/19/2014 20:10
10/19/2014 20:14
10/19/2014 20:18
10/19/2014 20:20
10/19/2014 20:31
10/19/2014 20:34
10/19/2014 20:42
10/19/2014 20:45
10/19/2014 21:56
10/19/2014 22:04
10/19/2014 22:30
10/19/2014 22:38
10/19/2014 22:40
X
10/19/2014 22:42
10/19/2014 22:44
10/19/2014 22:48
10/19/2014 22:52
10/19/2014 22:54
10/19/2014 22:57
10/19/2014 22:59
10/19/2014 23:09
10/19/2014 23:11
10/19/2014 23:21
10/19/2014 23:23
10/19/2014 23:36
X
10/19/2014 23:47
10/19/2014 23:52
10/20/2014 0:04
10/20/2014 0:16
10/20/2014 0:19
10/20/2014 5:41
10/20/2014 5:44
10/20/2014 5:47
10/20/2014 5:51
10/20/2014 5:57
10/20/2014 6:04
10/20/2014 6:08
10/20/2014 6:14
10/20/2014 6:20
10/20/2014 6:31
10/20/2014 6:37
10/20/2014 6:45
4/13/2015 6:24
10/20/2014 11:37
10/20/2014 11:39
10/20/2014 11:41
10/20/2014 11:44
10/20/2014 11:47
10/20/2014 11:49
10/20/2014 11:51
10/20/2014 11:55
10/20/2014 11:58
10/20/2014 12:10
X
10/20/2014 12:13
10/20/2014 12:17
10/20/2014 12:20
10/20/2014 12:24
10/20/2014 12:33
10/20/2014 12:35
10/20/2014 12:39
10/20/2014 12:41
10/20/2014 12:45
X
10/20/2014 12:47
10/20/2014 12:50
10/20/2014 12:54
10/20/2014 12:56
10/20/2014 12:59
10/20/2014 13:01
10/20/2014 13:04
10/20/2014 13:06
10/20/2014 13:10
10/20/2014 13:13
10/20/2014 13:16
10/20/2014 13:19
10/20/2014 13:22
10/20/2014 13:24
10/20/2014 13:27
10/20/2014 13:30
10/20/2014 13:33
10/20/2014 13:35
10/20/2014 13:38
10/20/2014 13:41
10/20/2014 13:47
10/20/2014 13:50
10/20/2014 13:53
10/20/2014 13:56
10/20/2014 13:59
10/20/2014 14:03
10/20/2014 14:10
10/20/2014 14:15
10/20/2014 14:18
10/20/2014 14:22
10/20/2014 14:24
10/20/2014 14:28
10/20/2014 14:30
10/20/2014 14:34
10/20/2014 14:37
10/20/2014 14:39
10/20/2014 14:43
10/20/2014 14:46
10/20/2014 14:51
10/20/2014 14:53
10/20/2014 14:56
10/20/2014 20:31
10/20/2014 20:34
10/20/2014 20:36
10/20/2014 20:41
10/20/2014 20:55
10/20/2014 21:23
10/20/2014 21:27
10/20/2014 21:30
X
10/20/2014 21:32
10/20/2014 21:35
10/20/2014 21:37
10/20/2014 21:40
10/20/2014 22:28
10/20/2014 22:40
10/20/2014 22:45
10/20/2014 22:48
10/20/2014 22:52
10/20/2014 22:55
10/20/2014 22:58
10/21/2014 0:18
10/21/2014 0:21
10/21/2014 0:31
10/21/2014 0:34
10/21/2014 0:38
10/21/2014 0:40
10/21/2014 0:43
10/21/2014 0:46
10/21/2014 0:50
10/21/2014 0:52
10/21/2014 0:55
10/21/2014 0:57
10/21/2014 1:00
10/21/2014 1:03
10/21/2014 1:08
10/21/2014 1:10
10/21/2014 1:13
10/21/2014 1:17
10/21/2014 1:20
10/21/2014 1:25
10/21/2014 1:28
10/21/2014 1:31
10/21/2014 1:35
10/21/2014 1:37
10/21/2014 5:50
10/21/2014 5:53
10/21/2014 5:56
10/21/2014 5:58
10/21/2014 6:01
10/21/2014 6:04
10/21/2014 6:08
10/21/2014 6:10
10/21/2014 6:13
10/21/2014 6:15
10/21/2014 6:19
10/21/2014 6:22
10/21/2014 6:24
10/21/2014 6:27
10/21/2014 6:29
10/21/2014 6:33
10/21/2014 6:37
10/21/2014 6:39
10/21/2014 6:43
10/21/2014 7:14
10/21/2014 9:14
10/21/2014 9:17
10/21/2014 9:20
10/21/2014 9:22
10/21/2014 13:19
10/21/2014 13:23
10/21/2014 13:26
10/21/2014 13:29
10/21/2014 13:32
X
10/21/2014 13:35
10/21/2014 13:38
10/21/2014 13:40
10/21/2014 13:42
10/21/2014 13:46
10/21/2014 13:50
10/21/2014 13:52
X
10/21/2014 13:58
10/21/2014 14:01
10/21/2014 14:06
10/21/2014 14:09
10/21/2014 15:55
10/21/2014 15:59
10/21/2014 16:03
10/21/2014 16:14
10/21/2014 16:42
4/13/2015 6:24
10/21/2014 20:20
10/21/2014 20:22
10/21/2014 20:25
10/21/2014 20:28
10/21/2014 20:44
10/21/2014 21:06
10/21/2014 21:14
10/21/2014 21:33
10/21/2014 21:43
X
10/21/2014 21:49
10/21/2014 22:00
10/21/2014 22:14
10/21/2014 22:28
10/21/2014 22:55
10/21/2014 23:01
10/21/2014 23:09
10/21/2014 23:20
X
10/21/2014 23:59
10/22/2014 0:01
10/22/2014 0:04
10/22/2014 0:07
10/22/2014 0:11
10/22/2014 0:15
10/22/2014 0:18
10/22/2014 0:20
10/22/2014 0:22
10/22/2014 0:26
10/22/2014 0:28
10/22/2014 0:31
10/22/2014 0:33
X
10/22/2014 0:36
10/22/2014 0:38
10/22/2014 0:40
10/22/2014 0:44
10/22/2014 0:48
10/22/2014 0:52
10/22/2014 0:54
10/22/2014 0:57
10/22/2014 1:00
10/22/2014 1:03
10/22/2014 1:06
10/22/2014 1:09
X
10/22/2014 1:12
10/22/2014 1:14
10/22/2014 1:17
10/22/2014 1:20
10/22/2014 1:22
10/22/2014 1:26
10/22/2014 6:26
10/22/2014 6:30
10/22/2014 4:08
10/22/2014 4:10
10/22/2014 4:12
10/22/2014 4:16
10/22/2014 4:19
10/22/2014 4:22
10/22/2014 4:25
10/22/2014 4:28
10/22/2014 4:31
10/22/2014 4:35
10/22/2014 4:38
10/22/2014 4:43
10/22/2014 4:45
10/22/2014 4:48
10/22/2014 4:50
X
10/22/2014 4:53
10/22/2014 4:55
10/22/2014 4:57
10/22/2014 5:00
10/22/2014 5:02
10/22/2014 5:05
10/22/2014 5:08
10/22/2014 5:10
10/22/2014 5:12
10/22/2014 5:15
10/22/2014 5:17
10/22/2014 5:20
10/22/2014 5:22
10/22/2014 5:24
10/22/2014 5:27
10/22/2014 5:30
10/22/2014 6:35
10/22/2014 6:38
10/22/2014 6:40
10/22/2014 6:44
10/22/2014 6:48
10/22/2014 6:50
10/22/2014 6:53
10/22/2014 7:27
10/22/2014 7:30
10/22/2014 7:34
10/22/2014 7:36
10/22/2014 7:39
10/22/2014 7:42
10/22/2014 7:48
10/22/2014 9:30
10/22/2014 9:34
10/22/2014 9:39
10/22/2014 9:42
10/22/2014 9:45
10/22/2014 9:48
10/22/2014 9:51
10/22/2014 9:55
10/22/2014 9:58
10/22/2014 10:01
10/22/2014 10:04
10/22/2014 10:07
10/22/2014 10:19
10/22/2014 10:21
10/22/2014 10:25
10/22/2014 10:28
10/22/2014 10:54
10/22/2014 10:57
10/22/2014 11:00
10/22/2014 11:02
10/22/2014 11:05
10/22/2014 11:09
10/22/2014 11:11
10/22/2014 11:14
10/22/2014 11:17
10/22/2014 11:19
10/22/2014 11:25
10/22/2014 11:27
10/22/2014 11:29
10/22/2014 11:39
10/22/2014 11:55
4/13/2015 6:24
10/22/2014 12:59
10/22/2014 13:01
10/22/2014 13:08
10/22/2014 19:45
10/22/2014 19:48
10/22/2014 19:52
10/22/2014 19:54
10/22/2014 19:57
10/22/2014 20:00
10/22/2014 20:02
10/22/2014 20:05
10/22/2014 20:08
10/22/2014 20:10
10/22/2014 20:14
10/22/2014 20:17
10/22/2014 20:20
10/22/2014 20:23
10/22/2014 20:25
10/22/2014 20:32
10/22/2014 20:34
10/22/2014 20:37
10/22/2014 22:06
X
10/22/2014 22:09
10/22/2014 22:14
10/22/2014 22:18
10/22/2014 22:22
10/22/2014 22:27
10/22/2014 22:29
10/22/2014 22:32
10/22/2014 22:34
10/22/2014 22:36
10/22/2014 22:40
10/22/2014 22:46
10/22/2014 22:50
10/22/2014 22:54
10/22/2014 22:56
10/23/2014 5:33
10/23/2014 5:36
10/23/2014 5:38
10/23/2014 5:41
10/23/2014 5:44
10/23/2014 5:47
10/23/2014 5:50
10/23/2014 5:54
10/23/2014 5:58
10/23/2014 6:01
10/23/2014 6:04
10/23/2014 6:07
10/23/2014 6:11
10/23/2014 6:14
10/23/2014 6:16
10/23/2014 6:18
10/23/2014 7:36
10/23/2014 7:38
10/23/2014 7:41
10/23/2014 7:43
10/23/2014 11:23
10/23/2014 20:25
10/23/2014 20:56
10/23/2014 20:59
10/23/2014 21:01
10/23/2014 21:48
10/23/2014 21:50
10/23/2014 21:52
10/23/2014 21:55
10/23/2014 21:57
10/23/2014 22:00
10/23/2014 22:02
10/23/2014 22:59
10/23/2014 23:05
10/23/2014 23:08
10/23/2014 23:12
10/23/2014 23:15
10/23/2014 23:17
10/23/2014 23:23
10/23/2014 23:25
10/23/2014 23:28
10/23/2014 23:32
10/23/2014 23:34
10/23/2014 23:43
10/23/2014 23:46
10/23/2014 23:49
10/23/2014 23:53
10/23/2014 23:57
10/24/2014 0:01
10/24/2014 0:05
10/24/2014 0:07
10/24/2014 0:10
10/24/2014 0:15
10/24/2014 0:19
10/24/2014 0:22
10/24/2014 0:26
10/24/2014 0:30
10/24/2014 0:33
10/24/2014 0:36
10/24/2014 0:39
10/24/2014 0:42
10/24/2014 0:47
10/24/2014 0:56
10/24/2014 1:01
10/24/2014 1:05
10/24/2014 1:11
10/24/2014 1:23
10/24/2014 1:27
10/24/2014 1:30
10/24/2014 1:32
10/24/2014 1:34
10/24/2014 1:38
10/24/2014 1:41
10/24/2014 1:43
10/24/2014 1:47
10/24/2014 1:49
10/24/2014 23:01
10/24/2014 1:52
10/24/2014 1:55
10/24/2014 1:59
10/24/2014 2:05
10/24/2014 2:07
10/24/2014 2:12
10/24/2014 2:15
10/24/2014 2:19
10/24/2014 2:24
4/13/2015 6:24
4/9/2015 10:27
4/9/2015 10:30
4/9/2015 10:32
4/9/2015 10:35
4/9/2015 10:37
4/9/2015 10:40
4/9/2015 10:42
4/9/2015 10:45
4/9/2015 10:47
4/9/2015 10:49
4/9/2015 10:52
4/9/2015 10:56
4/9/2015 10:58
4/9/2015 11:00
4/9/2015 11:03
4/9/2015 11:05
4/9/2015 11:08
4/9/2015 11:10
4/9/2015 11:13
4/9/2015 11:18
4/9/2015 11:20
4/9/2015 11:24
4/9/2015 11:26
4/9/2015 11:28
4/9/2015 11:31
4/9/2015 11:34
4/9/2015 11:36
4/9/2015 11:39
4/9/2015 11:41
4/9/2015 11:44
4/9/2015 11:47
4/9/2015 11:49
4/9/2015 11:51
4/9/2015 11:54
4/9/2015 11:56
4/9/2015 11:58
4/9/2015 12:01
4/9/2015 12:06
4/9/2015 12:09
4/9/2015 12:11
4/9/2015 12:18
4/9/2015 12:21
4/9/2015 12:24
4/9/2015 12:26
4/9/2015 12:29
4/9/2015 12:32
4/9/2015 12:35
4/9/2015 12:37
4/9/2015 12:40
4/9/2015 12:43
4/9/2015 12:45
4/9/2015 12:48
4/9/2015 12:51
4/9/2015 12:54
4/9/2015 12:57
4/9/2015 13:00
4/9/2015 13:02
4/9/2015 13:05
4/9/2015 13:08
4/9/2015 13:11
4/9/2015 13:13
4/9/2015 13:15
4/9/2015 13:17
4/9/2015 13:20
4/9/2015 13:22
4/9/2015 13:25
4/9/2015 13:28
4/9/2015 13:30
4/9/2015 13:33
4/9/2015 13:37
4/9/2015 13:39
4/9/2015 13:41
4/9/2015 13:44
4/9/2015 13:46
4/9/2015 13:48
4/9/2015 13:51
4/9/2015 13:53
4/9/2015 13:55
4/9/2015 13:58
4/9/2015 14:01
4/9/2015 14:05
4/9/2015 14:09
4/9/2015 14:13
4/9/2015 14:17
4/9/2015 14:21
4/9/2015 14:25
4/9/2015 14:29
4/9/2015 14:33
4/9/2015 14:36
4/9/2015 14:39
4/9/2015 14:42
4/9/2015 14:44
4/9/2015 14:46
4/9/2015 14:48
4/9/2015 14:51
4/9/2015 14:53
4/9/2015 14:55
4/9/2015 14:57
4/9/2015 14:59
4/9/2015 15:03
4/9/2015 15:05
4/9/2015 15:08
4/9/2015 15:11
4/9/2015 15:14
4/9/2015 15:16
4/9/2015 15:18
4/9/2015 15:21
4/9/2015 15:24
4/9/2015 15:27
4/9/2015 15:30
4/9/2015 15:33
4/9/2015 15:36
4/9/2015 15:38
4/9/2015 15:41
4/9/2015 15:43
4/9/2015 15:45
4/9/2015 15:48
4/9/2015 15:51
4/9/2015 15:54
4/9/2015 15:57
4/9/2015 16:01
4/9/2015 16:04
4/9/2015 16:07
4/9/2015 16:10
4/9/2015 16:13
4/9/2015 16:15
4/9/2015 16:17
4/9/2015 16:20
4/9/2015 16:22
4/9/2015 16:26
4/9/2015 16:28
4/9/2015 16:32
4/9/2015 16:34
4/9/2015 16:37
4/9/2015 16:40
4/9/2015 16:43
4/9/2015 16:45
4/9/2015 16:48
4/9/2015 16:50
4/9/2015 16:53
4/9/2015 16:55
4/9/2015 16:58
4/9/2015 17:00
4/9/2015 17:03
4/9/2015 17:06
4/9/2015 17:08
4/9/2015 17:10
4/9/2015 17:13
4/9/2015 17:15
4/9/2015 17:18
4/9/2015 17:20
4/9/2015 17:23
4/9/2015 17:26
4/9/2015 17:29
4/9/2015 17:31
4/9/2015 17:33
4/9/2015 17:36
4/9/2015 17:39
4/9/2015 17:41
4/9/2015 17:43
4/9/2015 17:48
4/9/2015 17:51
4/9/2015 17:54
4/9/2015 17:56
4/9/2015 17:59
4/9/2015 18:01
4/9/2015 18:04
4/9/2015 18:07
4/9/2015 18:09
4/9/2015 18:11
4/9/2015 18:14
4/9/2015 18:17
4/9/2015 18:20
4/9/2015 18:23
4/9/2015 18:25
4/9/2015 18:28
4/9/2015 18:30
4/9/2015 18:33
4/9/2015 18:36
4/9/2015 18:39
4/9/2015 18:41
4/9/2015 18:45
4/9/2015 18:47
4/9/2015 18:50
4/9/2015 18:52
4/9/2015 18:56
4/9/2015 18:58
4/9/2015 19:01
4/9/2015 19:04
4/9/2015 19:07
4/9/2015 19:09
4/9/2015 19:12
4/9/2015 19:14
4/9/2015 19:17
4/9/2015 19:20
4/9/2015 19:23
4/9/2015 19:26
4/9/2015 19:29
4/9/2015 19:32
4/9/2015 19:35